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 Dietary fat is a strong predictor of chronic diseases, such as cardiovascular 
diseases, obesity, diabetes, dyslipidemia and metabolic syndrome [1-2]. A great 
number of epidemiological and observational studies clearly show that in 
addition to the amount of fat consumed in a diet, fat composition is an equally 
important factor in the development of chronic diseases. Evidence abounds 
indicating that adherence to a diet with high content of polyunsaturated 
(PUFAs) and monounsaturated (MUFAs) fatty acids such as the Mediterranean 
diet has substantial health benefits [3-6], while diets with high content of 
saturated fatty acids (SFAs) such as the Western type diet increase the risk for 
the development of several chronic diseases [7-9]. Nutrition science has 
traditionally focused on the physiological aspects of food and epidemiological 
studies on the relation between diet and disease risk. This approach led to the 
generation of a great number of dietary guidelines, which are aimed at disease 
prevention rather than cure. Despite specific guidelines on consumption of 
certain nutrients, especially dietary fats, the rates of diet related diseases remain 
high [10,11], leading to the search of more efficient approaches of disease 
prevention. In response to this need, interest has grown into understanding the 
molecular mechanisms underlying the diverse effects of food components, 
which has been the basis for the appearance of the science of molecular 
nutrition and nutrigenomics.  
 
Nutrigenomics  
 
 Nutritional genomics or nutrigenomics investigates the interaction between 
nutrients and genes at the molecular level by using genomic tools. The advent of 
high throughput technology led to the emergence of a novel field generally 
referred to as genomics, which includes transcriptomics, proteomics and 
metabolomics. Currently, transcriptomics is the most developed and feasible 
tool used in nutrigenomics research. Transcriptomics is extensively used to 
measure global changes in mRNA level (the transcriptome) of cell or tissue in 
response to external stimuli such as nutrients, pharmacological compounds or 
certain diets or diseases. Taking advantage of that technology, nutrigenomics 
research aims to provide a clear mechanistic framework that links uptake of 
specific nutrients such as fatty acids to specific biological pathways and disease 
process. To raise our understanding on food-metabolism interactions above 
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purely descriptive type of information, it is important to carry out studies on 
mutant mice or in cell cultures, in order to identify molecular targets of nutrients 
[12]. 
 As a part of nutrition research, nutrigenomics approaches have focused on 
understanding the early stages of disease development, as a response to 
consumption of a certain diet or certain food compounds. One of the main goals 
is to distinguish healthy individuals from those that are in a pre-diseased or 
diseased stage, based on information derived from gene or protein expression 
levels. Nutrigenomics research in humans focuses on tissues that are relatively 
easily accessible, including blood cells, adipose tissue and skeletal muscle. This 
approach is anticipated to produce novel and more sensitive markers of disease 
onset compared to those currently used in disease prevention. In such a way, 
increasing our understanding on the transition from pre-disease to the disease 
stage may allow early intervention that can restore health [13]. 
 
PPARα – major nutritional sensor of fatty acids 
 
 Within the field of nutrigenomics, dietary nutrients and their metabolites are 
seen as signaling molecules that target specific cellular response systems. An 
important set of signaling molecules in our diet are fatty acids. An important 
mechanism of action of fatty acids is via stimulation or inhibition of DNA 
transcription. The family of nuclear receptors represents an extensively 
characterized group of transcription factors that is involved in mediating the 
cellular responses of fatty acids [14,15]. Among them, the Peroxisome 
Proliferator Activated Receptors (PPARs) perhaps comprise the best recognized 
sensor system for fatty acids. PPARs are nuclear receptors that physically bind 
fatty acids and other lipophilic compounds. Ligand binding triggers a series of 
processes that include recruitment of specific coactivator proteins, leading to 
induction or inhibition of the expression of PPAR target genes. Investigating the 
type of target genes and their biological role has substantially improved our 
knowledge on the function of PPARs in different tissues. Three different 
subtypes of PPARs have been cloned, each characterized by an unique tissue 
expression pattern. PPARα shows the highest expression in tissues with high 
oxidative capacity, such as brown adipose tissue, cardiac muscle, skeletal 
muscle and liver. PPARβ/δ is found in many cell types, while PPARγ 
expression is more restricted in adipocytes and macrophages. Chapter 1 
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provides an extensive review on fatty acid sensing, explaining the role of 
Peroxisome Proliferator Activated receptors and other fatty acid sensors in fat 
recognition and regulation of fatty acid target genes.  
 
Heart, a highly oxidative muscle  
 
 The mammalian heart relies highly on fat oxidation for covering its energy 
demands. The main site of fat oxidation is the cardiomyocyte, which covers 
75% of the total number of cells in the heart. Under resting conditions fat 
oxidation covers up to 70% of cardiac energy demands and the remainder is 
covered by glucose utilization (20%-30%) [16,17]. In order to maintain the high 
rates of fat oxidation the heart can use a variety of metabolic fuels and its 
preference is determined to a large extent by the body’s metabolic state. After a 
meal heart takes up most of the fat in the form of chylomicron triglycerides, that 
are formed in the small intestine [18]. Chylomicron triglycerides are lipolysed 
via lipoprotein lipase activity to provide the heart with free fatty acids (FFAs). 
A small part of FFAs is also derived from albumin-bound FFA, that are taken 
up by the heart without the intermediate role of LPL. Finally, in case of 
nutritional deprivation the heart can catabolize ketones, amino acids or lactate 
[19]. 
 High rates of mitochondrial oxidation and oxygen utilization are coupled 
with enzymatic and non-enzymatic mechanisms, aiming to counterbalance the 
production of highly reactive secondary products of the respiratory chain, the 
reactive oxygen species (ROS) [20]. Among the best characterized enzymatic 
mechanisms are the catalase and glutathione peroxidase, superoxide dismutase 
(SODs), thioredoxin and thioredoxin reductase. Non-enzymatic mechanisms 
include the intracellular antioxidants, such as Vitamin E, C and beta carotene, 
ubiquinone, lipoic acid and urate [21]. ROS can play an important role in 
cardiac inflammation and their unbalanced production may lead to damage of 
cell membrane, organelle structures, DNA and peroxidation of lipids giving rise 
to lipotoxic metabolites, such as ceramide. Additionally, ROS have been 
described to directly regulate specific transcription factors involved in 
inflammation, such as NFkB and Nrf2 [22,23]. Under conditions of increased 
lipids uptake by the heart, such as chronic high fat diet or insulin resistance, 
increased rates of fatty acid oxidation, in combination with uncontrolled 
production of ROS and lipid intermediates may result in mitochondrial 
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malfunctioning and lipid accumulation [24]. Myocardial lipotoxicity refers to 
the accumulation of intramyocardial lipids and is associated with contractile 
dysfunction and even myocyte death [25]. 
  Previous studies have suggested that PPARα plays a central role in cardiac 
function. At initial stages of cardiomyopathy increased PPARα activity results 
in upregulation of beta oxidation genes and ROS production, whereas at later 
stages PPARα activity decreases, leading to mitochondrial malfunction and 
lipid accumulation [26-28]. Since the heart takes up substantial amounts of 
dietary fat, we set out to investigate the direct transcriptional targets of dietary 
lipids in the healthy heart. In chapter 2 we provide a detailed description of 
target genes and metabolic pathways that are regulated acutely after an oral 
gavage of triglyceride consisting of one type of fatty acid (C22:6, C18:3, C18:1 
or C18:1). In addition, the role of PPARα is investigated by conducting the 
experiment in PPARα  -/- mice. In chapter 3, we describe in depth a fatty acid 
induced mechanism that serves to inhibit the LPL dependent uptake of fatty 
acids and thereby protect against cardiomyocyte lipotoxicity.  
 
LPL- Angptl4 axis and its role in regulation of lipid uptake  
 
 Plasma levels of lipoproteins are considered a risk factor for atherosclerosis 
and coronary heart disease. Elevated levels of low-density lipoprotein (LDL) 
have been shown to increase the risk for atherosclerosis developement, while 
high levels of high density lipoprotein (HDL) are considered to be protective. In 
recent years plasma triglycerides (TG) are increasingly recognized as an 
independent factor for cardiovascular disease (CVD). Triglycerides (TGs) 
circulate in the plasma in the form of VLDL remnants and chylomicrons. VLDL 
remnants derive from the liver, whereas chylomicrons derive from the small 
intestine. Thus, levels of TGs in the plasma depend on the rate of production of 
TG-rich lipoproteins in the small intestine and liver, and their clearance in 
skeletal muscle, heart and adipose tissue. Clearance of plasma triglycerides is 
catalyzed by lipoprotein lipase (LPL), which is anchored to the capillary 
endothelium via heparin sulphate proteoglycans and the protein GPIHBP1. For 
an extended review on the function and regulation of LPL activity the reader is 
referred to the review of Lichtenstein L. and Kersten S.; BBA;2010 [29]. Here 
we briefly describe the regulation of LPL by Angptl4, a target gene of PPARs 
and a sensitive fatty acid target.  
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 Angptl4 is a secreted protein of size about 50KDa. It belongs to the family of 
fibrinogen/angiopoietin like proteins that includes Angptl1, Angptl2, Angptl3, 
and Angptl6. Similar to other angiopoietin-like proteins, Angptl4 is divided into 
distinct regions, which include a N-terminal signal sequence, a unique 
sequence, a coiled-coil domain and a large fibrinogen/angiopoietin-like domain. 
During protein maturation Angptl4 is cleaved to release an N-terminal and C-
terminal fragment. Angptl4 is now well accepted as a potent inhibitor of LPL 
activity. It has been shown in vivo and in vitro that the inhibitory role of 
Angptl4 on LPL activity is mediated by the N-terminal domain, which favors 
the formation of inactive LPL monomers at the expense of active LPL dimers 
[30,31]. Both Angptl4 and LPL are expressed in several tissues and cell types, 
such as liver, skeletal muscle, adipose tissue, heart, small intestine, and 
macrophages. Angptl4 was originally cloned as target gene of PPARs and is 
highly upregulated by fatty acids. Apart from being a potent inhibitor of LPL 
activity, Angptl4 has been reported to have angiogenic and wound healing 
functions  [32,33]. The C-terminal part of the protein, whose role is less 
understood compared to the N-terminal domain, seems to be involved in these 
functions. 
 
Outline of this thesis 
 
 In Chapter 2 we provide an overview of existing knowledge on gene 
regulation by fatty acids. The objective of this thesis was to provide a 
comprehensive analysis of gene regulation by dietary polyunsaturated fatty 
acids. We chose heart as the most relevant organ to investigate this question, 
because after a meal heart preferentially utilizes fatty acids released via LPL-
mediated lipolysis of chylomicron triglycerides. Chapter 3 is a transcriptomics 
study investigating the effect of different PUFAs on cardiac gene expression. 
We take advantage of a unique experimental design in which mice are fed a 
single bolus of dietary triglycerides consisting of one type of fatty acid. In 
addition, the role of PPARα, previously described as the master regulator of 
lipid homeostasis in the heart is explored.  
 In Chapter 3, we identify Angptl4 as the gene most strongly induced by 
PUFAs in the heart. Based on previous knowledge on the inhibitory role of 
Angptl4 on LPL activity, we hypothesized that increased influx of PUFA in the 
heart may result in upregulation of Angptl4, in order to inhibit LPL dependent 
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release of FFAs, thereby protecting against the toxic consequences of increased 
fat influx. In Chapter 4, we investigated in depth the transcriptional regulation 
of this mechanism and its contribution to regulate oxidative stress and prevent 
lipotoxicity in the heart.   
 LPL is anchored to the endothelium via heparin sulphate proteoglycans and 
its activity determines the plasma levels of triglycerides. Increased triglyceride 
levels are considered a risk factor for atherosclerosis. Therefore, in Chapter 5 
we investigate the role of Angptl4 in atherosclerosis development, using a 
model of whole body Angptl4 overexpression on a atherosclerosis-prone 
ApoE3Leiden background.  
 Macrophages are central players in atherosclerosis development. They 
function primarily as scavengers of lipids and modified lipids and excessive 
lipid accumulation leads to the formation of pro-inflammatory foam cells. In 
Chapter 6, we describe the identification and initial characterization of the gene 
Hig-2, which is sensitive to fatty acids uptake in macrophages. Finally, 
conclusions and suggestions deriving from this thesis are discussed in Chapter 
7. 
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Abstract:  
Consumption of specific dietary fatty acids has been shown to influence risk 
and progression of several chronic diseases, such as cardiovascular disease, 
obesity, cancer, and arthritis. In recent years, insights into the mechanisms 
underlying the biological effects of fatty acids have improved considerably and 
have provided the foundation for the emerging concept of fatty acid sensing, 
which can be interpreted as the property of fatty acids to influence biological 
processes by serving as signalling molecules. An important mechanism of fatty 
acid sensing is via stimulation or inhibition of DNA transcription. Here, we will 
focus on fatty acid sensing via regulation of gene transcription and address the 
role of Peroxisome Proliferator Activated receptors, Sterol Regulatory Element 
Binding Protein 1, Toll-like receptor 4, G-protein coupled receptors, and other 
putative mediators. 
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Introduction 
 Consumption of specific dietary fatty acids has been shown to impact risk 
for a wide range of chronic diseases. What traditionally has been lacking is a 
clear mechanistic framework that links uptake of specific lipids to a biological 
pathway and disease process. Such a molecular framework should 
accommodate the often differential effects of fatty acids differing in chain 
length and saturation on numerous biological parameters. In recent years, 
insights into the mechanisms underlying the biological effects of fatty acids 
have progressed rapidly, partly thanks to the widespread use of in vivo and in 
vitro gene targeting, and have provided the foundation for the emerging concept 
of fatty acid sensing. Fatty acid sensing can be interpreted as the property of 
fatty acids to influence biological processes by serving as signalling molecules. 
While it is well established that fatty acid derivatives such as eicosanoids have a 
major signalling function, there is convincing evidence that fatty acids 
themselves also carry this property. Part of this regulation occurs via regulation 
of gene transcription, which is the topic of this review. 
 
Trafficking and cellular sensing of dietary fat  
 
 Every day our body processes an amount of fat equivalent to almost half a 
cup. In the intestine, dietary triglycerides are first hydrolyzed into fatty acids 
and monoglycerides that together with bile acids associate into micelles in the 
intestinal lumen. After being taken up into enterocytes, fatty acids are 
reesterified into triglycerides (TG) and secreted as part of chylomicrons, 
initially to the intestinal lymph vessels and from there on into the blood 
circulation. The increase in circulating chylomicrons after a meal gives rise to 
the post-prandial peak in plasma triglycerides. The time-course and magnitude 
of the plasma triglyceride peak may differ between individuals and is elevated 
in obese and diabetic subjects, giving rise to post prandial lipaemia. Plasma 
chylomicrons undergo rapid lipolytic processing via the action of lipoprotein 
lipase (LPL) anchored to the capillary endothelium, leading to the release of 
fatty acids and their subsequent uptake into the underlying tissue [1]. 
 One of the major sinks for meal-derived fatty acids is the adipose tissue, 
which acquires most of the absorbed fatty acids via elevated local LPL activity. 
Other tissues that substantially contribute to post-prandial clearance of 
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chylomicron-TG are skeletal muscle, heart, and, after conversion to 
chylomicron remnants, the liver [2]. In contrast to plasma TG, circulating levels 
of adipose tissue derived non-esterified free fatty acids decrease rapidly after a 
mixed meal and again increase at the end of the post prandial period. A 
significant portion of circulating FFAs are taken up by the liver, where together 
with remnant-derived fatty acids and fatty acids produced via de novo 
lipogenesis they form the substrate for (re-)esterification and subsequent 
secretion into the plasma as VLDL-TG. Depending on the tissue and feeding 
status, either plasma FFA or TG-derived fatty acids comprise the major share of 
fatty acids for tissue uptake [2]. Irrespective of the specific route of delivery, it 
is evident that the rate of fatty acid uptake into many tissues is very variable and 
influenced by numerous factors, including tissue metabolic activity, feeding 
status, fat intake, and the intake of other nutrients, especially carbohydrates. 
Furthermore, circulating concentrations and tissues fluxes of FFA and TG-
derived fatty acids are often altered during obesity, type 2 diabetes or other 
metabolic disturbances. 
 A number of proteins are involved in cellular uptake of FFAs, including 
CD36 and various FATPs [3]. After uptake, fatty acids are bound by fatty acid 
binding proteins (FABPs) and can undergo a number of metabolic fates 
including oxidation in mitochondria and esterification and storage in lipid 
droplets. In addition, fatty acids can serve as signaling molecule by impacting 
intra- and extra-cellular receptor sensor systems either directly or after 
conversion to specific fatty acid derivatives. An example of these lipid sensors 
are the nuclear receptors, which mediate activation of gene transcription by a 
variety of hydrophobic compounds, including retinoic acid, steroid hormones, 
oxysterols and bile acids [4]. This review will provide an overview of our 
current knowledge on the various cellular receptor systems enabling the cell to 
sense the intra- or extracellular fatty acid concentration and respond by altering 
gene transcription. 
 
Peroxisome Proliferator Activated Receptors  
 
 The Peroxisome Proliferator Activated Receptors (PPARs) perhaps comprise 
the best recognized sensor system for fatty acids (Figure 1). PPARs are 
transcription factors that are members of the superfamily of nuclear hormone 
receptors, which also include receptors for fat soluble vitamins A and D and 
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steroid hormones [5]. Nuclear receptors function as ligand-activated 
transcription factors by binding small lipophilic molecules. They share a 
modular structure consisting of a DNA- and ligand-binding domain and play a 
role in a numerous biological processes [6]. Three different PPARs subtypes 
have been cloned, each characterized by a unique tissue expression pattern. 
PPARα (Nr1c1) is found in many tissues but is predominant in oxidative tissues 
such as brown adipose tissue, cardiac muscle, skeletal muscle and liver. 
PPARβ/δ (Nr1c2) is found in many cell types, while PPARγ (Nr1c3) expression 
is more restricted with adipocytes and macrophages expressing the highest level 
[7,8]. Binding of ligand is believed to trigger the physical association of PPARs 
to specific DNA sequences called PPAR response elements in and around target 
genes. Additionally, ligand binding leads to recruitment of co-activator proteins 
and loss of co-repressor proteins, resulting in activation of DNA transcription 
[5]. Similar to many other nuclear receptors, PPARs bind to DNA as 
heterodimer with the nuclear receptor RXR, which binds the vitamin A 
derivative 9-cis retinoic acid.  
 PPARs serve as a receptor for structurally diverse compounds. Although 
substantial specificity towards one particular PPAR subtype has been achieved 
in the design of synthetic PPAR agonists, there seems to be comparatively little 
subtype specificity among endogenous PPAR agonists. In several landmark 
papers from the 1990’s it was demonstrated that all three PPARs are able to 
bind fatty acids with a general preference towards long chain polyunsaturated 
fatty acids (PUFAs) [9-13]. Subsequent studies using a variety of biochemical 
techniques have firmly corroborated the direct physical association between 
fatty acids and PPARs and have thus established fatty acids as bona fide PPAR 
ligands [14-18]. In addition, numerous fatty acid-derived compounds and 
compounds showing structural resemblance to fatty acids, including acyl-CoAs, 
oxidized fatty acids (9(S)-HODE, 13(S)-HODE), eicosanoids, 
endocannabinoids, and phytanic acid, have been shown to activate PPARs (19-
26). Whereas the eicosanoid 15-Deoxy-Delta-12,14-prostaglandin J2 behaves as 
a specific high affinity agonist for PPARγ, (8S)-hydroxyeicosatetraenoic acid 
and prostacylin PGI2 show preference for PPARα and PPARδ, respectively [9, 
27-29]. Since the intracellular concentration of fatty acids (free and bound to 
fatty acid binding proteins) far exceeds the intracellular concentration of 
eicosanoids and other endogenous PPAR agonists, and since fatty acids are able 
to bind PPARs with high affinity, the question can be raised to what extent 
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eicosanoids and other fatty acid-derived compounds substantially contribute to 
the activation of PPARs in vivo. Rather, it can be argued that PPARs serve as 
general fatty acid sensors with comparatively limited ligand specificity. 
However, this concept is not universally embraced, and has clearly not stopped 
the quest to identify the potentially elusive single true endogenous PPAR 
ligand. Recently, Semenkovich and colleagues identified the 
phosphatidylcholine 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine as the 
lipid compound likely responsible for the activation of PPARα in mice carrying 
a targeted deletion of the fatty acid synthase gene [30]. Since 
phosphatidylcholines are abundant in any cell, it is unclear how activation of 
PPARα by 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine fits into the 
notion of PPARα being a lipid sensor that responds to changes in metabolic 
status and lipid fluxes.  
 As discussed above, dietary fatty acids mostly enter the liver as TG within 
chylomicron remnants, and are liberated after degradation of the remnant 
particles by hepatic and lysosomal lipase. It has been shown that PPARα is 
dominant in mediating the effects of dietary fatty acids on hepatic gene 
expression, including many genes involved in fatty acid catabolism, as revealed 
by experiments in which wildtype and PPARα -/- mice were provided with a 
single oral bolus of synthetic TG consisting of one type of fatty acid [17]. 
Lipolysis of circulating lipoproteins, whether hydrolysis of HDL by endothelial 
lipase or lipolysis of VLDL by lipoprotein lipase, was shown to be an important 
mechanism for generating ligands for PPARα in endothelial cells [31, 32], while 
hydrolysis of VLDL by hepatic lipase and lipoprotein lipase was shown to 
provide ligands for PPARβ/δ in hepatocytes and macrophages, respectively [33, 
34]. 
 In contrast and very surprisingly, circulating FFA, which primarily originate 
from adipose tissue lipolysis, do not seem to be able to activate PPARα, at least 
in the liver [35, 36]. The precise mechanism behind the differential effect of 
circulating FFA (“old fat”) versus dietary and endogenously synthesized fatty 
acids (“new fat”) on hepatic PPARα activation remain unclear but may be 
related to existence of distinct intracellular fatty acids pools with distinct 
metabolic and signaling properties [35]. In contrast, hepatic PPARβ/δ can be 
activated by plasma FFA (36), and likely the same is true in skeletal muscle, as 
revealed by the stimulatory effect of elevated FFA on expression of PPARβ/δ 
target Angptl4 in skeletal muscle [37, 38]. 
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 Interestingly, it was recently proposed that in the mouse heart, PPARα-
mediated gene transcription requires the prior esterification of fatty acids and 
subsequent hydrolysis catalyzed by Adipose Triglyceride Lipase (ATGL) [39]. 
Conversion to TG and subsequent lipolysis seems to be necessary in order for 
fatty acids to become active signaling lipids, but it is unclear whether the 
specific routing of fatty acids leads to the formation of a specific high affinity 
ligand or feeds a distinct intracellular fatty acid pool. In contrast, evidence was 
also provided that in liver ATGL promotes PPARα activity independently of 
ligand-induced activation [40]. 
 PPARα acts as a master regulator of hepatic lipid catabolism by inducing the 
expression of numerous genes involved in mitochondrial and peroxisomal fatty 
acid oxidation, as well as other lipid related pathways, inflammatory pathways, 
and glucose metabolism [41]. Accordingly, it can be argued that activation of 
PPARα by fatty acids in liver and heart is part of a feed-forward mechanism 
aimed at promoting oxidation of incoming fuels and thereby preventing the 
intracellular accumulation and consequent lipotoxicity of fatty acids by 
stimulating their oxidation. A similar role can be envisioned for PPARβ/δ in 
skeletal muscle. Besides via stimulation of fatty acid oxidation and possibly by 
stimulating conversion of fatty acids into triglycerides [41], activation of PPAR 
by fatty acids may protect against lipotoxicity by inhibiting LPL-dependent 
hydrolysis of circulating TG and consequent uptake of fatty acids via induction 
of the LPL-inhibitor Angptl4 [42]. 
 The role of PPARs in gene regulation by fatty acids is less clear in adipose 
tissue. Marine oil fatty acids have major effects on adipose tissue function and 
metabolism, as well as on adipose tissue gene regulation [43]. Although PUFAs 
are direct agonists for PPARγ [12], it is unclear to what extent the observed 
changes in adipose gene expression upon chronic PUFA feeding reflect direct 
ligand-activation of PPARγ or other PPARs, or are secondary effects conferred 
by specific eicosanoids or other fatty acid-derived compounds. Activation of 
PPARγ by fatty acids may be aimed at promoting conversion of incoming fatty 
acids to TG and stimulating overall TG storage capacity, thereby protecting 
against lipotoxicity.  
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Sterol-regulatory element binding protein 1  
 Dietary PUFAs suppress hepatic expression of genes involved in fatty acid 
synthesis (Figure 1). The underlying mechanism involves a member of the 
family of basic-helix-loop-helix-leucine zipper transcription factors named 
sterol regulatory element binding protein-1 (SREBP-1, Srebf1). There are two 
SREBP isoforms, designated SREBP-1c and SREBP-2, which differ in their 
tissue specific expression and their target genes selectivity. Whereas SREBP-1c 
preferentially activates genes involved in de-novo lipogenesis, SREBP-2 has a 
preference towards genes involved in cholesterol synthesis and uptake, at least 
in liver [44]. Together, SREBPs activate the expression of more than 30 genes 
involved in the synthesis and uptake of cholesterol, fatty acids, triglycerides, 
and phospholipids. 
 Although SREBP1 and SREBP2 have both been suggested to be inhibited by 
PUFAs, there is a lot more evidence implicating SREBP1 in downregulation of 
gene expression by PUFAs. Studies over the last decade have indicated that 
PUFAs potently lower SREBP-1 mRNA levels and inhibit proteolytic 
processing of SREBP-1 [45-49]. The latter process is required for maturation of 
precursor membrane-bound SREBP-1 to the mature SREBP-1, which moves to 
the nucleus and serves as the actual transcription factor. Recently, the target of 
PUFAs was identified as Ubxd8, a ER membrane-bound protein that facilitates 
the degradation of Insig-1, which normally sequesters the SCAP-SREBP 
complex in the ER and prevents its activation [50]. Specifically, it was shown 
that PUFAs inhibit the activity of Ubxd8, thus causing the SCAP-SREBP 
complex to stay in the ER. In addition to the mechanism described above, 
evidence has been provided that DHA but not other PUFAs stimulate the 
removal of mature nuclear SREBP-1 via a mechanism dependent on 26S-
proteosome and ERK signaling [51]. Downregulation of SREBP-1 mRNA by 
PUFAs has been proposed to be mediated by stimulation of SREBP-1 mRNA 
decay [52], or by antagonizing the activity of the nuclear receptor LXRα, a 
potent inducer of SREBP-1 gene transcription [53, 54]. Since a role of LXR in 
mediating effects of PUFAs is contentious [55], the reduction in SREBP-1 
mRNA by PUFA is more likely to be secondary to inhibition of SREBP-1 
maturation, which via autoregulation of SREBP-1 transcriptional activation 
leads to reduced SREBP-1 mRNA levels [56].  
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 PUFAs have also been shown to reduce expression of the glycolytic gene 
pyruvate kinase via a mechanism independent of PPARα [57]. This effect may 
be mediated by inhibiting nuclear translocation of either carbohydrate 
responsive element binding protein (ChREBP) or MAX-like protein X (MLX) 
(Figure 1) [58, 59]. ChREBP and MLX form a heterodimer functioning as 
glucose-responsive transcription factor that induces expression of genes 
involved in glycolysis and lipogenesis, including pyruvate kinase, acetyl-CoA 
carboxylase 1, and fatty acid synthase. However, additional data need to be 
collected to more precisely define how PUFAs influence ChREBP or MLX 
nuclear translocation and what are the direct molecular target of PUFAs. 
 
Hepatocyte nuclear factor 4α  
 The hepatocyte nuclear factor 4α (HNF4α, Nr2a1) is a nuclear receptor that 
is exclusively expressed in the gastrointestinal tract, liver and kidney [7]. 
Targeted disruption of HNF4α leads to early embryonic lethality related to 
defects in the expression of visceral endoderm proteins required for maintaining 
gastrulation [60]. Using liver-specific HNF4α-/- mice it was shown that liver 
HNF4α is important for hepatocyte differentiation and for governing the 
expression of genes involved in lipid homeostasis (61). In 1998 evidence was 
provided that saturated fatty acyl-CoA may be able to serve as agonists for 
HNF4α, whereas unsaturated fatty acyl-CoA were proposed to serve as 
antagonistic ligands [62]. These data have been contested experimentally and 
are not widely accepted [63]. Elucidation of the molecular structure using X-ray 
crystallography revealed the presence of a fatty acid that appeared to be 
constitutively bound [64, 65]. More recently, it was shown using affinity 
isolation/mass-spectrometry that HNF4α is occupied by linoleic acid in COS-7 
cells as well as in liver of fed but not fasted mice, suggesting fatty acid binding 
is exchangeable. However, no induction of HNF4α targets by linoleic acid was 
observed in a human colon cancer cell line, raising questions about the purpose 
of binding of linoleic acid to HNF4α [66]. Overall, the binding and especially 
the activation of HNF4α by fatty acids or acyl-CoAs remains controversial. 
Indeed, there is only very limited evidence that changes in the concentration of 
fatty acids or acyl-CoA lead to activation of HNF4α targets. 
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 In addition to PPARs and HNF4α, the nuclear receptors LXR, FXR and 
RXR have been proposed to serve as mediators of the effects of fatty acid on 
gene transcription. With respect to LXR, it was suggested that unsaturated fatty 
acids suppress Srebp1c gene expression by inhibiting LXR [53]. However, 
another study found that unsaturated fatty acids do not influence LXR-
dependent gene regulation in primary rat hepatocytes or in liver [55]. 
 Docosahexanoic acid was originally picked up as ligand for RXR when 
looking for a factor in brain tissue that activates RXR in a cell-based assay [67]. 
Subsequent experiments showed the direct binding of PUFAs to RXR, with 
strongest RXR activation observed for DHA and arachidonic acid, followed by 
linolenic, linoleic, and oleic acid [68]. Recent studies confirmed the direct 
binding of DHA to RXR, although with much lower affinity compared to 9cRA 
[69]. In as much as DHA also binds PPARs and PPARs form a permissive 
heterodimers with RXR, it is technically challenging to distinguish between 
DHA gene signaling via PPAR versus RXR. Interestingly, using RXR and 
PPARγ antagonists, it was found that DHA induces expression of Adrp (Plin2) 
in human choriocarcinoma cells via activation of RXR [70]. Recently, effect of 
DHA on despair behaviors and working memory could be attributed to 
activation of RXRγ [71]. 
 
NF-E2-related factor-2 (NRF2)  
 An oral lipid load with PUFAs causes rapid upregulation of numerous 
oxidative stress genes in several organs, likely representing an adaptive 
mechanism aimed at preventing cellular lipotoxicity [72]. Increased levels of 
reactive oxygen species and derivatives of fatty acid peroxidation activate the 
transcription factor NRF2 (NFE2L2), which governs the expression of multiple 
genes involved in the oxidative stress response. Compounds that activate NRF2, 
ranging from diphenols to hydroperoxides and heavy metals, are believed to 
modulate the sulfhydryl group of cysteine residues with KEAP1, which serves 
as NRF2-specific adaptor protein for the Cullin-3 ubiquitin ligase complex [73]. 
As a result, these compounds cause the dissociation of Cullin-3 and thereby 
inhibit NRF2 ubiquitination, leading to stabilization and nuclear translocation of 
NRF2 and subsequent induction of NRF2 target genes. Studies have shown that 
oxidation products of linoleic acid, eicosapentanoic acid and DHA can react 
with KEAP1, while the intact fatty acids cannot [74-76]. Thus, the effects of 
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(dietary) PUFA on expression of genes involved in the oxidative stress response 
are likely mediated by specific fatty acid oxidation products via NRF2-
dependent signaling.  
 
Toll-like receptor 4  
 Numerous studies have investigated the impact of fatty acids on the 
inflammatory response in a great variety of cell types and tissues. These studies 
overwhelmingly point to a pro-inflammatory effect of saturated fatty acids, 
whereas n-3 PUFA exhibit mostly anti-inflammatory properties [77]. Most of 
the modulatory effect of fatty acids on inflammation can probably be attributed 
to fatty acid metabolites, including prostaglandins, leukotoxins, resolvins, 
endocannabinoids, ceramides and diacylglycerols [77]. However, there is 
accumulating evidence that fatty acids may be able to directly activate or 
suppress inflammatory pathways.  
 Most of the biological activities of LPS are mediated via its lipid A moiety. 
It is well established that the fatty acids that are part of lipid A play an 
important role in ligand recognition and receptor activation of Toll-like receptor 
4 (TLR4), leading to the suggestion that saturated fatty acids may promote 
inflammation by direct activation of TLR4 (Figure 1). Subsequent studies have 
provided compelling evidence that saturated fatty acids activate NF-κB and 
stimulate expression of NF-κB targets such as COX-2, iNOS and IL-1α in 
macrophages by activating TLR4 signaling in a MyD88, IRAK-1 and TRAF6 
dependent manner [78-80]. In contrast, unsaturated fatty acids are ineffective or 
may even act as antagonists. It was reported that saturated fatty acids activate 
TLR4 by promoting its recruitment to lipid rafts via a mechanism involving 
reactive oxygen species [81]. Data showing direct physical binding of saturated 
fatty acids to TLR4 are still lacking, leaving open the mechanism of TLR4 
activation [82]. Others have argued against TLR4 activation by saturated fatty 
acids [83]. Using TLR4-/- macrophages, the role of TLR4 in mediating the 
inflammatory effects of saturated fatty acids was convincingly demonstrated 
[84, 85]. Loss of TLR4 was also shown to partially protect against diet-induced 
obesity and insulin resistance, suggesting TLR4 may be involved in mediating 
the detrimental effects of chronic high saturated fat consumption [84, 86, 87].  
 
 
Chapter 2: Mechanisms of gene regulation by fatty acids 
 
32 
G-protein coupled receptors  
 
 Members of the G-protein coupled receptor (GPCRs) family are involved in 
mediating the stimulatory effects of fatty acids on insulin secretion by 
pancreatic β-cells and on secretion of various gastrointestinal hormones in the 
gut [88, 89]. These receptors, which include GPR40 (FFAR1), GPR41 
(FFAR3), GPR43 (FFAR2), GPR84, and GPR120, each exhibit preference for a 
specific set of fatty acids. To what extent activation of GPRs by fatty acids 
directly influences gene transcription remains to be determined (Figure 1). 
Nevertheless, due to the emerging importance of GPRs in fatty acid sensing in a 
variety of tissues, some discussion on GPRs is warranted. 
 In addition to being activated by short chain FAs such as acetate, propionate, 
butyrate and pentanoate, GPR41 and GPR43 have in common that they are well 
expressed in the colon, which is exposed to elevated concentrations of SCFAs 
via bacterial fermentation [88]. Furthermore, GPR41 is expressed in numerous 
immune cells and adipose tissue, where it was shown to be involved in 
regulation of leptin production [90]. The relative role of GPR41 versus GPR43 
as sensor for SCFAs in the enteroendocrine system is not clear.  Recently, it 
was proposed that GPR41 mediates the effect of gut microbiota on fat mass 
[91], while stimulation of GPR43 by SCFAs was shown to be necessary for the 
normal resolution of certain inflammatory responses [92]. 
 In contrast to GPR41 and GPR43, GPR40 is activated by medium and long 
chain fatty acids , which include saturated and unsaturated fatty acids. GPR40 is 
expressed at high levels in pancreatic β-cells, where it mediates the stimulatory 
effect of fatty acids on glucose-stimulated insulin secretion [93, 94]. Apart from 
the pancreatic β-cells, GPR40 is known to be expressed in various other cell 
types such as enteroendocrine cells. In these cells, GPR40 is involved in the 
stimulation of production of GLP-1 and GIP by fatty acids [95].  
Other relevant members of the GPCR family are GPR84, GPR119 and GPR120. 
GPR84 is well expressed in bone-marrow derived macrophages and has been 
proposed as receptor for medium chain fatty acids [96]. GPR119 has a similar 
expression pattern as GPR40 but the receptors shares only little homology. 
Endogenous ligands of GPR119 have been identified and include the fatty acid 
derivatives monoacyl glycerol, lysophosphatidylcholine and 
oleoylethanolamide [97, 98]. GPR120 is activated by saturated and unsaturated 
fatty acids with twelve or more carbons. GPR120 is most abundant in mouse 
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large intestine, lung and adipose tissue, but is also expressed in enteroendocrine 
cells where it mediates the effect of fatty acids on release of glucagon-like 
peptide-1 and cholecystokinine [99-101]. Remarkably, GPR120 was recently 
proposed to serve as a specific sensor for n-3 fatty acids in macrophages that 
may mediate the putative insulin sensitizing and anti-diabetic effects of n-3 fatty 
acids in vivo by repressing macrophage-induced tissue inflammation [102]. So 
far, evidence is lacking that activation of these receptors is directly linked to 
regulation of gene expression.  
 
Conclusion 
While the importance of dietary fatty acids as determinants of risk for numerous 
chronic diseases has been well recognized, only recently have we started to gain 
appreciation for the vast regulatory functions of dietary fatty acids in the human 
body. It is now evident that fatty acids, either directly or via its metabolites, act 
via a great variety of signaling pathways to influence numerous metabolic, 
inflammatory, and other biological processes. In the past decade, nutrigenomics 
has provided the ideal conceptual framework and the necessary technological 
tools to address the global effects of dietary fatty acids, and has importantly 
contributed to a major advancement in our understanding of the molecular 
action of dietary fatty acids. So far the focus has been on the molecular 
characterization of specific signaling routes, coupled to the description of the 
whole genome effects of dietary fatty acids. In the future, greater emphasis will 
have to be placed on the functional consequences of specific target gene 
regulation in order to fully understand the functional impact of dietary fatty 
acids and their potentially preventive effect in specific disease conditions. It can 
be foreseen that nutrigenomics will continue to make a push towards a more 
mechanistic and genomics-driven approach within the domain of nutritional 
sciences and further promote the implementation of high throughput 
technologies. 
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Figure 1: General mechanisms of gene regulation by fatty acids 
The mechanisms shown mainly apply to hepatocytes. PUFAs reduce expression of 
genes involved in fatty acid and cholesterol synthesis by binding and inactivating 
UBXD8, thereby inhibiting proteolytic processing of SREBP-1. PUFAs reduce 
expression of L-type pyruvate kinase (glycolysis) in liver most likely by inhibiting 
nuclear translocation of MLX-ChREBP. Various fatty acids but especially PUFAs act 
as ligand for PPARs. Activation of PPARα by PUFAs in liver leads to stimulation of 
fatty acid catabolism. DHA has been reported as a ligand for RXR. GPR40-43 and 
GPR120 are expressed by enterocytes, enteroendocrine cells and other cell types and 
serve as membrane receptors for various types of fatty acids including SCFAs. It is 
uncertain whether they are involved in the effects of fatty acids on gene expression. 
TLR4 is present macrophages and other cell types and has been proposed to be activated 
by saturated fatty acids. bHLH, basic helix loop helix. 
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Abstract 
Fatty acids comprise the primary energy source for the heart and are mainly 
taken up via hydrolysis of circulating triglyceride-rich lipoproteins. While most 
of the fatty acids entering the cardiomyocyte are oxidized, a small portion is 
involved in altering gene transcription to modulate cardiometabolic functions. 
So far, no in vivo model has been developed enabling study of the 
transcriptional effects of specific fatty acids in the intact heart. In the present 
study, mice were given a single oral dose of synthetic triglycerides composed of 
one single fatty acid.  Hearts were collected 6h thereafter and used for whole 
genome gene expression profiling. Experiments were conducted in wild-type 
and PPARα-/- mice to allow exploration of the specific contribution of PPARα. 
It was found that: 1) C18:3 had the most pronounced effect on cardiac gene 
expression. 2) The largest similarity in gene regulation was observed between 
C18:2 and C18:3. Large similarity was also observed between PPARα agonist 
Wy14643 and C22:6. 3) Many genes were regulated by one particular treatment 
only. Genes regulated by one particular treatment showed large functional 
divergence. 4) The majority of genes responding to fatty acid treatment were 
regulated in a PPARα-dependent manner, emphasizing the importance of 
PPARα in mediating transcriptional regulation by fatty acids in the heart. 5) 
Several genes were robustly regulated by all or many of the fatty acids studied, 
mostly representing well-described targets of PPARs (e.g. Acot1, Angptl4, 
Ucp3) but also including Zbtb16/PLZF, a transcription factor crucial for Natural 
Killer T cell function. 6) Deletion and activation of PPARα had a major effect 
on expression of numerous genes involved in metabolism and immunity. Our 
analysis demonstrates the marked impact of dietary fatty acids on gene 
regulation in the heart via PPARα. 
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Introduction 
 Fatty acids serve as the primary energy substrate for the contracting heart via 
their oxidation in the mitochondria. Oxidation of fatty acids in the heart may be 
altered during specific disease conditions impacting the heart, including cardiac 
failure, myocardial ischemia and diabetes [23]. Impaired oxidation or excess 
delivery of fatty acids in the heart may give rise to cardiomyocellular lipid 
storage. Limited variation in cardiac lipid storage can be considered normal and 
occurs as a direct consequence of physiological fluctuations in circulating FFA 
[35]. However, chronically elevated cardiac lipid storage is considered harmful 
and may lead to lipotoxic cardiomyopathy [24]. 
 Fatty acids entering the cardiomyocyte can originate from two principal 
sources, which are circulating triglyceride-rich lipoproteins and circulating 
albumin-bound free fatty acids. The former pathway, shown to be the main 
source of fatty acids for the heart [3, 31], requires the catalytic activity of 
lipoprotein lipase (LPL), which is anchored into the capillary endothelium. To 
what extent fatty acids from different extracellular sources are channeled into 
different intracellular pathways in the heart remains to be investigated.  
 While most of the fatty acids entering the cardiomyocyte are oxidized, a 
small portion of the incoming fatty acids are transported towards the nucleus 
and alter gene transcription to modulate cardiometabolic functions. Several 
transcription factors are implicated in mediating effect of fatty acids on gene 
transcription in various tissues, including SREBP-1c, HNF4α, and PPARs [25]. 
PPARs are ligand-activated transcription factors that govern DNA transcription 
by direct binding to promoters of target genes [16]. In addition, they down-
regulate gene expression by interfering with the activity of other transcription 
factors. The family of PPARs consists of three members encoded by distinct 
genes: α, δ, and γ, which are each characterized by specific tissue- and 
developmental patterns of expression.  
 PPARα serves as the molecular target for the fibrate class of drugs. In 
addition, PPARα is activated by fatty acids and various fatty acid derivatives 
such as eicosanoids and endocannabinoids. In vitro studies show that PPARα 
has a preference towards long-chain poly-unsaturated fatty acids (PUFAs) [12, 
18, 19]. While several studies have examined the effect of fatty acids on PPAR 
target genes in isolated cardiomyocytes, showing induction of typical PPARα 
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target such as Ucp2, Cpt1a, Cd36, Fabp3, Acsl1, Acot1, and Acadl [5, 10, 32, 
34], little is known about gene regulation by fatty acids in the intact heart. 
 Previously, we described an in vivo model that allows characterization of the 
transcriptional targets of PUFAs in diverse tissues in vivo [14, 26]. In this 
model, mice are given a single oral bolus of synthetic triglycerides composed of 
a single fatty acid. We showed that the Angptl4 gene is a very sensitive target of 
fatty acids in the heart and furthermore that its upregulation is part of a 
protective mechanism against cardiac lipotoxicity [14]. The present study 
examines the whole genome effects of individual dietary fatty acids in the heart 
via transcriptional profiling. By conducting these experiments in wild-type and 
PPARα-/- mice, the specific contribution of PPARα could be determined. 
 
Methods 
Chemicals: Wy14643 was obtained from Eagle Picher Technologies 
laboratories (Lenexa, KS, USA). Triolein, trilinolein, trilinolenin, 
tridocosahexaenoin were from Nu-Chek-Prep, Inc. (Elysian, MN, USA). Cell 
culture media, fetal bovine serum and penicillin/streptomycin were from Lonza 
(Verviers, Belgium).  
Animals and oral lipid load: Pure-bred Sv129 and PPARα-/- mice (2-6 
months of age) on a Sv129 background were used. In the short term experiment, 
animals were switched to a run-in diet consisting of a modified AIN76A diet 
(corn oil was replaced with olive oil to minimize baseline intake of 
polyunsaturated fatty acids, which are more potent activators of PPARα) two 
weeks before the start of the experiment (Research Diet Services, Wijk bij 
Duurstede, the Netherlands). Starting at 5 a.m. the animals were fasted for 4 
hours followed by an intragastric gavage of 400 µL synthetic triolein, 
trilinolein, trilinolenin, or tridocosahexaenoin. Wy14643 was given as 400 µL 
of a 10 mg/mL suspension in 0.5% carboxylmethyl cellulose. The latter also 
served as control treatment  (400uL). 6 hours after the oral gavage the mice 
were anaesthetized with a mixture of isofluorane (1.5%), nitrous oxide (70%) 
and oxygen (30%). Blood was collected by orbital puncture, followed by 
sacrifice of the mice by cervical dislocation. Hearts were removed, snap-frozen 
in liquid nitrogen and stored at -80ºC.  
Chapter 3: Detailed transcriptomics analysis of the effect of dietary fatty acids on gene 
expression in the heart 
49 
 In the long term experiment, wild-type and PPARα-/- mice were fed a chow 
diet (RMH-B diet, Arie Blok, Woerden, the Netherlands) containing 0.1 % 
Wy14643 for 5 days. The animal experiments were approved by the animal 
ethics committee of Wageningen University. 
Microarray analysis: RNA from total heart was extracted with TRIzol reagent 
and purified using RNeasy Mini kit (Qiagen, Venlo, Netherlands). RNA quality 
was assessed on an Agilent 2100 bioanalyzer (Agilent Technologies, 
Amsterdam, the Netherlands) with 6000 Nano Chips using a Eukaryote Total 
RNA Nano assay.  Expression profiling was carried out on individual mouse 
hearts using Affymetrix Mouse Genome 430 2.0 Arrays (short term experiment) 
or on pooled RNA from 4-5 mice using Affymetrix Mouse NuGO arrays (long 
term experiment). Hybridization, washing and scanning of the arrays were done 
according to standard Affymetrix protocols. Scans of the Affymetrix arrays 
were processed using packages from the Bioconductor project [13]. Raw signal 
intensities were normalized by using the GCRMA algorithm [36]. Probesets 
were defined according to Dai et al. using remapped CDF version 11.0.2 based 
on the Entrez gene database [8]. The Bioconductor R package Linear models for 
microarray data (LIMMA) was used to identify differentially expressed genes. 
All comparisons were simultaneously analysed.  In order to balance between 
random responses and relative weak transcriptional effects by the treatments, 
genes that met the cut-off of mean absolute fold change > 1.2 and p-value<0.01 
were considered significantly regulated. A regularized t-test was used, which 
has the same interpretation as an ordinary t-test except that the standard errors 
have been moderated across genes, i.e. shrunk to a common value, using a 
Bayesian model [30]. The microarray datasets have been submitted to NCBI 
Gene Expression Omnibus (GEO numbers pending).  
 
Functional classification of genes: For functional classification of probe 
sets/genes into gene sets clusters or biological pathways, Gene set enrichment 
analysis (GSEA) and ingenuity software v.6.5 were used. For identifying 
specific pathways regulated by each treatment we used Ingenuity canonical 
pathways, considering only differentially expressed genes with a p-value<0.01 
(fatty acids and Wy treatment) or differentially expressed genes with a p-
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value<0.01 and fold-change>1.2 (baseline wildtype vs. PPARα-/-). For GSEA 
differentially expressed gene sets with a p-value<0.05 were considered. 
Correlation Plot: Signal log ratios were calculated between intensity values for 
individual animals and the mean intensity value of the wildtype control group. 
Signal log ratios of genes significantly regulated by at least one treatment were 
used as input for a correlation plot in Biowisdom Omniviz 6.0.3 (Cambridge, 
UK). 
 
Results 
Oral feeding of synthetic triglycerides 
 To study the effect of individual fatty acids on in vivo gene expression in the 
heart, mice fasted for 4 hours were given a single oral dose (400 µL) of 
synthetic triglycerides (TGs) consisting of one single fatty acid, followed by 
collection of the heart 6 hours thereafter (26). Those dosage mirrors the amount 
of dietary fat provided in a post-prandial lipid test in humans. The fatty acids 
studied were oleic acid (C18:1), linoleic acid (C18:2), linolenic acid (C18:3), 
and docosahexaenoic acid (C22:6). In addition, a set of mice was given a single 
oral dose of the synthetic PPARα agonist Wy14643. No saturated fatty acids 
were included because triglycerides composed of common dietary saturated 
fatty acids are solid at room temperature and could not be administered orally. 
The 6-hour time point was chosen because dietary triglycerides enter into the 
circulation within 1 hour after intake and a constant rate of absorption is 
sustained for at least 4 hours thereafter (Figure  1A). The focus of the present 
study is on heart since heart shows the highest relative rate of uptake of dietary 
fatty acids, when expressed per gram organ weight [31]. No major differences 
in metabolic processing of dietary fat between WT and PPARα−/− mice and 
between different dietary fatty acids were observed in this study [26]. 
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Figure 1: Whole genome effects of dietary fatty acids on gene expression in the 
heart. A. Mice fasted for 5h were intravenously injected with lipoprotein lipase 
inhibitor tyloxapol and immediately thereafter given 400 µL of olive oil containing 
7µCi glycerol-tri[
3
H] oleate (triolein). Blood was collected every hour and used to 
determine radioactivity, which is expressed as a percentage of total oral dose. Results 
illustrate the constant rate of absorption of dietary triglycerides for several hours. B. 
Number of genes up- or down regulated (P<0.01) in mouse hearts six hours after a 
single oral dose of Wy14643 or synthetic triglycerides containing one specific fatty 
acid. Mice receiving carboxymethylcellulose served as reference. C. Number of genes 
regulated by each of the fatty acid treatments that were also significantly regulated by 
Wy14643 (P<0.01). 
 
Similarity in gene regulation between fatty acids 
 Expression profiling carried out on individual mouse hearts indicated that 
the largest number of genes was changed following treatment with C18:3, 
followed by C22:6, C18:2, Wy14643 and finally C18:1 (Figure 1B). The 
proportion of genes up- and downregulated was approximately equal, and was 
consistent throughout the various treatments. C22:6 showed the most 
pronounced overlap in gene regulation with Wy14643, followed by C18:3, 
C18:2 and C18:1 (Figure 1C). Next we studied the similarity in gene regulation 
between the various fatty acids via scatter plot analysis, in which the mean fold-
change in expression of a gene by one treatment is expressed in one dimension, 
and the mean fold-change in expression of the same gene by another treatment 
is expressed in the other dimension. Results indicated that mean changes in 
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gene expression elicited by C18:3 and C18:2 were highly similar (Figure 2A), 
as illustrated by the limited scatter. Much less similarity in gene regulation was 
observed between C18:2 (or C18:3) and C22:6. Consistent with the above data, 
Wy14643 showed the least scatter, indicating highest similarity, when plotted 
against C22:6, compared to the other fatty acids. Similar results were obtained 
via correlation analysis, which determines the magnitude of correlation in 
overall gene expression between two individual mice (Figure 2B). High 
correlation in gene expression was observed between mice that received C18:2 
and mice that received C18:3. Compared to C22:6, mice that received C18:2 or 
C18:3 correlated relatively poorly with mice given Wy14643. 
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Figure 2: Similarity in gene regulation between different fatty acids. A. Scatter 
plots showing similarities in gene regulation between two treatments.  The mean fold-
change in expression of a gene by one treatment (relative to control treatment) is 
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expressed in one dimension (y-axis), and the mean fold-change in expression of the 
same gene by another treatment (relative to control treatment) is expressed in the other 
dimension (x-axis). The more pronounced the scatter, the lower the similarity in gene 
regulation. B. Correlation plot showing correlation in gene expression between 
individual mice. Signal log ratios were calculated between intensity values for 
individual animals and the mean intensity value of the control group. Signal log ratios 
of genes significantly regulated by at least one treatment were used as input for a 
correlation plot. Red indicates high correlation, blue indicates weak correlation. 
 To compare the effects of the various treatments, we determined the top 10 
of genes most significantly up- or down-regulated by each treatment (Table 1). 
Some of the top upregulated genes were regulated by all five treatments 
(Zbtb16/PLZF) or by four treatments (Hmox1, Angptl4, Ucp3). Many of the 
commonly upregulated genes are involved in metabolic pathways (Hmgcs2, 
Acot1, Angptl4) or oxidative stress (Hmox1, Ucp3, Mt2). Genes that were 
consistently downregulated by Wy and fatty acids included the nuclear receptor 
Nurr1 (Nr4a1) and fibroblast growth factor 16 (Fgf16). To illustrate specific 
patterns of gene regulation, examples of genes that were regulated by all 
treatments, by all fatty acids, or by only one treatment are shown in Figure 3A. 
Only a small proportion of the genes were regulated by all five treatments or by 
all fatty acids (Figure 3B). Many more genes were either exclusively regulated 
by one particular treatment (Figure 3B) or shared between two treatments (data 
not shown). 
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Table 1: Top 10 of genes most significantly regulated by the various treatments 
ranked according to fold-change (FC). Genes regulated by more than one 
treatment are shown in bold. 
 
 
Chapter 3: Detailed transcriptomics analysis of the effect of dietary fatty acids on gene 
expression in the heart 
56 
 
Figure 3: Fatty acid specific gene regulation in mouse heart. A. Changes in 
expression of selected genes in wildtype mice by the different treatments, illustrating 
gene regulation by all treatments (Hmgcs2), specific/selective regulation by Wy14643 
(PGC1a), C22:6 (Lrrc52), C18:3 (Gsta3), C18:2 (Cldn5), and regulation by all fatty 
acids (Tbx5). B. Number of genes exclusively up- or down-regulated by one specific 
treatment or shared between one or more treatments (P<0.01). C. Comparative 
functional analysis of the whole genome effects of the various treatments. Gene sets up- 
and down-regulated by the various treatments as identified by GSEA (P<0.05) were 
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classified into broad functional categories. Results illustrate aberrant effect of C22:6 
with respect to upregulated genes, and aberrant effect of Wy14643 with respect to 
downregulated genes. 
 
 We next investigated whether similarities in gene regulation between the 
various treatments were also observed at the level of pathways. To that end, 
Ingenuity pathway analysis was carried out on the changes in gene expression 
caused by each treatment. The results reveal that many pathways are commonly 
regulated by the various fatty acids, including several pathways related to 
metabolism of amino acids and fatty acids (Table 2). The number of pathways 
specifically regulated by one fatty acid was limited, with the exception of 
C22:6, which specifically regulated several pathways related to inflammation 
and cytokine/growth factor signalling. Similar data were obtained by Gene Set 
Enrichment Analysis (Figure  3C). Most of the gene sets enriched among genes 
unregulated by the various treatments were related to nutrient/energy 
metabolism, except for C22:6 which induced gene sets involved in a variety of 
biological functions. The special status of C22:6 was not evident among down-
regulated gene sets. These data indicate that C22:6 induces the most diverse 
biological response in cardiac gene expression compared to the other fatty acids 
studied.  
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Table 2: Results of Ingenuity canonical pathway analysis considering only 
differentially expressed genes with a p-value<0.01. 
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Role of PPARα in gene regulation by fatty acids 
 Several of the top regulated genes by fatty acids are target genes of PPARα 
(Table 1). In addition, significant overlap was observed between gene regulation 
by fatty acids and Wy14643 (Figure 1C, Figure 2A). These results suggest that 
PPARα plays a role in gene regulation by dietary fatty acids in heart in vivo. To 
better define the role of PPARα in heart, we first determined the impact of 
PPARα deletion on basal whole genome gene expression in the heart using 
PPARα-/- mice. Using a cut-off of fold-change >1.2 and P<0.01, we found that 
294 genes showed elevated expression and 297 genes showed reduced 
expression in PPARα-/- mice (Figure 4A). Many of the top downregulated 
genes represented known targets of PPARα involved in lipid metabolism, 
including Acot1, Acot2, Ucp3, Gpam and Slc22a5 (Figure 4B). The functional 
roles of the top upregulated genes in PPARα-/- mice were more diverse, 
including genes involved in lipid metabolism (Acsl6, Angptl4) but also genes 
involved in immune response, cell cycle, and oxidative stress response. 
Pathways differentially expressed between wild-type and PPARα-/- mice 
according to Ingenuity pathways analysis fell into four main categories: lipid 
metabolism, amino acid metabolism, carbohydrate metabolism, and 
inflammation/immunity, reflecting the established role of PPARα in these 
processes (Figure 4C). 
 We next set out to investigate the importance of PPARα in gene regulation 
by dietary fatty acids in the heart. Regulation of a particular gene by dietary 
fatty acids or synthetic agonists was defined as PPARα-dependent when 
expression was statistically significantly up- or downregulated in WT but not 
PPARα-/- mice. As expected given the high specificity of the Wy14643 
compound, gene regulation by WY14643 was almost completely dependent on 
PPARα, which was equally observed for up- or down-regulated genes (Figure 
5A,B). The importance of PPARα in gene regulation by dietary fatty acids was 
less pronounced but still remarkably high. Interestingly, a very uniform picture 
was observed for the three PUFAs studied. Specific examples of genes showing 
clear PPARα-dependent or –independent gene regulation by dietary fatty acids 
are shownin Figure 5C. Induction of Ucp3 and Acot1 expression by Wy14643 
and fatty acids was entirely dependent on PPARα, whereas induction of 
Zbtb16/PLZF was completely independent of PPARα. Expression of Pdk4 and 
Hmox1 showed a mixed picture: Whereas induction by Wy14643 was entirely 
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PPARα-dependent, this was not or only partially observed for the various fatty 
acids. Taken together, these data indicate that PPARα plays a major role in gene 
regulation by dietary fatty acids in heart, although other mechanisms contribute 
as well.  
 
 
Figure 4: Effect of PPARα deletion on gene expression in mouse heart. A. Number 
of genes upregulated or downregulated in PPARα-/- mice compared to wildtype mice at 
baseline (control treatment, carboxymethylcellulose) according to P<0.01 and mean fold 
change>1.2. B. Heatmap showing changes in expression of the 20 genes exhibiting the 
highest mean fold increase (top panel) and decrease (lower panel) in PPARα-/- mice 
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compared to wildtype mice at baseline. Each column represents one individual mouse. 
Mean fold change of wildtype mice was set at 1.0. C. Ingenuity canonical pathway 
analysis of changes in gene expression between wildtype and PPARα-/- mice at 
baseline. Line reflects –log(P-value). The coloured bars reflect the percentage of genes 
within a particular pathway that was downregulated (green bar), upregulated (red bar) or 
absent from the dataset (white bars). 
 
 
Figure 5: Role of PPARα in gene regulation by fatty acids in the heart. Bars show 
the percentage of genes upregulated A. or downregulated B. in the different treatment 
groups in a PPARα-dependent manner (black bars, changed in wildtype but not in 
PPARα-/- mice), or PPARα-independent manner (white bars, changed in wildtype and 
PPARα-/- mice). Genes were considered statistically significantly regulated if P<0.01. 
C. Changes in expression of selected genes by the various treatments in wildtype and 
PPARα-/- mice, illustrating complete PPARα-dependent gene regulation (Ucp3, Acot1), 
partial PPARα-dependent up- (Pdk4, Hmox1) and down- (Nr4a1) regulation, and 
PPARα-independent regulation (Zbtb16). Error bars represent SEM. 
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Role of PPARα in cardiac gene regulation 
 As mentioned above, gene regulation by Wy14643 in heart was entirely 
mediated by PPARα. To further understand the impact of PPARα on cardiac 
gene regulation, we carefully analyzed the whole genome effects of short term 
or long term administration of Wy14643, focusing on metabolism and immunity 
related genes. Genes were classified according to 1) differential expression in 
PPARα-/- mice in the absence of Wy14643, 2) induction after short-term 
Wy14643 treatment, 3) induction after long-term Wy14643 treatment. A limited 
number of metabolic genes were regulated in all three conditions, representing 
robust PPARα targets such as Ucp3, Hmgcs2, Acot1 and Ehhadh (Appendix 
table 1). Interestingly, many genes classified as PPARα targets based on 
literature were not induced by Wy14643, even though their expression was 
decreased in the PPARα-/- mice. Conversely, a considerable number of genes 
was induced by Wy14643 but was unaltered in the PPARα-/- mice at baseline. 
The former could be classified as baseline PPARα targets whereas the latter 
may be classified as inducible targets. 
 A large number of genes altered by PPARα deletion or by Wy14643 was 
related to inflammation and immunity (Appendix table 2). Although the 
maximal magnitude of fold-change of inflammation/immunity related genes 
was less compared to metabolism-related genes, the number of genes altered 
was at least as high, demonstrating the impact of PPARα on inflammation and 
immunity in heart. One gene that was robustly regulated by PPARα in all three 
conditions was Serpine1, also known as plasminogen activator inhibitor 1 (PAI-
1). A complete list of genes can be found in Appendix table 1,2. 
  
 
Discussion  
 In this study we set out to study the impact of individual dietary unsaturated 
fatty acids on whole genome gene regulation in the intact mouse heart and 
assess the role of PPARα. Our findings can be summarized as follows: 1) C18:3 
had the most pronounced effect on cardiac gene expression. 2) The largest 
overall similarity in gene regulation was observed between C18:2 and C18:3, 
which was equally true for genes regulated in a PPARα-dependent and 
independent manner (Appendix Figure 1). The synthetic PPARα agonist 
Wy14643 and C22:6 also showed marked similarity in gene regulation. 3) 
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Many genes were regulated by one particular treatment only. Genes regulated 
by one particular treatment showed large functional divergence. 4) The majority 
of genes responding to fatty acid treatment were regulated in a PPARα 
dependent manner, emphasizing the importance of PPARα in mediating 
transcriptional regulation by fatty acids in the heart. 5) Several genes were 
robustly regulated by all or many of the fatty acids studied. A number of these 
genes are well-described targets of PPARs whereas others seem to be regulated 
via a different mechanism. 
 Dietary fatty acids enter the circulation packaged in triglyceride-rich 
chylomicron particles and enter the heart after lipolytic processing by 
lipoprotein lipase. The importance of hydrolysis of triglyceride-rich lipoproteins 
for generating endogenous ligands for cardiac PPARα has been recognized [9, 
37]. Our data extend these previous findings and show that dietary fatty acids 
cause marked induction of several PPARα target genes. In addition, it is shown 
that dietary fatty acids –and therefore the lipolysis pathway- also leads to gene 
regulation via other signaling routes. Part of the PPARα-independent regulation 
may occur via PPARβ/δ (e.g. Pdk4, Angptl4), but other mediators are likely 
also involved, including Nrf2. Nrf2 is a transcription factor that is activated by 
unsaturated fatty acids after their conversion to electrophilic oxo or nitro 
derivatives, and stimulates anti-oxidant gene regulation [15]. An important 
property of PUFAs is that they not only serve as metabolic substrates, but are 
also sources of lipotoxic derivatives such as lipid peroxides and reactive oxygen 
species as secondary products of fatty acid oxidation. Thus, the effects of 
(dietary) PUFA on expression of genes involved in the oxidative stress response 
are likely mediated by specific fatty acid oxidation products via NRF2-
dependent signaling. Activation of Nrf2 may explain why a large number of 
genes induced by dietary unsaturated fatty acids are involved in oxidative stress 
response. Recent data point to cross talk between regulation of lipid metabolism 
and the oxidative stress response. It was found that the anti-oxidant 
transcription factor Nrf2, besides governing oxidative stress target genes, also 
alters expression of numerous genes involved in lipid metabolism [17]. 
Conversely, PPARs, which have a primary function in lipid metabolism, 
directly regulate expression of a number of oxidative stress genes, exemplified 
by Hmox1 [1, 20, 21].  
 One surprising gene that was markedly and consistently induced by all fatty 
acids was Zbtb16/PLZF, encoding a transcription factor that controls the 
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development of effector functions in Natural Killer T (NKT) cells [2]. NKT 
cells represent an unique subset of lymphocytes that are reactive to so called 
lipid antigens, which include a broad range of microbial lipids that are unique 
structures of specific microorganisms. Based on its sensitive regulation by fatty 
acids, one could speculate whether Zbtb16/PLZF may link dietary lipids to 
NKT cell function. 
 Previously, we studied the impact of dietary fatty acids on gene expression 
in the liver under the same experimental settings [26]. When expressed per 
gram organ weight, the liver and heart both exhibit very high and very similar 
rates of fatty acid uptake from TG-rich lipoproteins [26]. Remarkably, the 
percentage of genes regulated by fatty acids independently of PPARα is 
considerably higher in heart compared to liver. Additionally, the panel and 
functional categories of genes regulated by fatty acids in the liver mostly 
reflects regulation of lipid metabolism, which is less the case in heart. 
Furthermore, relative inductions of PPARα target genes by dietary fatty acids 
are less pronounced in heart. Together, these data clearly demonstrate a less 
dominant role of PPARα in cardiac gene regulation by dietary fatty acids 
compared to the liver. Apart from differences in PPARα expression level 
between heart and liver, this finding may be related to differences in the route of 
uptake of fatty acids between the two tissues in the postprandial state. Whereas 
the heart takes up dietary fatty acids as non-esterified fatty acids after LPL-
mediated hydrolysis, the liver internalizes dietary fatty acids as TG within 
chylomicron remnant particles [3, 31]. The ability of fatty acids to directly 
activate PPARα may depend on the form in which they are presented to the cell 
[7, 27]. Free fatty acids may need to be converted to TG and undergo 
subsequent hydrolysis before they can activate PPARα. Alternatively, it is 
possible that within the heart fatty acids are more efficiently shuttled towards 
oxidative pathways to meet the high energetic demands of the contracting heart. 
 It can be argued that direct comparison of the various fatty acid treatments 
requires comparable levels of cardiac uptake of the different fatty acids. 
Unfortunately, the unavailability of radioactive triglycerides except triolein 
makes it impossible to get precise information on the kinetic behaviour of the 
fatty acids used. Our previous study did not reveal major differences in 
metabolic processing of dietary fat between WT and PPARα-/- mice and 
between different dietary fatty acids [26]. Even while assuming some 
differences exist in kinetic behaviour between the fatty acids used, they are 
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unlikely to account for the major qualitative differences in gene regulation 
between the fatty acids studied. It is difficult to directly compare our results 
with in vitro data. Lockrigde and colleagues performed microarray analysis on 
isolated cardiomyocytes treated with various fatty acids [22]. Remarkable, the 
number of genes altered by saturated fatty acids was much higher compared to 
unsaturated fatty acids. One of the limitations of this study is that we were 
unable to investigate the effects of saturated fatty acids, as triglycerides 
composed of saturated fatty acids are solid at body temperature. 
 Differential gene regulation by the various fatty acids via PPARα may be 
hypothesized to occur via the Selective PPAR Modulator (SPARM) concept, in 
which different PPARα ligands may not only give rise to quantitative 
differences but also cause qualitative differences in gene regulation due to the 
differential recruitment and release of coactivators and corepressors, 
respectively. While we previously found support for differential coactivator 
recruitment between Wy14643 and DHA, no differences were found between 
various fatty acids [26]. 
 Most of our understanding of the role of cardiac PPARα is based on studies 
of transgenic mice overexpressing PPARα in the heart. These mice are 
characterized by marked induction of genes involved in cardiac fat oxidation 
but also fatty acid uptake, resulting in cardiac lipid accumulation and 
subsequent cardiomyopathy [4, 6, 11]. A few genes within these pathways have 
been identified as direct targets of PPARα in heart. Our data underscore the 
importance of PPARα in lipid metabolism in the heart, and reveal a large 
resemblance between the PPARα transcriptome in heart and liver. Similar to the 
dietary fatty acids, Wy14643 was surprisingly much less potent in inducing 
gene expression in heart compared to liver. A possible explanation is that 
Wy14643 is taken up more poorly by the heart, although no actual data are 
available to support this notion.  
 Deletion of PPARα had a marked effect on cardiac gene regulation after a 10 
hour fast, representing the baseline condition, which suggests that 1) PPARα 
has a high constitutive activity, or 2) PPARα is already mostly ligand-activated 
after a 10 hour fast [33], which would be consistent with the high rate of fatty 
acid uptake under those conditions. Although expression of numerous genes 
involved in lipid metabolism was markedly reduced in PPARα-/- mice, this 
does not result in cardiac dysfunction, at least in the absence of an additional 
stressor [28]. 
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 Apart from metabolism related genes, many genes involved in 
inflammation/immunity were altered upon PPARα deletion. Our findings are 
supported by recent studies describing differential expression of immunity and 
cellular defence related genes in hearts of PPARα-/- mice compared to wildtype 
mice [28, 29]. Many of those genes are regulated via NF-κB, pointing towards 
transrepression by PPARα. This anti-inflammatory effect of PPARα may be 
especially relevant in the context of cardiac hypertrophy, which is characterized 
by induction of inflammatory pathways. 
 In conclusion, our study provides the first comprehensive analysis of the 
acute effects of dietary fatty acids on gene expression in the heart. The data 
demonstrate the importance of PPARα in mediating gene regulation by dietary 
fatty acids in the heart.  
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APPENDIX 
Appendix Table1: Table of genes altered by PPARα deletion or by Wy14643 and 
they are related to energy metabolism  
 
Chapter 3: Detailed transcriptomics analysis of the effect of dietary fatty acids on gene 
expression in the heart 
72 
 
 
 
Chapter 3: Detailed transcriptomics analysis of the effect of dietary fatty acids on gene 
expression in the heart 
73 
Appendix Table2: Table of genes altered by PPARα deletion or by Wy14643 and 
they are related to inflammation and immunity 
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Appendix Figure 1: Correlation plot of PPARα dependent genes and PPARα 
independent genes, showing correlation in gene expression between individual 
mice. Signal log ratios were calculated between intensity values for individual animals 
and the mean intensity value of the control group. Signal log ratios of genes 
significantly regulated by at least one treatment were used as input for a correlation plot. 
Red indicates high correlation, blue indicates weak correlation. 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Induction of Cardiac Angptl4 by Dietary 
Fatty Acids Is Mediated by Peroxisome 
Proliferator-Activated Receptor β/δ and 
Protects Against Fatty Acid–Induced 
Oxidative Stress 
 
Anastasia Georgiadi, Laeticia Lichtenstein, Tatjana  Degenhardt, Mark 
V. Boekschoten, Mark van Bilsen, Beatrice Desvergne, Michael Müller 
and Sander Kersten  
 
 
 
 
 
 
Chapter published in Circulation Research 2010 Jun 11;106(11):1712-21 
 
Chapter 4: Induction of cardiac Angptl4 by dietary fatty acids is mediated by PPARβ/δ 
and protects against fatty acid induced oxidative stress 
78 
Abstract 
Although dietary fatty acids are a major fuel for the heart, little is known about 
the direct effects of dietary fatty acids on gene regulation in the intact heart. 
Objective: To study the effect of dietary fatty acids on cardiac gene expression 
and explore the functional consequences. Methods and Results: Oral 
administration of synthetic triglycerides composed of one single fatty acid 
altered cardiac expression of numerous genes, many of which are involved in 
the oxidative stress response. The gene most significantly and consistently 
upregulated by dietary fatty acids encoded Angiopoietin-like protein (Angptl)-4, 
a circulating inhibitor of lipoprotein lipase expressed by cardiomyocytes. 
Induction of Angptl4 by the fatty acid linolenic acid was specifically abolished 
in peroxisome proliferator-activated receptor (PPAR)β/δ−/− and not PPARα−/− 
mice and was blunted on siRNA-mediated PPARβ/δ knockdown in cultured 
cardiomyocytes. Consistent with these data, linolenic acid stimulated binding of 
PPARβ/δ but not PPARα to the Angptl4 gene. Upregulation of Angptl4 resulted 
in decreased cardiac uptake of plasma triglyceride-derived fatty acids and 
decreased fatty acid-induced oxidative stress and lipid peroxidation. In contrast, 
Angptl4 deletion led to enhanced oxidative stress in the heart, both after an 
acute oral fat load and after prolonged high fat feeding. Conclusions: 
Stimulation of cardiac Angptl4 gene expression by dietary fatty acids and via 
PPARβ/δ is part of a feedback mechanism aimed at protecting the heart against 
lipid overload and consequently fatty acid–induced oxidative stress. 
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Introduction  
 Cardiac contractility is dependent on the adequate delivery of oxygen and 
energy substrates to the heart followed by their efficient metabolic degradation 
to yield ATP. The energy requirements of the contracting heart are primarily 
met by fatty acid oxidation, with the remainder of energy coming from glucose 
and lactate [1,2]. Although fatty acids are thus of major importance to the heart, 
excessive uptake of fatty acids causes lipid overload or lipotoxicity and may 
compromise cardiac function, possibly leading to cardiomyopathy [3]. 
Consequently, cardiac uptake of fatty acids needs to be well adjusted to fatty 
acid utilization. Because most of the fatty acids taken up by the heart are 
derived from lipoprotein lipase (LPL)-dependent hydrolysis of circulating 
triglyceride-rich lipoproteins [4] the activity of LPL needs to be carefully 
regulated via specific activators and inhibitors, especially after a fatty meal. 
 Besides serving as a major fuel for the heart and a potential lipotoxic 
substrate, fatty acids are able to regulate gene expression [5]. In vitro 
experiments in rat cardiomyocytes have shown that fatty acids increase 
expression of uncoupling protein 2, carnitine palmitoyltransferase 1, fatty acid 
transporter Cd36, fatty acid binding protein 3, acyl-coenzyme (Co)A synthetase 
long-chain family member 1, acyl-CoA thioesterase, and long chain acyl-CoA 
dehydrogenase [6–9]. As these genes all represent target genes of peroxisome 
proliferator-activated receptor (PPAR)α [10,11] they suggest an important role 
of PPARα in fatty acid-dependent gene regulation in the heart [12]. However, 
little is known about the direct effects of dietary fatty acids on gene expression 
in the intact heart. In addition, it is unclear what pathways are activated by fatty 
acids besides their own catabolism. 
 Here we studied the comprehensive effects of dietary fatty acids on cardiac 
gene expression in vivo by giving mice a single oral bolus of synthetic 
triglyceride composed entirely of one single fatty acid, which were either 
linolenic acid (C18:3), linoleic acid (C18:2) or oleic acid (C18:1). Subsequent 
microarrays analysis yielded Angptl4 as the gene most highly induced in the 
heart after oral fat administration. The collective data suggest that induction of 
Angptl4 by dietary fatty acids is mediated by PPARβ/δ and is part of a feedback 
mechanism aimed at protecting cardiomyocytes against lipid overload and 
consequently fatty acid–induced oxidative stress, eg, lipotoxicity. 
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Methods 
Materials: GW501516 was purchased from Alexis (Axxora, Raamsdonkveer, 
The Netherlands). Wy14643 was obtained from Eagle Picher Technologies 
laboratories (Lenexa, Kan). Trilinolein (9c,12c) and trilinolein (9c,12c,15c) 
were from Larodan Free Chemicals (Malmo, Sweden). SYBR green was from 
Eurogentec (Seraing, Belgium), and all other chemicals were from Sigma 
(Zwijndrecht, The Netherlands).  
Animals: Pure-bred Sv129 PPARα−/− mice (129S4/SvJae) and corresponding 
wild-type mice (129S1/SvImJ) were purchased from Jackson Laboratory (Bar 
Harbor, Maine). The Angptl4−/− and transgenic mice were on C57Bl/6 
background and have been previously described [13,14]. The PPARβ/δ−/− mice 
were on a mixed background (Sv129/C57Bl/6) and have been previously 
described [15]. Males mice were used at 2.5 to 4 months of age. Mice were 
anesthetized with a mixture of isoflurane (1,5%), nitrous oxide (70%), and 
oxygen (30%). Blood was collected via orbital puncture into EDTA tubes. After 
euthanasia, the hearts were excised and stored in −80°C. The animal studies 
were approved by Animal Ethics Committee of Wageningen University and the 
University of Lausanne, Switzerland.  
Oral Lipid Load: Starting at 5:00 am, the animals were fasted for 4 hours, 
followed by an intragastric gavage of 400 μL of synthetic triglyceride (triolein, 
trilinolein, and trilinolein). The control group received only 
carboxymethylcellulose (CMC). The mice were killed 6 hours thereafter. Four 
to 5 mice per group were used.  
High-Fat Diet: Angptl4-/-, +/+, and transgenic mice on C57Bl/6 background 
received a low-fat diet (LFD) or high-fat diet (HFD) for 8 weeks, providing 10 
or 45 energy percent in the form of triglycerides, respectively (D12450B or 
D12451, Research Diets, New Brunswick). The major source of fat in the diet 
was palm oil, with 5 energy percent provided as soybean oil.  
Cell Culture: Neonatal cardiomyocytes were isolated and cultured as described 
using differential plating to separate myocytes from nonmyocytes [16]. The 
experiments were approved by the Animal Ethics Committee of Maastricht 
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University. Neonatal cardiomyocytes were incubated with 1 μmol/L GW501516 
or 62.5 μmol/L, 125 μmol/L, or 250 μmol/L linolenic for 6 hours as previously 
described [17]. In a second experiment, cardiomyocytes were incubated with 1 
μmol/L GW501516, 10 μmol/L Wy14643, or 250 μmol/L linolenic acid for 24 
hours.  
Plasma Lipid Parameters: Plasma was obtained from blood by centrifugation 
for 10 minutes at 10,000 g. The plasma free fatty acids and triglyceride 
concentration were determined using kits from Instruchemie (Delfzijl, The 
Netherlands).  
RNA isolation and qRT-PCR: Total RNA was isolated with TRIzol Reagent 
(Invitrogen, Breda, the Netherlands). 1μg of total RNA for the in vivo studies 
and 350ng of total RNA for the in vitro experiment was reverse transcribed 
using iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA was amplified on 
BioRad MyIQ or iCycler machine using Platinum Taq polymerase (Invitrogen, 
Breda, the Netherlands). PCR primer sequences were taken from the 
PrimerBank and ordered from Eurogentec (Seraing, Belgium). Sequences of the 
primers used are presented on Table I. To compare expression of the three 
PPAR isotypes in adult mouse heart and in rat neonatal cardiomyocytes, 
primers were used that yielded amplicons of equal length. A standard curve was 
included to confirm an amplification efficiency of 100%±2 for all PPARs and 
for the 18S control gene. PPAR expression was calculated as 1/(2^(CtPPAR-
Ct18S)), allowing for direct comparison between the PPAR isotypes (Appendix 
Figure 3) 
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Chromatin immunoprecipitation assay (ChIP): Wildtype C57Bl/6 mice were 
fasted for 4 hours followed by an oral gavage of Trilinolenin (n=3). Six hours 
thereafter the mice were killed by cervical dislocation and the hearts excised. 
The fresh hearts were cut into half and placed into PBS containing 1% 
formaldehyde. Crosslinking was stopped after 15 min by adding glycine to a 
final concentration of 0.125M for 5 min at room temperature. The samples were 
centrifuged for 5 min at 700 g at 4 °C to collect the heart pieces, the supernatant 
was removed and washed once again with ice-cold PBS. Fresh PBS containing 
protease inhibitors (Roche, Almere, Netherlands) was added and the tissue was 
disaggregated with a homogenizer Ultra Turrax T25 basic (Ika Werke, Staufen, 
Germany). The tissue was distributed into 3 tubes (2 mL each), centrifuged for 
5 min at 700 g at 4°C. After the supernatant was removed, heart homogenate 
was resuspended in lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-HCl pH 
8.1, protease inhibitors) and the lysates were sonicated with a Bioruptor TM 
(Diagenode, Liège, Belgium) to achieve a DNA length of 300- 800 bp. After 
removal of cellular debris by centrifugation, supernatants were diluted 1:10 in 
ChIP dilution buffer (150mM NaCl, 1% Triton X-100, 2mM EDTA, 20 mM 
Tris-HCl pH 7.5, protease inhibitors). Chromatin was incubated overnight at 
4oC with 2μg antibody, 25μl BSA (100 mg/ml) and 2.4μl sonicated salmon 
sperm (10 mg/ml). The following antibodies were used: anti-PPARα (sc-9000), 
and anti-PPARβ/δ (sc-7197). All were obtained by Santa Cruz Biotechnologies 
(Heidelberg, Germany). Immunocomplexes were collected with 25μl 
MagaCell® Protein A Magnetic beads (Isogen Life Science) for 1hour at room 
temperature, and subsequently washed with 700μL of the following buffers: 
ChIP was buffer 1 (150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 20 mM 
Tris-HCl pH 8, protease inhibitors) two times, ChIP wash buffer 2 (500mM 
NaCl, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, protease 
inhibitors), ChIP wash buffer 3 (250 mM LiCi, 1% NP40, 1% Deoxycholate, 
1mM EDTA, 10 mM Tris-HCl pH 8), two times TE buffer (1 mM EDTA, 10 
mM Tris-HCl pH 8). Elution of immucomplexes were carried out in 250μL 
elution buffer (10 mM EDTA, 0.5% SDS, 25mM Tris-HCl pH 7.5) at 64oC for 
30 min. After collection of supernatant, elution was repeated with 250μl elution 
buffer at room temperature for 2 min. After combining the supernatants, cross-
linking was reversed at 64oC overnight with 2.5μl Proteinase K (20 mg/ml) for 
digestion of any remaining proteins. Genomic DNA fragments were recovered 
by phenol-chloroform extraction with phase lock gel (Eppendorf, Wesseling-
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Berzdorf, Germany), followed by salt-ethanol precipitation. Samples were 
diluted in sterile H2O, and analyzed with qPCR. The ChIP data are normalized 
against IgG to account for non-specific immunoprecipitation. A fold-enrichment 
value of 1 represents baseline thus no enrichment and no specific precipitation. 
Primers were chosen to study binding of PPARs to the transcriptional start site 
of the Angptl4 and Ucp3 genes, and to the previously identified PPRE within 
intron 3 of the Angptl4 gene. The ribosomal phosphoprotein P0 (Rplp0) was 
used as negative control for PPAR binding. The sequences of primers used in 
ChIP were as follows: Ucp3-TSS:(For:5’-GAGCCCCAGGTCACGGAAG-
3’,Rev:5’CTGTGCGTCTAGCCAAGGTTG-3’), 
Angptl4-TSS:(For:5’CCAGCAAGTTCATCTCGTCC-3’, 
Rev:5’TCCCTCCCACTCCCACACC-3’),  
Angptl4:PPRE:(For:5’TCTGGGTCTGCCCCCACTCCTGG-3’ 
,Rev:5’GTGTGTGTGTGGGATACGGCTAT-3’),Rplp0(For:5’–
CGAGGACCGCCTGGTTCTC-3’,Rev:5’–GTCACTGGGGAGAGAGAGG- 
3’). 
In Vivo Clearance of very low density lipoprotein (VLDL)-Like Emulsion 
Particles: Tissue uptake of [
3
H]-labeled TG packaged into VLDL-like emulsion 
particles was measured as previously described [21]. The data shown represent 
the percentage of injected radioactivity taken up by the heart after 30 min 
Immunohistochemistry : Deep frozen tissues (-80ºC) were cryosectioned 
(5μm) with a cryostat (Leica, CM1900 UV). Immunostaining of protein adducts 
of the lipid peroxidation byproduct 4-hydroxy-2-nonenal (4-HNE) was 
performed on freshly cut frozen sections using a rabbit polyclonal antibody 
(Calbiochem, San Diego, CA, USA). All steps were carried out at room 
temperature. The tissue was fixed in 70% ethanol for 3 min and then rinsed in 
PBS 1X for 3 min. To block endogenous peroxidase activity, slides were 
incubated with 3% H2O2 for 10 min. Incubation with the primary antibody 
(rabbit anti 4-HNE protein-adducts, 1:50 dilution in PBS 1X) was performed for 
1h. After rinsing with PBS 1X, tissue was incubated for 45 min with the 
secondary antibody (Dako EnVision+® System Labelled Polymer-HRP 
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AntiRabbit). Visualization of the complex was carried out using AEC substrate 
chromogen (Dako Cytomation) for 15 minutes. Sections were mounted with 
Kaiser’s glycerol gelatin mounting medium (Merck KGaA, Darmstadt, 
Germany). Normal rabbit serum was used as a negative control (Vector 
Laboratories). Immunostaining of Angptl4 in human heart was performed using 
an antibody directed against the C-terminus of Angptl4. Five-micrometer 
sections of paraffin-embedded human heart were mounted on Superfrost 
microscope slides. These sections were dewaxed in xylene and rehydrated in a 
series of graded alcohols. To block endogenous peroxidase activity, slides were 
incubated with 3% H2O2 for 20 min. Antigen retrieval was performed by 
placing the slides in citrate buffer (pH 6.0) and heat them in a microwave oven 
5 min 700 W (without lid) and 4 times 5 min 500 W (with lid). After cooling 
down to room temperature, the sections were briefly washed with PBS. Prior to 
staining, a 20 min preincubation was performed using 20% normal goat serum 
(Vector Laboratories, Burlingame, CA, USA). Incubation with the primary 
antibody (1:50) was performed for 1h. After rinsing with PBS 1X, tissue was 
incubated for 45 min with the secondary antibody (Dako EnVision+® System 
Labelled Polymer-HRP AntiRabbit). Visualization of the complex was carried 
out using AEC substrate chromogen (Dako Cytomation) for 15 minutes. After 
counterstaining with Meyer’s hematoxylin, sections were mounted with DePex 
mounting medium (Gurr, BDH, Poole, Dorset, UK). Negative control staining 
was performed using only the secondary antibody. 
Tissue homigenization and quantification of oxidative stress: The extent of 
lipid peroxidation in heart homogenates was determined by measuring the levels 
of hydroxynonenal-histidine (HNE-His) protein adducts and malondialdehyde 
(MDA) adducts. 25mg of heart tissue were homogenized in 250μL of tissue 
homogenation buffer (1mM EDTA, PBS 1X pH 7.4 containing protease 
inhibitors). Heart tissue was homogenized over ice by needle sonication for 
15sec at 40V. Heart homogenates were centrifuged at 1600xg for 10min at 4ºC. 
Protein content was determined in tissue supernatants by BCA Protein assay 
reagent. Starting from a protein concentration of 10 μg/mL 4-HNE-His protein 
adducts and MDA adducts content were quantified using the Oxiselect HNE-
His Adduct ELISA kit (Cell Biolabs Inc., San Diego, USA) and MDA Adduct 
ELISA kit (Cell Biolabs Inc.), respectively. The quantity of HNE-His protein 
adducts was determined by using a standard curve containing known amounts 
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of HNE-BSA (0-10μg/ml). For the quantification of MDA adducts a standard 
curve of known amounts of MDA-BSA (0-120pmol/mg) was used. 
Tissue triglyceride content: Triglycerides content was measured in tissue 
homogenates with Triglyceride LiquiColor® Test (Mono) HUMAN GmbH, kit 
(Instruchemie, Delfzijl, The Netherlands). 5% tissue homogenates were 
prepared by needle sonication over ice in tissue homogenization buffer 
consisting of 10mM Tris, 2mM EDTA, 0.25M sucrose pH 7.5. 
Table 1: Primer Sequences used for QPCR 
 
Affymetrix microarray and pathway analysis: Expression profiling was 
carried out on individual mouse hearts. Total RNA (5 mg) was labeled using the 
Affymetrix One-cycle Target Labeling Assay kit (Affymetrix, Santa Clara, CA). 
The correspondingly labeled RNA samples were hybridized on Affymetrix 
Mouse Genome 430 2.0 Arrays, washed, stained and scanned on an Affymetrix 
GeneChip 3000 7G scanner. Packages from the Bioconductor project, integrated 
in an in-house developed on-line management and analysis database for 
multiplatform microarray experiments, were used for analyzing the scanned 
arrays [54]. Probesets were redefined according to Dai et al. as the genome 
information utilized by Affymetrix at the time of designing the arrays is not 
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current anymore, resulting in unreliable reconstruction of expression levels [55]. 
In this study probes were reorganized based on the Entrez Gene database, build 
36, version 2 (remapped CDF v10). Expression estimates were obtained by GC-
robust multi-array (GCRMA) analysis, employing the empirical Bayes approach 
for background adjustment, followed by quantile normalization and 
summarization. Differentially expressed probesets were identified using linear 
models, applying moderated t-statistics that implement empirical Bayes 
regularisation of standard errors [56]. A probeset was found to be significantly 
changed after treatment if p<0.05. For the pathway analysis ingenuity software 
version 6.5 was used. 
siRNA-mediated silencing of PPARα and PPARβ/δ in H9c2 
cardiomyocytes: H9c2 cardiomyoblasts at passage number 18 were seeded at a 
density of 40000 cells/well in 6-well plates and subsequently grown for 24h in 
DMEM, antibiotic-free medium containing 10% FCS. After 24h, cells were 
transfected for 72h with siRNA molecule (100pmol/ml) according to the 
DharmaFECT 1 siRNA Transfection Protocol Thermo Scientific for H9c2. The 
siRNA oligos used were selected from a set of 4 individual sequences (ON-
TARGETplus Set of 4) designed by Dharmacon that we tested for efficient 
silencing of PPARα and PPARβ/δ expression in H9c2 cells. The final target 
sequence used for PPARα was 5’- UCACCGAGCUCACGGAAUU-3’ and for 
PPARβ/δ 5’-CAUGAGUUCUUGCGCAGUA- 3’. Transfection medium was 
replaced with DMEM, antibiotic-free medium containing 10% FCS 48h after 
the siRNA transfection. After 72h, linolenic acid (250 μM) was added for 6h, 
followed by harvesting of the cells. Cell viability was assessed with trypan blue 
and exceeded 80 % 
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Results 
Dietary Fatty Acids Have a Major Impact on Cardiac Gene 
Expression 
 To study the acute effects of dietary fatty acids on cardiac gene expression in 
vivo, SV129 mice were given a single oral gavage of synthetic TGs composed 
entirely of either C18:1, C18:2, or C18:3 [18], thus mimicking a postprandial 
lipid challenge. Animals receiving carboxymethylcellulose were used as control 
to study the absolute effect of dietary fatty acids. Expression profiling was 
carried out on individual mouse hearts collected 6 hours after the gavage using 
Affymetrix Mouse Genome 430 2.0 Arrays. Pathway analysis using Ingenuity 
revealed that the dominant pathway affected by the oral fat load was nuclear 
factor-like 2 (Nrf2)-related oxidative stress, indicating that the fatty acids 
induced oxidative stress (Appendix Figure 1). This was supported by 
examination of the top 20 of upregulated genes, most of which were involved in 
the oxidative stress response, including uncoupling protein 3 (Ucp3), heme 
oxygenase 1 (Hmox1), FK506 binding protein 5 (Fkbp5), lipocalin 2 (Lcn2), 
glutathione S-transferase A3 (Gsta3), and metallothionein 2 (Mt2) (Figure 1). A 
large correspondence in gene regulation between the fatty acids was observed, 
especially between C18:2 and C18:3. Indeed, scatter plot analysis indicated that 
the effects of C18:2 and C18:3 on cardiac gene expression were remarkably 
similar, whereas effects of C18:1 were somewhat different (Appendix Figure 2). 
Therefore, the remainder of the present article focuses on effects of C18:3. 
 Apart from genes involved in the oxidative stress response, various genes 
involved in lipid metabolism were also induced by the fatty acids. Interestingly, 
the gene most significantly and consistently upregulated by each of the dietary 
fatty acids was Angptl4 (Figure 1), which encodes a secreted protein involved 
in the regulation of plasma triglyceride levels. Previous studies have shown that 
Angptl4 potently inhibits LPL and accordingly plasma triglyceride clearance by 
converting active LPL-dimers into inactive LPL-monomers [19–21]. 
 Although Angptl4 is known to be expressed in heart [22,23] the specific 
cardiac cell types that produce Angptl4 remain unclear. Accordingly, we 
performed immunohistological staining of Angptl4 in human heart samples. 
The results reveal the presence of Angptl4 protein in cardiomyocytes and 
vascular smooth muscle cells but not endothelial cells and fibroblasts (Figure 
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2A). Significant production of Angptl4 by cardiomyocytes was confirmed by 
the relatively low Ct values for amplification of Angptl4 cDNA from rat 
cardiomyocytes (Ct 22 to 23, data not shown). 
 
 
Figure 1: Cardiac Angptl4 expression is highly sensitive to dietary fatty acids. Top 
20 of genes upregulated after oral gavage of synthetic triglyceride composed of either 
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linolenic acid (C18:3), linoleic acid (C18:2), or oleic acid (C18:1). The heat maps were 
generated directly from the GCRMA normalized microarray data. Genes are ranked 
according to mean fold change with wild-type mice receiving CMC serving as control. 
Only probe sets showing significant upregulation by the different fatty acids were 
included in the analysis (P<0.05).  
 
 
Figure 2: Angptl4 protein localizes specifically to the cardiomyocytes and not to 
endothelial cells. A. High-magnification image (×200) of the human heart tissue 
stained with an antibody against Angptl4 (bottom) or negative control (top). Arrows 
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point to endothelial cells (EC), vascular smooth muscle cells (VSM), and 
cardiomyocytes (CM). (Inset) The antibody used specifically recognizes human 
Angptl4. HEK293 cells were transfected with an expression vector encoding hAngptl4 
and the medium was collected and used for immunoblotting. The protein recognizes the 
C-terminal portion of Angptl4 generated by endogenous proteolytic cleavage. B. mRNA 
expression of the 3 PPARs in adult mouse heart and rat neonatal cardiomyocytes as 
determined by quantitative PCR. Error bars represent SEM. A standard curve was 
included to confirm an amplification efficiency of 100±2% for all PPARs (Appendix 
Figure 3). PPAR expression was calculated as 1/[−2^(CtPPAR−Ct18S)], allowing for 
direct comparison between the PPAR isotypes.  
 
Regulation of Angptl4 by Dietary PUFA Is Entirely Mediated by 
PPARβ/δ 
 Long-chain fatty acids are bona fide ligands for PPARs. The previous 
demonstration that Angptl4 is a direct PPAR target gene prompted us to 
investigate the role of PPARs in Angptl4 gene regulation by dietary fatty acids. 
We first determined the relative expression of PPARs in mouse heart. All three 
PPAR isotypes were well expressed in heart, with expression of PPARγ and 
PPARβ/δ being ≈50% of PPARα (Figure 2B). In cultured neonatal rat 
cardiomyocytes, expression of PPARγ was markedly lower compared to both 
PPARα and PPARβ/δ (Figure 2B). Because PPARγ appears to be rather 
insensitive to (dietary) fatty acids, [24] we focused our studies on PPARα and 
PPARβ/δ. PPARα−/− mice, PPARβ/δ−/− mice, and the corresponding wild-type 
mice were given an oral gavage of C18:3 as synthetic TG. Hearts were collected 
6 hours thereafter for analysis of gene expression by quantitative PCR. 
Remarkably, upregulation of Angptl4 by C18:3 was entirely abolished in the 
PPARβ/δ−/− mice, whereas it was retained in the PPARα−/− mice (Figure 3A). 
In contrast, upregulation of Ucp3, another well-characterized PPAR target gene, 
was retained in PPARβ/δ−/− mice and completely abolished in PPARα−/− mice 
(Figure 3B). No compensatory increase in PPARβ/δ and PPARα expression was 
observed in PPARα−/− and PPARβ/δ−/− mice, respectively (Appendix Figure 
4) 
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 To examine whether regulation of Angptl4 by PPARβ/δ and not PPARα was 
supported by binding of PPARβ/δ to the Angptl4 gene, we performed chromatin 
immunoprecipitation (ChIP). Previously, we located the response element 
responsible for PPAR-mediated upregulation to intron 3 of the Angptl4 gene 
[25]. Consistent with data on Angptl4 gene regulation, ChIP on hearts of wild-
type mice six hours after oral gavage of C18:3 showed enhanced binding of 
PPARβ/δ but not PPARα to the intronic PPRE (Figure 3C). 
 Nuclear receptors and other transcription factors bound to such distal sites 
likely contact the basal transcription machinery via DNA looping, and 
accordingly binding of PPAR to distant PPREs can be demonstrated by showing 
cross-linking of PPAR to the transcriptional start site (TSS) [26,27]. Indeed, 
oral gavage of C18:3 enhanced binding of PPARβ/δ but not PPARα to TSS of 
the Angptl4 gene (Figure 3D), whereas C18:3 enhanced binding of PPARα but 
not PPARβ/δ to the TSS of the Ucp3 gene (Figure 3E). No binding of either 
PPARα or PPARβ/δ to the negative control gene Rplp0 was observed (Figure 
3F). These results demonstrate that the induction of cardiac Angptl4 gene 
expression by dietary C18:3 is mediated by PPARβ/δ. 
 The fatty acid- and PPARβ/δ-mediated induction of cardiac Angptl4 
expression likely occurred in cardiomyocytes, as treatment of rat neonatal 
cardiomyocytes for 6 hours with C18:3 dose-dependently increased Angptl4 
mRNA, which at the highest concentration was equivalent to that obtained 
using GW501516 (Figure 3G). To further investigate the specific role of 
PPARβ/δ in Angptl4 upregulation by fatty acids in cardiomyocytes, we 
knocked-down PPARα or PPARβ/δ in the cardiomyocyte cell line H9c2, which 
expresses both receptors, using siRNA and studied the effect on Angptl4 gene 
induction by C18:3 (Figure 3H). We observed that knock-down of PPARβ/δ 
almost entirely abolished the induction of Angptl4 gene expression by C18:3, 
whereas knock-down of PPARα had little to no effect (Figure 3I). 
 Our results do not imply that Angptl4 is an exclusive target gene of 
PPARβ/δ under any type of circumstances. Indeed, we find that in rat neonatal 
cardiomyocytes, Angptl4 is induced to a similar extent by synthetic PPARα and 
PPARβ/δ agonists, as are other cardiac PPAR targets such as Acsl1 and Acox1 
(Figure 3J). Instead, our data suggest that the stimulatory effect of dietary fatty 
acids on cardiac Angptl4 expression is mediated specifically by PPARβ/δ. 
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Figure 3: PPARβ/δ but not PPARα mediates the induction of Angtpl4 expression 
by dietary linolenic acid. Wild-type, PPARα−/−, and PPARβ/δ−/− mice were given a 
single oral gavage of 0.5% CMC (open bars) or synthetic triglycerides composed 
entirely of C18:3 (closed bars). mRNA expression levels of Angptl4 (A) and Ucp3 (B) 
were determined in mouse heart using real-time PCR. Results are expressed as fold 
change compared to the wild-type control mice. C through F, ChIP was performed on 
hearts of wild-type mice given an oral gavage of either CMC or C18:3. Chromatin was 
precipitated using antibodies against PPARα or PPARβ/δ. Rabbit IgG was used as a 
specificity control. Real-time quantitative PCR was performed on reverse–cross-linked 
chromatin templates using primers specific to the known PPRE in intron 3 of the 
Angptl4 gene (C), the TSS of Angptl4 (D), the TSS of Ucp3 (E), and the negative 
control gene RpLp0 (F). G, Angptl4 expression in rat neonatal cardiomyocytes 
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incubated with increasing concentrations of linolenic acid (0, 62.5, 125, and 250 
μmol/L) or GW501516 (1 μmol/L) for 6 hours. H. Expression of PPARα and PPARβ/δ 
in H9c2 cardiomyocytes transfected with siRNA against PPARα and PPARβ/δ. I. Fold 
induction of Angptl4 expression by 6 hours of linolenic acid treatment (250 μmol/L) in 
H9c2 cardiomyocytes transfected with siRNA against PPARα and PPARβ/δ. J. 
Expression of Angptl4 and known PPAR targets Acsl1 and Acox1 in rat neonatal 
cardiomyocytes incubated for 24 hours with linolenic acid (250 μmol/L), GW501516 (1 
μmol/L), or Wy14643 (10 μmol/L). Error bars represent SEM. Statistical significance 
was determined with a Student’s t test (P<0.05).  
 
Induction of Angptl4 Protects Against Fatty Acid–Induced Oxidative 
Stress 
 To study the effect of Angptl4 on the metabolic response to dietary fat, we 
performed the oral fat load with C18:3 triglyceride in wild-type, Angptl4−/− 
and Angptl4 transgenic (Angptl4-Tg) mice. In agreement with inhibition of LPL 
by Angptl4, the postprandial increase in plasma triglyceride was dramatically 
increased in Angptl4-Tg mice, whereas it was entirely blunted in Angptl4−/− 
mice (Figure 4A). Consistent with LPL inhibition, Angptl4 overexpression 
markedly reduced cardiac fatty acid uptake from [3H]triolein-labeled very-low-
density lipoprotein (VLDL)-like particles (Figure 4B). These results suggest 
that upregulation of Angptl4 by dietary fatty acids will lead to reduced cardiac 
uptake of fatty acids via inhibition of LPL, thereby suppressing the stimulus that 
led to induction of Angptl4 expression. 
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Figure 4: Angptl4 overexpression raises postprandial plasma triglyceride levels 
and decreases cardiac fatty acid uptake. A. Wild-type (gray squares), Angptl4−/− 
(open squares), and Angptl4-Tg (black squares) mice were given a single oral gavage of 
synthetic triglyceride (TG) composed entirely of C18:3. Plasma triglycerides were 
determined in blood collected via the tail vein. B. [3H]-labeled triolein was incorporated 
into VLDL-like emulsion particles and directly injected into the tail vein of wild-type 
and Angptl4-Tg mice. The heart was collected 30 minutes after the injection for 
determination of radioactivity. *Significantly different between wild-type and Angptl4-
Tg mice according to Student’s t test (P<0.05). Error bars represent SEM.  
 
 To examine whether the inhibitory effect of Angptl4 on cardiac fatty acid 
uptake is associated with reduced fatty acid-induced oxidative stress, expression 
of Fkbp5, Lcn2, and Gsta3 was determined 6 hours after oral gavage with either 
control treatment (CMC) or C18:3 triglyceride in wild-type, Angptl4−/− and 
Angptl4-Tg mice. All three genes represent markers of oxidative stress [28–30]. 
Consistent with a protective role of Angptl4 against fatty acid-induced oxidative 
stress, the magnitude of induction of Fkbp5, Lcn2, and Gsta3 by C18:3 was 
dependent on Angptl4 genotype and inversely correlated with Angptl4 
expression (Figure 5A and 5B). Expression of Fkbp5, Lcn2, and Gsta3 after the 
oral fat load was not related to plasma free fatty acid (FFA) levels, which 
followed an opposite pattern (Figure 5C). Expression of the endoplasmic 
reticulum stress marker Herpud1 mimicked the pattern of oxidative stress 
markers (Figure 5A). 
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Figure 5: Markers of oxidative stress are inversely correlated with Angptl4 
expression after oral fat load. Wild-type, Angptl4−/−, and Angptl4-Tg mice were 
given a single oral gavage of 0.5% CMC (open bars) or synthetic triglyceride composed 
entirely of C18:3 (closed bars). Mice were euthanized 6 hours later. A. mRNA 
expression levels of oxidative stress genes Fkbp5, Lcn2, and Gsta3 and endoplasmic 
reticulum stress marker gene Herpud1, as determined by real-time PCR. B. mRNA 
expression levels of Angptl4. C. Plasma levels of FFA and TG. Differences were 
evaluated statistically using two-way ANOVA. Significance (probability value) of 
effect of genotype (G), treatment (T), and interaction (I) between genotype and 
treatment is indicated in each graph. n.s. indicates non significant. Error bars represent 
SEM.  
 
 Finally, we examined whether Angptl4 may exert a similar effect in the 
context of a chronic fat overload. To that end, we measured expression of the 
oxidative stress markers and performed immunohistochemical and quantitative 
analysis of 4-HNE protein adducts in wild-type and Angptl4−/− mice fed a 
HFD for 8 weeks. 4-HNE is one of the major biologically active aldehydes 
formed during inflammation and oxidative stress. Formation of 4-HNE protein 
adducts is a marker for lipid peroxidation. 
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 Although high fat feeding did not influence expression levels of Fkbp5, 
Lcn2 and Gsta3, expression was significantly higher in Angptl4−/− mice fed 
HFD compared to wild-type mice fed HFD (Figure 6A). A similar tendency was 
observed for Herpud1. Furthermore, lipid peroxidation was increased in 
Angptl4−/− mice fed HFD, as shown by enhanced 4-HNE staining (Figure 6B). 
These results were supported by quantitative analysis of 4HNE protein adducts 
(Figure 6C) and MDA adducts (Figure 6D), which were significantly increased 
in Angptl4−/− mice fed HFD compared to wild-type mice fed HFD. These data 
indicate that Angptl4 protects against oxidative stress in the context of a chronic 
fat overload. No differences in cardiac triglyceride levels were observed 
between wild-type and Angptl4−/− mice (Figure 6E). 
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Figure 6: Angptl4 protects against oxidative stress in the context of chronic fat 
overload. A. Wild-type and Angptl4−/− mice were fed a LFD or HFD for 8 weeks. 
Expression levels of Fkbp5, Lcn2, Gsta3, and Herpud1 in the heart were measured by 
real-time PCR. Results are expressed as fold change compared to wild-type mice on 
LFD. B. Immunohistochemistry of 4-HNE protein adducts in mouse cardiac tissue from 
mice fed HFD for 8 weeks. Representative sections are shown. Magnification, ×400. 
Right, Negative control obtained using rabbit serum. Quantitative measurement of 
4HNE protein adducts (C) and MDA adducts (D). E. Cardiac triglyceride content. Gray 
bars indicate wild-type mice; black bars, Angptl4−/− mice. *Significantly different 
between wild-type and Angptl4−/− mice according to Student’s t test (P<0.05). Error 
bars represent SEM.  
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Discussion 
 In the present article we show that the gene most significantly and 
consistently upregulated by short term treatment with dietary fatty acids is 
Angptl4. Induction of Angptl4 by dietary fatty acids is mediated by PPARβ/δ 
and confers a protective effect against fatty acid-induced oxidative stress by 
restricting cardiac fatty acid uptake via inhibition of LPL. Overall, our data 
suggest that upregulation of Angptl4 by fatty acids is part of a feedback 
mechanism aimed at preventing myocardial fatty acid accumulation, thereby 
minimizing lipid-induced oxidative stress and lipotoxicity (Figure 7). Although 
our follow-up studies only included linolenic acid, the results are likely 
generalizable to other dietary fatty acids. 
 Lipotoxicity describes the untoward consequences of fat overload in a 
particular tissue and may be related to fatty acid-induced oxidative stress, 
accumulation of lipotoxic intermediates such as ceramides and fatty acyl-CoA, 
and excess storage of triglycerides [31]. Chronic lipotoxicity in the heart has 
been shown to promote cardiomyopathy in several animal models [12,32–34]. 
Most of these models are characterized by a mismatch between myocardial fatty 
acid uptake and utilization, as in mice with heart-specific overexpression of 
acyl-CoA synthetase, fatty acid transport protein 1, or lipoprotein lipase [32–
34]. Although triglycerides are unlikely to be the actual culprit in cardiac 
lipotoxicity, they may be guilty by association as its levels may be positively 
correlated with lipotoxic intermediates. However, we did not see increased 
cardiac triglyceride levels in Angptl4−/− mice compared to wild-type mice after 
8 weeks of high fat feeding, suggesting that the increase in fatty acid uptake is 
limited or that the incoming fatty acids are efficiently oxidized. In the present 
study, it was not possible to investigate the effect of Angptl4 deletion on cardiac 
lipid storage, oxidative stress, and parameters of cardiac dysfunction after a 
more prolonged period of HFD, as a cachectic phenotype progressively emerges 
after 12 weeks of HFD [53]. 
 In a previous study, heart-specific Angptl4 overexpression reduced cardiac 
LPL activity and reversed the excessive lipid storage in hearts of lipotoxic acyl-
CoA synthetase transgenic mice [22]. In agreement with these data, we find that 
Angptl4 overexpression reduced cardiac fatty acid uptake and protects against 
fatty acid-induced oxidative stress. In contrast, Angptl4 deletion aggravated 
oxidative stress both acutely and after chronic HFD. Because we used whole 
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body Angptl4 overexpression and deletion models, strictly we cannot rule out 
that the observed effects may be related to changes in extracardiac Angptl4 
expression. However, the current literature mainly supports a paracrine function 
of Angptl4, and the role of Angptl4 as endocrine factor remains somewhat 
uncertain. 
 Angptl4 was discovered by screening for target genes of PPARα and PPARγ 
in liver and adipose tissue, respectively [35,36]. It is member of a family of 
angiopoietins and angiopoietin-like proteins and is produced by a variety of 
organs. Numerous studies using Angptl4 transgenic or knock-out mice have 
invariably shown a stimulatory effect of Angptl4 on plasma triglyceride levels, 
which is achieved by inhibiting LPL activity [13,14,19,22,37–40]. These data 
have established Angptl4 as an important regulator of plasma triglyceride 
levels. The present data suggest that Angptl4 is upregulated by dietary fatty 
acids to inhibit local LPL activity and consequently reduce fatty acid uptake and 
lipid-induced oxidative stress. 
 To study the role of PPARs in cardiac gene regulation by dietary fatty acids, 
we ideally should have used cardiomyocyte-specific PPAR−/− mice but 
unfortunately we did not have access to these animals. The PPAR-dependent 
upregulation of Angptl4 and Ucp3 by dietary linolenic acid underscores the 
importance of TG-rich lipoproteins as source of PPAR ligands in the heart, 
which are liberated via LPL [41,42] Remarkably, upregulation of Angptl4 by 
C18:3 in intact heart and cultured cardiomyocytes was entirely mediated by 
PPARβ/δ and not PPARα. These data were supported by ChIP data showing 
C18:3-induced binding of PPARβ/δ and not PPARα to the Angptl4 gene in the 
intact heart. Because we did not study PPARγ, strictly we cannot rule out a role 
for PPARγ in mediating the effect of (dietary) fatty acids on cardiac Angptl4 
expression. However, as similar results were obtained in cultured 
cardiomyocytes, which express little PPARγ, the data favor a specific role of 
PPARβ/δ in the regulation of cardiac Angptl4 by C18:3. It is unclear what 
mechanism may underlie the differential role of PPARβ/δ versus PPARα in 
mediating induction of Angptl4 and Ucp3 by C18:3, respectively. Induction of 
Ucp3 by linoleic acid via PPARα rules out a PPARβ/δ-specific ligand activity 
that is generated by linolenic acid in heart. Gel shift and transactivation studies 
have failed to provide convincing evidence for the existence of response 
elements or promoters that are specifically or selectively bound or regulated by 
a particular PPAR isotype [43,44]. Indeed, in vitro experiments have revealed 
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that all three PPARs are intrinsically able to (trans)activate the human and 
mouse Angptl4 gene [25]. However, the situation may be different in vivo in the 
absence of PPAR overexpression or when PPARs are activated via endogenous 
ligands rather than via high-affinity synthetic agonists. Thus, the dominant 
receptor in the regulation of a particular PPAR target is likely context- and 
tissue-dependent and additionally depends on whether PPAR is activated via 
endogenous or synthetic agonists. When as in cardiomyocytes two or more 
PPARs are expressed in the same cell and are simultaneously activated, it is 
possible that specific binding of one PPAR isotype to a particular PPRE is 
promoted via interactions with another protein that binds adjacent to the PPRE 
and is expressed in a tissue-specific manner. In this context, it is interesting to 
mention that recent genome wide profiling of PPARα and PPARγ binding sites 
revealed colocalization of PPAR binding with other transcription factor binding 
sites and demonstrated interplay between PPARs and other transcription factors 
in PPAR-mediated gene regulation [45–47]. 
 Recently, targeted PPARβ/δ overexpression in the heart was shown to have a 
clear differential effect on cardiac metabolism compared to PPARα 
overexpression [48]. In contrast to PPARα, PPARβ/δ overexpression did not 
impact fatty acid transport and failed to induce myocardial lipid accumulation. 
Based on the data presented here it can be hypothesized that PPARβ/δ is neutral 
toward cardiac lipid storage by inducing Angptl4 expression, which in turn 
feeds back on fatty acid uptake. 
 Multiple studies support an effect of Angptl4 on endothelial function, mostly 
pointing to an antiangiogenic activity of Angptl4 [49–51]. Our 
immunohistochemical results indicate that Angptl4 is absent from vascular 
endothelial cells in the heart, whereas it is abundantly present in 
cardiomyocytes. These data are in line with previous studies showing that 
Angptl4 is absent from a number of different endothelial cells, yet is 
dramatically induced under hypoxic conditions [50]. Hypoxia also upregulates 
Angptl4 in cardiomyocytes [52]. Induction of Angptl4 by hypoxia and the 
associated inhibition of fatty acid uptake may be an adaptive mechanism to shift 
fuel use toward glucose, which requires less oxygen for oxidation. 
 In conclusion, our data show that an acute oral load of triglycerides 
stimulates an oxidative stress response in the heart. The concomitant 
upregulation of Angptl4 by dietary fatty acids is mediated by PPARβ/δ and is 
part of a feedback mechanism aimed at protecting the heart against lipid 
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overload and consequently fatty acid–induced oxidative stress, one of the 
hallmarks of lipotoxic cardiomyopathy. 
 
 
Figure 7: Model of the role of Angptl4 in the heart. Triglycerides arrive at the 
heart packaged into chylomicrons or VLDL particles. Plasma triglycerides are 
hydrolyzed by lipoprotein lipase to release fatty acids, that are taken up by the 
cardiomyocyte. Excess uptake of fatty acids gives rise to oxidative stress and leads to 
induction of Angptl4 expression via PPARβ/δ. Angptl4 will feed back on fatty acid 
uptake by inhibiting lipoprotein lipase.  
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Appendix Figure 1: Induction of oxidative stress response 6 hours after the oral 
ingestion of linolenic acid (A), linoleic acid (B) or oleic acid (C). Bars show the 
percentage of upregulated genes (red) and downregulated genes (green) out of the total 
number of eligible genes for each pathway, based on the Ingenuity knowledge database. 
The white part represents the percentage of genes that do not overlap with the 
experimental dataset. The pathways are displayed from the direction of the most 
significantly regulated to least significantly regulated based on Fisher’s Exact Test p-
value (cut off p<0.05). The –log(p-value) is displayed on the top of each pathway 
(yellow square). 
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Appendix Figure 2: Similarity in cardiac gene regulation between fatty acids. 
Graphs show fold-change in gene expression after treatment with C18:3TG (y-axis) 
plotted against fold-change in gene expression after treatment with C18:2TG (A) or 
C18:1TG (B) (x axis). Analysis shows more significant similarity in gene regulation 
between C18:3 andC18:2, compared to between C18:3 and C18:1. 
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Appendix Figure 3: Equal efficiency of amplification of mPPARα, mPPARβ/δ, and 
mPPARγ in mouse heart. A standard curve was generated from cDNA prepared from 
mouse heart. cDNA wasamplified by qPCR using primers specific for the three PPAR 
isotypes. Similar efficiencies of amplification were obtained using cDNA from rat 
neonatal cardiomyocytes. 
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Appendix Figure 4: No compensatory increase in PPARβ/δ and PPARα expression 
in PPARα-/- and PPARβ/δ -/- mice, respectively. Wild type, PPARα-/-, and 
PPARβ/δ-/- were given a single oral gavage of 0.5% CMC (open bars) or synthetic TG 
composed entirely of C18:3 (closed bars). mRNA expression levels of PPARβ/δ (left 
panel) and PPARα (right panel) were determined in mouse heart using real time PCR. 
Results are expressed as fold-change compared to the WT control mice. Error bars 
represent SEM. 
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Abstract 
 
Atherosclerosis is a multi-factorial chronic disease characterized by lipid 
retention and inflammation in the arterial intima. Inflammatory activation of 
macrophages combined with increased lipid uptake leads to formation of foam 
cells, which form the core of atherosclerotic plaques. Inhibition of lipoprotein 
lipase-mediated lipolysis by the protein Angptl4 was shown to prevent 
macrophage foam cell formation in vitro, as well as in mesenteric lymph nodes 
upon high fat feeding. Accordingly, we hypothesized that Angptl4 may affect 
atherosclerosis development by reducing foam cell formation. To investigate 
this hypothesis, we studied Angptl4 expression in atherosclerotic lesions and 
macrophages and determined the effect of Angptl4 transgenic overexpression in 
atherosclerosis prone ApoE3Leiden (E3L) mice fed a Western diet containing 
0.4% cholesterol. Angptl4 was localised to macrophages in human 
atherosclerotic lesions and was regulated by inflammatory stimuli in human 
THP-1 macrophages. During the 24 weeks of diet intervention, plasma 
cholesterol and triglyceride level were not different between the two groups. 
Remarkably, Angptl4Tg.E3L mice showed a 34% decrease in lesion area 
compared to E3L mice. In addition, content of macrophages and numbers of 
adhering monocytes were decreased in Angptl4Tg.E3L mice compared to E3L 
mice. Furthermore, Angptl4 decreased uptake of oxLDL in mouse and human 
macrophages. Our results suggest that Angptl4 is involved in an anti-
inflammatory signaling that suppresses development of atherosclerosis by 
reducing foam cell formation. 
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Introduction 
Despite a major decrease in mortality from atherosclerosis in many Western 
countries in recent decades, atherosclerosis-related morbidity and mortality 
remain a major global health concern. Atherosclerosis is a multi-factorial 
chronic disease characterized by lipid retention and inflammation in the arterial 
intima, forming the so called atheromas. While traditionally atherosclerosis was 
mostly viewed as a lipid retentive disease caused by elevated plasma lipids, in 
the past two decades the interplay between inflammatory mechanisms and 
dyslipidemia in development of atherosclerosis has been increasingly 
recognized. It is well accepted that circulating monocytes responding to 
chemotactic stimuli adhere to endothelial cells and subsequently migrate into 
the sub-endothelial space where they become activated. Activated macrophages 
may subsequently accumulate lipid and become foam cells by scavenging 
oxidized lipoprotein remnants - mainly oxidised LDL (oxLDL) - trapped in the 
sub-endothelial space [1]. 
Uptake of oxLDL and formation of foam cells via macrophage scavenger 
receptors are thus considered key events in the development and progression of 
arterial intimal inflammation. According to this view, scavenger receptors are 
proatherogenic proteins, although recent data present a more complicated 
picture in which these multifunctional receptors may both protect and 
exacerbate atherosclerosis development [2-5]. Furthermore, innate immune 
mechanisms also appear to contribute to macrophage activation and subsequent 
fat accumulation in macrophages [6]. Specifically, the finding that oxidized 
lipoproteins or their component oxidized lipids may act as ligands for Toll-like 
receptors (TLRs) coupled with the recent demonstration that mice deficient in 
TLR2 or TLR4 exhibit reduced atherosclerosis points to a key role of Toll-like 
receptor signaling in atherosclerosis development [7, 8]. 
While macrophage foam cell formation has been studied primarily in the 
context of atherosclerosis, they also participate in other pathologies including 
multiple sclerosis [9], non-alcoholic fatty liver disease, and kidney disease. 
Recently, we described the accumulation of macrophage foam cells in 
mesenteric lymph nodes of mice fed a high saturated fat diet. Foam cell 
formation was specific for mice lacking Angptl4, an endogenous inhibitor of the 
triglyceride hydrolyzing enzyme lipoprotein lipase (LPL), which catalyzes 
uptake of circulating lipids into tissues [10, 11]. Specifically, the N-terminal 
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portion of Angptl4 irreversibly inhibits LPL activity by converting active LPL 
dimers into inactive monomers [10]. As a consequence, overexpression of 
Angptl4 leads to hypertriglyceridemia and reduced fatty acid uptake into 
tissues, whereas Angptl4 deletion results in lowering of circulating triglyceride 
levels [12-16]. Angptl4 is a protein secreted by a variety of tissues including 
adipose tissue, liver, skeletal muscle, and intestine. In addition, Angptl4 as well 
as LPL are well expressed in macrophages [17]. Angptl4 expression in 
macrophages is governed by PPARβ/δ and PPARγ.  
Considering the importance of foam cells in atherosclerosis and the 
stimulatory effect of LPL on atherosclerosis [18], we were interested to examine 
the potential impact of Angptl4 on atherosclerosis development. For these 
studies we took advantage of the atherosclerosis prone ApoE3Leiden (E3L) 
mouse model.  E3L mice carry a partially disabled ApoE gene that is associated 
with familial hypercholesterolemia in humans [19, 20]. E3L mice represent an 
unique human-like model for studies on atherosclerosis characterized by: 1) 
plasma cholesterol levels that are proportional to the cholesterol content in the 
diet, 2) development of diet-induced atherosclerosis in the presence of the LDL 
receptor and apoE. In the present study, we show that whole body 
overexpression of Angptl4 protects against atherosclerosis as manifested by a 
decreased size of atherosclerotic plaques. 
 
Materials and Methods 
Materials: Human Recombinant Angptl4 (full length 4487-AN) was purchased 
by R&D systems. Mouse recombinant MCP-1 was purchased by ITK 
Diagnostics, The Netherlands. Intralipid was purchased from Fresenius Kabi. 
TLR agonists were purchashed from Sigma, Fluka, Brunwich amd InvivoGen. 
Animals: Animal studies were done using pure-bred WT and Angptl4Tg mice 
on a C57BI/6 background [13]. The ApoE3Leiden were also on C57BI/6 
background (n=19-18). Mice were housed under standard conditions with a 12-
hour light/dark cycle and had free access to food and water. Female mice were 
fed a Western type diet with 15% w/w cacao butter (diet T, Hope Farms, 
Woerden, the Netherlands) supplemented with 0.4% (wt/wt) cholesterol, 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Detailed description of diet T is 
shown in Apprendix Table 1. 
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Plasma Lipids: Blood was collected into EDTA containing tubes to prevent 
coagulation. Blood samples were placed on ice and centrifuged at 4°C for 10 
minutes at 10,000 g. The plasma concentration of triglycerides was determined 
using the Triglycerides liquicolor mono kit by Instruchemie (Delfzijl, 
Netherlands). Plasma cholesterol was determined using the Elitech cholesterol 
PAP SL from Sopachem (Wageningen, Netherlands). 
Lipoproteins profiling: Plasma lipoproteins of Angptl4Tg.E3L and E3L mice 
were separated using fast liquid chromatography (FPLC). For fast protein liquid 
chromatography (FPLC) fractionation of lipoproteins, 18μl were pooled from 
each mouse up to 0.4ml per group. 0.35ml of pooled plasma was injected into a 
Superose 6B 10/300 column (GE Healthcare Bio-Sciences AB, Roosendaal, 
Netherlands) and eluted at a constant flow of 0.5 mL/minute with phosphate 
buffered saline (pH 7.4). The effluent was collected in 0.5 mL fractions and TG 
and cholesterol levels were determined as described above. 
Atherosclerosis quantification and plaque composition (immunohistology): 
After 24 weeks on diet T + 0.4% cholesterol, final blood collection was 
withdrawn from the eye, after the mice have been anaesthetized with injection 
of VDF (Vetranquil, Dormicum, Fentanyl). Mice were killed by CO2 inhalation 
and organs were perfused followed by heart perfusion with PBS. Hearts were 
isolated and later fixed in phosphate-buffered 4% formaldehyde, dehydrated, 
embedded in paraffin, and cross-sectioned (5 µm), throughout the aortic root 
area. Four sections per mouse with 50-µm intervals were used for 
atherosclerosis measurements. For further histological analysis, sections were 
stained with hematoxylin-phloxin-saffron (HPS staining). Lesions were 
categorized for severity according to the guidelines of the American Heart 
Association, adapted for mice [37, 38]. Briefly, we describe the criteria: severity 
type 0 -no lesion, type 1- early fatty streaks containing up to 10 foam cell 
macrophages in the intima, type 2- early fatty streaks with more than 10 foam 
cell macrophages in the intima, type 3- early fatty streak, containing foam cells 
in the intima, covered by a fibrous cap, type 4- advanced lesions with foam cell 
macrophages in the intima, signs of fibrosis, lipid core, but no disruption of the 
media, type 5 - advanced lesions containing foam cells in the media, presence of 
fibrosis, cholesterol clefts, mineralization, and/or necrosis. Lesion area was 
determined with Leica Qwin image analysis software (Image J). AIA 31240 
antiserum (1:3000, Accurate Chemical and Scientific, Westbury, NY) was used 
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to quantify the macrophage area and the number of monocytes adhering to the 
endothelium. Sirius Red was used to quantify the collagen area and 
M0851(1:800, Dako) against smooth muscle cell actin to quantify the smooth 
muscle cell area. 
 Paraffin preserved sections from human carotid artery embedded in paraffin 
cross sectioned (5 µm) and used for histological analysis. A general HE 
(hematoxylin eosin) staining, to visualize the structure of the tissue was 
performed. Human Antibody for Cd68 staining was purchased from Abdserotec 
and human Angptl4 antibody, which recognizes the C-terminus was a gift from 
Andrew Tan. The first day, sections were left overnight at 37
o
C. Second day, 
we performed deparafinization of the sections, followed by inhibition of 
endogenous peroxidases for 30min. Antibody for Cd68 and for Angplt4 was 
used in dilution 1:100. Staining with primary antibody was performed 
overnight. Negative control was not incubated with primary antibody. 
Secondary antibody was used in dilution 1:200 and it was applied on the 
sections for 45min. Visualization of the complex was done with DAB staining. 
Hematoxyline staining was perfomed, as well. Areas of positive staining 
obtained a brown colour. 
 
Migration assay: QCM™ Chemotaxis 96 well (5 iM) Cell Migration Assay 
Fluorimetric assay from Millipore was used. Boyden chambers with filters of 
5µm pore size were used. Mouse bone marrow cells were differentiated into 
macrophages for 9 days in DMEM medium, containing 10% heat inactivated 
FCS and 20% L929 conditioned medium. Medium was changed every day after 
day 9 and cells were used at day 12. Before the migration assay cells were 
starved from FCS for 24hrs (medium containing only 1,5% of FBS deriving 
from L929 medium). At the upper part of the filter we added 2000 cells in 
100uL serum free DMEM medium with additional 1% BSA. At the bottom part 
of the filter, we added serum free DMEM medium with additional 1% BSA, 
with or without mouse recombinant MCP-1 (5µg/ml). Migration was stopped 
after 3hours. Cells attached at the bottom of the filter were detached, via 
incubation with a detachment buffer, provided with the kit and pooled with 
those that have migrated towards the MCP-1 containing medium at the bottom 
chamber. A mix of lysis buffer/DNA binding fluorescent dye (CyQuant GR 
Dye) was added on the migrated cells for 15 min at RT. Fluorescence was 
measured at 480/520nm.  
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RNA isolation and qRT-PCR: Total RNA was isolated with TRIzol Reagent 
(Invitrogen, Breda, the Netherlands). 1µg of total RNA was reverse transcribed 
using Fermentas (Bio-Rad, Veenendaal, the Netherlands). cDNA was amplified 
on BioRad iCycler machine using Sensimix (Invitrogen, Breda, the 
Netherlands). PCR primer sequences were ordered from Eurogentec (Seraing, 
Belgium). List of primers used are shown in Table 1. 
 
Table 1: Sequences of primers used for qRT-PCR.  
Primer 
Name Forward sequence Reverse sequence 
hAngptl4 CACAGCCTGCAGACACAACTC GGAGGCCAAACTGGCTTTGC 
mAngptl4 GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG 
mPtgs2 TGAGCAACTATTCCAAACCAGC 
 
 
 
GCACGTAGTCTTCGATCACTATC 
mCxcl2 CCAACCACCAGGCTACAGG GCGTCACACTCAAGCTCTG 
mDdit3 CTGGAAGCCTGGTATGAGGAT CAGGGTCAAGAGTAGTGAAGGT 
mGdf15 CTGGCAATGCCTGAACAACG GGTCGGGACTTGGTTCTGAG 
 
Oil red O staining on fixed cells: Oil red O stock solution was prepared by 
dissolving 0.5 g oil red O (Sigma, #O0625) in 500 ml isopropanol. Oil red O 
working solution was prepared by mixing 30 ml oil red O stock with 20 ml 
dH2O, followed by filtration. Attached cells were washed twice with PBS and 
fixed for 10 min in formal calcium (4% formaldehyde, 1% CaCl2). After that 
cells were washed twice with PBS and covered with Oil Red O working 
solution for 20min, followed by two rinses with dH2O. 
Lipoprotein isolation and tritium labelling: Isolation of human lipoproteins 
was achieved by sequential ultracentrifugation at the respective density at 
40,000 rpm in a Ti-50 fixed-angle rotor (Beckman Instruments, Geneva, 
Switzerland) for 18h at 5°C, followed by dialysis at 4°C overnight against PBS, 
pH 7.4. VLDL and LDL fraction was isolated and labelled with tritium, using 
glycerol tri
3
[H]oleate (
3
[H]TO) and 
3
[H]cholesteryl oleoyl ether (
3
[H]COEth), 
respectively. Labeling protocol has been previously described [39]. Protein 
concentrations in the lipoporteins fractions were determined with BCA Pierce 
assay using a BSA standard curve. 
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Quantification of cellular uptake of tritium labelled lipoproteins: After 
incubation of macrophages with tritium labelled lipoproteins, cells were washed 
twice with 500μL PBS and cell lysates were precipitated in 500μL of 0,1M 
NaOH, with gentle shaking for 15min. 250μL of cell lysates were used for 
quantification of radioactivity. dmp values were normalised to the total amount 
of protein (mg) present in 250μL of cell lysates. Protein from cell lysates was 
quantified with BCA Pierce assay. 
LDL oxidation with CuSO4 : LDL preserved in Kbr was dialysed overnight in 
PBS. Oxidation of LDL was done with CuSO4 at a final concentration of 20uM 
for 3hours in 37
o
C. Oxidation was terminated by adding 200uM EDTA and 
palce the tube on ice. EDTA and CuSO4 were removed with overnight dialysis 
in PBS.  
Cells: Bone marrow cells were grown in DMEM +10% heat inactivated (HI) 
FCS +1% P:S with additional 20% L929 conditioned medium DMEM (10% HI 
FCS, 1% P:S), in order to stimulate macrophage differentiation. Differentiation 
was allowed up to 7-9 days. During that period fresh medium was added to the 
cells without removing the old medium. After that period medium was renewed 
every day. Bone marrow derived macrophages were used for experiments at day 
10 or 11. 
THP-1 monocytes were differentiated into macrophages after 2 days incubation 
in RPMI medium, 10% HI FCS, 1% PS containing 100ng.ml phorbol-12-
myristate-13-acetate (PMA). After 2days, PMA was washed away and THP-1 
macrophages were kept in complete medium without PMA, for 2 days further 
and then used for experiments.  
RAW 264.7 cells were grown in DMEM supplemented with 10% FCS and 1% 
P:S. 
Intralipid was purchased from Sigma and used in final concentration of 2mM. 
Recombinant Angptl4 was used in concentration 1.5ug/ml 
Activation of macrophages with TLR agonists: The different TLR agonists used 
and their concentrations are shown in Table 2 
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Table 2: Targeting receptors and experimental concentrations of TLR agonists  
TLR ligands Receptor Concentration 
TLR4 LPS 1ug/ml 
TLR1+2 Pam3Cys 1ug/ml 
TLR5 Flageline 10ng/ml 
TLR2+6 FSL-1 1ug/ml 
TLR3 Poly(I:C) 2ug/ml 
Dectrin 1+TLR2+6 b-glucan 4ug/ml 
NOD1 MTP 18nM 
NOD2 MDP 10ug/ml 
NOD1 Tri-dap 5ug/ml 
 
Results 
Angptl4 is induced by Toll- like receptors 3 and 4 in macrophages 
Previous studies have shown that Angptl4 expression is highly upregulated 
by chylomicrons and fatty acids in peritoneal macrophages [17]. In line with 
these data we observed that incubation of RAW 264.7 macrophages with a 
triglyceride emulsion, which causes foam cell formation and macrophage 
activation (Figure 1A), increases Angptl4 mRNA expression, as well as 
expression of several inflammatory markers and ER stress marker, Ddit3 
(Figure 1B). Similar results were obtained in bone marrow derived 
macrophages (BMDMs) (Figure 1C,D). To investigate whether activation of 
macrophages independent of foam cell formation may induce Angptl4 
expression, macrophages were treated with various Pattern Recognition 
Receptor (PRR) agonists. Human THP-1 macrophages were used to enable 
measurement of Angptl4 protein secretion using ELISA [21]. TLR3 and TLR4 
agonist potently induced Angptl4 mRNA and protein secretion (Figure 1E,F), 
whereas the other agonists were weak or not effective. These data show that 
macrophage activation induced by PRR agonists or lipid overload leads to 
upregulation of Angptl4 gene expression. 
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Figure 1: Angptl4 expression is induced in macrophages, after lipid overload or 
activation with TLR4 and TLR3 agonists A. Oil red O staining of RAW 264.7 mouse 
macrophages treated 6hrs with intralipid (IL) B. Mean fold change of mRNA levels of 
highly responding genes to 6 hrs intralipid (IL) treatment of RAW 264.7 cells black 
bars-IL, white bars-control C. Oil red O staining of bone marrow derived mouse 
macrophages (BMDMs) treated 6hrs with intralipid (IL) D. Mean fold change of mRNA 
levels of highly responding genes to 6 hrs intralipid (IL) treatment of bone marrow 
derived macrophages, black bars-IL, white bars-control (Mean fold change over the 
control,which is 1) E. THP-1 macrophages treated for 4h, 12h and 24h with a panel of 
TLR agonists. Human Angptl4 mRNA levels were quantified with qRT-PCR and 
expressed as mean fold change over its basal levels for each time point. F. Protein levels 
of Angptl4 were quantified with ELISA, in medium collected from THP-1 macrophages 
treated 24 hrs with different TLR agonists. Error bars represent SEM. *Significantly 
different between treatment and control, according to Student’s t-test (*P<0.05, ** 
P<0.01). 
A pathological condition characterized by macrophage activation and lipid 
overload is atherosclerosis. To study the potential role of Angptl4 in 
atherosclerosis, we first ascertained the presence of Angptl4 in human 
atherosclerotic plaques. Staining of serial sections from human carotid tissue 
with antibodies against Cd68 and Angptl4 revealed co-localization of Angptl4 
with Cd68, suggesting Angptl4 is present in macrophages (Figure 2).  
 
Figure 2: Angptl4 protein localizes to the macrophages at the arterial wall A. 
Staining of serial sections of human carotid artery. Top left, top middle: High 
magnification of x200 and x400 of section of human carotid artery stained with HE 
staining in order to inspect the structural morphology of the arterial wall. Arrows point 
to lipid-loaded macrophages (foam cells). Top right: Staining with human Cd68 
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recognizing antibody, diluted 1:100, magnification x400. Bottom right: Staining with 
human Angptl4 recognizing antibody, diluted 1:100, magnification x400. The antibody 
recognizes specifically the C-terminal portion of Angptl4. Bottom left: negative control. 
  
Overexpression of Angptl4 on an E3L background does not affect 
plasma cholesterol and triglyceride levels 
To further explore the role of Angptl4 in atherosclerosis development, we 
crossed mice with whole body overexpression of Angptl4 with ApoE3 Leiden 
(E3L) mice to generate the Angptl4Tg.E3L mice. E3L mice represent an unique 
human-like model for studies on atherosclerosis characterized by: 1) plasma 
cholesterol levels that are proportional to the cholesterol content in the diet, 2) 
development of diet-induced atherosclerosis in the presence of the LDL receptor 
and apoE. Both Angptl4Tg.E3L mice and control E3L mice were fed a Western 
type diet containing 0.4% cholesterol for 24 weeks. Weight gain was equal 
between the two groups (Figure 3A). In contrast, Angptl4Tg.E3L ate slightly 
less than the E3Lgroup (Figure 3B). After 4 weeks all animals were 
hypercholesterolemic and plasma cholesterol levels remained high until the end 
of the study. Importantly, plasma cholesterol levels were not significantly 
different between the two groups (Figure 3C). Whereas plasma triglycerides 
were increased in Angptl4Tg.E3L mice up to week 4, triglycerides subsequently 
dropped to levels that were not significantly different from the E3L group 
(Figure 3D). Elevated plasma cholesterol and triglyceride levels in 
Angptl4Tg.E3L and E3L mice could be attributed to elevated VLDL/LDL 
levels, as determined by fast liquid protein chromatography (FPLC) (Figure 
3E).  
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Figure 3: No difference in plasma cholesterol and triglyceride levels between 
Angptl4Tg.E3L and E3L after 24 weeks on Western diet + 0.4% cholesterol. A. 
Body weight, in grams, of Angptl4Tg.E3L and E3L mice after 24 weeks on a Western 
diet + 0.4% cholesterol B. Food intake expressed in grams/day C,D. Plasma cholesterol 
and triglycerides levels (mM). E. Quantification of plasma cholesterol and 
triglycerideslevels in FPLC fractions. Black squares refer to Angptl4Tg.E3L group and 
white squares to ApoE3Leiden group. Y-axis values represent mean, error bars 
represent SEM.* Significantly different between Angptl4Tg.E3L and E3L, for the 
specific time point, according to Student’s t-test (P<0.05). Numbers of animals per 
group were 16 to 18. 
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Angptl4Tg.E3Leiden mice developed smaller lesions 
 
We further investigated the severity of atherosclerosis by measuring the 
lesion area and by assigning lesions to different levels of severity based on 
cellular composition of the plaques (for criteria see Methods/Materials). 
Whereas Angptl4Tg.E3L mice developed on average an equal number of 
plaques compared to the E3L mice (Figure 4A), average lesion size was reduced 
by 34% in Angptl4Tg.E3L mice (Figure 4B). We next classified lesions 
according to severity and determined the distribution of lesions according to 
severity in the two groups. Angptl4Tg.E3L mice showed a tendency towards the 
development of less severe lesions compared to E3L mice (Figure 4C). We next 
evaluated the effect of Angptl4 overexpression on monocyte recruitment and 
lesion composition including macrophage content, collagen content and smooth 
vascular muscle cells content. Angptl4 overexpression significantly decreased 
the number of adhering monocytes to the vessel wall compared to E3L mice 
(Figure 5A). The decrease in adhering monocytes was accompanied by a 2-fold 
(P<0.05) decrease in macrophage content in the intima of Angptl4Tg.E3L mice 
(Figure 5B). No statistically significant differences in collagen and smooth 
vascular muscle cells content were observed between the two groups (Figure 
5C,D). Thus, overexpression of Angptl4 reduces lesion size compared to the 
E3L group and leads to a less inflammatory lesion phenotype characterized by 
decreased monocyte/macrophage accumulation. 
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Figure 4: Angptl4Tg.E3Leiden mice developed smaller lesions A. Average number 
of lesions in Angptl4Tg.E3L and E3L mice (E3L n=15, Angptl4Tg.E3L n=16) Number 
of lesions were counted in four sections per mouse, each of those containing three 
segments B. The total lesion area (μm2) in Angptl4Tg.E3L and E3L mice. Lesion area 
was counted in four sections (50-µm intervals) per mouse, three segments per section. 
C. Percentage of lesions per type of severity over the total number of lesions belonging 
in each type of severity are shown. Numbers of animals per group were 15-16. 
*Significantly different between Angptl4Tg.E3L and E3L group, according to Student’s 
t-test (P<0.05). Error bars represent SEM. 
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Figure 5: Decreased monocyte and macrophage content in atherosclerotic plaques 
of Angptl4Tg.E3L mice A. Counted numbers of monocytes adhered to the endothelial 
layer. B, C, D. (Right) Absolute area (µm
2
)
 
of staining is shown. (B, right ) Mean area 
of AIA 31240 antiserum staining for macropahage area (brown staining), (C,right) 
Sirius Red staining collagen area (red staining) and (D,right) a-actin staining for smooth 
vascular muscle cell area (brown staining) is shown. (Left) Representative images of 
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stained atherosclerotic lesions of camplarable size are presented. A black line is drawn 
to define the lesion area. Y-axis represent mean in Angptl4Tg.E3L and E3L group and 
error bars SEM. Numbers of animals per group were 15-16. *Significantly different 
between Angptl4Tg.E3L and E3L group, according to Student’s t-test (*P<0.05, 
**P<0.01). 
In the early stages of atherogenesis, monocytes/macrophages are recruited to the 
vessel wall in response to chemokines such as MCP-1 produced by the inflamed 
endothelium [22]. To further investigate the effect of Angptl4 on the 
chemotactic recruitment of macrophages, we performed an in vitro macrophage 
migration assay. BMDMs from Angptl4-Tg mice, characterized by 4-fold 
elevated Angptl4 mRNA levels (Figure 6A), migrated significantly less towards 
chemotactic signal (MCP-1) compared to WT macrophages (Figure 6B). These 
results suggest a suppressive effect of Angptl4 overexpression on macrophage 
migration and chemotaxis.  
 
 
Figure 6: Decreased migration of Angptl4-Tg BMDMs towards MCP-1 A. Mean 
fold change of mouse Angptl4 mRNA expression levels in BMDMs derived from 
Angptl4-Tg mice, compared to BMDMs derived from WT mouse. Quantification was 
done with qRT-PCR (Ct values: 25-27) B. BMDMs from WT or Angptl4-Tg mice were 
added on the top chamber of QCM™ Chemotaxis 96 well (5 ìM) Cell Migration Assay 
plate from Millipore. At the bottom chamber 5µg/ml MCP-1 mouse recombinant 
protein was added. Number of cells migrated to the bottom chamber were quantified via 
measurements of fluorescence DNA binding substance introduced to the cells during 
cell lysis. Y-axis represent mean and error bars SEM. *Significantly different between 
Angptl4-Tg and WT group, according to Student’s t-test (P<0.05) 
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Angptl4 decreased the uptake of oxLDL in macrophages  
Oxidized LDL (oxLDL) is known to promote atherogenesis by causing foam 
cell formation and inducing secretion of proinflammatory cytokines like MCP-1 
[23]. Since Angptl4 overexpression decreased the recruitment of 
monocytes/macrophages, we were interested to assess its role in oxidized LDL 
uptake and subsequent formation of foam cells. For this purpose, we used 
BMDMs from WT and Angptl4-Tg mice. We first assessed whether BMDMs 
may transform into foam cells after uptake of oxLDL. OxLDL efficiently 
promoted foam cell formation in WT and Angptl4-Tg BMDMs. In contrast, 
native LDL did not have any effect on foam cell formation (Figure 7A). In order 
to quantitatively assess macrophage uptake of oxLDL, we incubated BMDMs 
from WT and Angptl4-Tg mice with [
3
H] labelled oxLDL and LDL for 48hrs. 
Uptake of oxLDL was lower in Angptl4-Tg compared to WT macrophages, 
while uptake of LDL was unaltered (Figure 7B).  
TG-rich VLDL particles have been also shown to stimulate foam cell 
formation and provoke the release of proinflammatory cytokines [24, 25], which 
may further stimulate uptake of oxLDL and thereby accelerate the formation of 
foam cells [26]. To mimic that sequence of events, we first treated THP-1 with 
VLDL for 2h in order to induce lipid uptake and a pro-inflammatory phenotype. 
Thereafter, after 2hours, VLDL was washed away, and cells were treated with 
oxLDL in the presence of human recombinant Angptl4 for 6 hours. 
Interestingly, recombinant Angptl4 reduced the uptake of oxLDL by 2-fold, but 
had no effect on uptake of native LDL (Figure 7C). 
Previously, we showed that by inhibiting LPL activity, Angptl4 reduces 
macrophage uptake of TG-derived fatty acids and impairs macrophage 
activation [17], which may be suspected to indirectly lead to decreased uptake 
of oxLDL. To explore this possibility, THP-1 macrophages were incubated with 
VLDL in the presence of Angptl4 for 24 hours followed by a wash and 
treatment of the cells with oxLDL for 6 hours. Human recombinant Angptl4 
decreased the uptake of triglycerides from VLDL (Figure 7D), which led to 
decreased uptake of oxLDL but not LDL (Figure 7E). Overall, the data indicate 
that Angptl4 suppresses oxLDL uptake. 
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Figure 7: Angptl4 reduced the uptake of oxLDL in macrophages A. Oil Red O 
staining on BMDMs derived from WT and Angptl4-Tg mice, treated with 10ug/ml 
oxLDL or LDL for 24hrs B. Quantification of the uptake of tritium labelled 
3
[H]oxLDL 
and 
3
[H]LDL from BMDMs of WT and Angptl4-Tg mice, after 48hrs of incubation 
with each of the lipoproteins C. Quantification of the uptake 
3
[H]LDL and 
3
[H]oxLDL. 
THP-1 macrophages were preincubated for 2hrs with VLDL (150ug protein /ml), 
subsequently washed and treated for 6hrs with 
3
[H]LDL or 
3
[H]oxLDL, in the absence 
of presence of human recombinant protein Angptl4 (full length,1.5ug/ml) D. 
Quantification of the uptake of 
3
[H] VLDL from THP-1 macrophages after 24hrs 
incubation with 
3
[H]VLDL (30ug protein /ml), in the presence of absence of human 
recombinant protein Angptl4 (full length,1.5ug/ml) E. Quantification of the uptake of 
3
[H]LDL and 
3
[H]oxLDL. THP-1 macrophages were preincubated for 24hrs with 
VLDL (30ug protein /ml) in the presence or absence of human recombinant protein 
Angptl4 (full length,1.5ug/ml), subsequently washed and incubated with 
3
[H]LDL and 
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3
[H]oxLDL, for 6hrs. Values are expressed as mean of dpm 3[H] /mg of protein (see 
methods). Errors bars represent SEM. * Significantly difference between the compared 
groups is indicated in the graph, according to Student’s t-test (*P<0.05,**P<0.01). 
 
Recently, it was suggested that atherosclerosis and NASH (non-alcoholic 
steatohepatitis) are two aspects of a shared disease characterized by infiltration 
of activated macrophages in the arterial wall and liver, respectively [27]. To 
study the potential impact of Angptl4 overexpression on macrophage abundance 
in liver, we measured Cd68 and F4/80 mRNA expression. Although, F4/80 did 
not show any difference between Angptl4Tg.E3L and E3L mice, Cd68 mRNA 
was reduced by approximately 20% in Angptl4Tg.E3L mice (Appendix Figure 
1). Despite the small reduction in Cd68 mRNA levels, these data provide a hint 
of less macrophage infiltration in livers of Angptl4Tg.E3L mice. 
 
Discussion 
 In this study we have investigated the role of Angptl4 in atherosclerosis 
development. For that purpose we crossed Angptl4-Tg mice characterized by 
whole body overexpression of Angptl4 with atherosclerosis prone E3L mice. 
Here, we show that after 24 weeks on an atherogenic diet, Angptl4Tg.E3L mice 
showed less atherosclerosis. This effect was independent of the plasma 
cholesterol and triglyceride levels, since levels were similar between the two 
groups. Importantly, Angptl4Tg.E3L exhibited a less pro-inflammatory 
phenotype with decreased accumulation of monocytes/macrophages in the 
atherosclerotic plaque, suggesting an anti-inflammatory role of Angptl4 in 
atherosclerosis development. 
 The impact of Angptl4 on atherosclerosis has been previously investigated 
by Adachi H. et al. [28]. In that study Angptl4-/- mice on a ApoE-/- background 
developed less atherosclerotic lesions on a chow diet compared to control mice. 
ApoE-/- mice are characterized by a severe deficiency in clearance of VLDL 
remnants and develop severe atherosclerosis from birth, whereas E3L mice only 
develop hyperlipoproteinemia when fed a diet rich in fat and cholesterol, which 
we believe better mimics the lifestyle-dependent development of atherosclerosis 
in humans. Angptl4-/- mice on ApoE-/- background exhibited a significant 
decrease in circulating LDL-C and triglyceride levels, which very likely 
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accounted for the improvement in atherosclerosis in that model. In contrast, 
plasma VLDL/LDL-cholesterol and total cholesterol as well as plasma 
triglycerides were unaffected in Angptl4Tg.E3L mice compared to E3L mice 
after several weeks on the atherogenic diet. Previously, we found that whole 
body Angptl4 overexpression was associated with elevated plasma total and 
VLDL-cholesterol and triglycerides in FVB and C57Bl/6 mice. This effect was 
prominent in the fasted state and minimal in the fed state, and could be 
attributed to inhibition of LPL-dependent lipolytic processing of triglyceride-
rich lipoproteins[10, 13]. The exact reason why Angptl4 overexpression did not 
alter plasma triglycerides and cholesterol in E3L mice is not clear but maybe the 
inhibitory effect of Angptl4 on LPL is dependent on a fully functional ApoE 
molecule.  
 The absence of any changes in plasma lipoproteins suggests that Angptl4 
overexpression reduces atherosclerosis via a mechanism independent of 
inhibition of LPL-mediated systemic lipid clearance and consequent lipid 
lowering. Previously, we have shown that Angptl4 dramatically reduced foam 
cell formation and inflammatory gene expression in peritoneal macrophages 
incubated with chylomicrons in a LPL-dependent manner [17]. The present 
study indicates that inhibition of LPL-dependent lipid loading and activation of 
macrophages by Angptl4 also leads to downregulation of subsequent oxLDL 
uptake. In addition, Angptl4 seems to directly inhibit oxLDL uptake by 
macrophages. Consistent with Angptl4 exerting its effect via LPL, externally 
added and endogenously-produced LPL was previously found to enhance 
binding and uptake of oxLDL in macrophages [29-32]. Supporting a stimulatory 
effect of macrophage LPL on atherosclerosis in vivo, macrophage-specific 
overexpression of LPL was found to stimulate the formation of atherosclerotic 
lesions and accumulation of macrophage-derived foam cells, which occurred in 
the absence of any changes in circulating lipoproteins [18]. It was shown using 
transgenic mice expressing catalytically active or inactive LPL that the 
noncatalytic bridging function of LPL is sufficient for its proatherogenic effect 
[33]. Whereas Angptl4 is known to potently inhibit LPL catalytic activity, it is 
unclear whether Angptl4 inhibits the bridging function of LPL. It should be 
realized that Angptl4 may lower oxLDL uptake via a mechanism entirely 
independent of LPL and that may be mediated by its C-terminal Angiopoietin-
like domain. Future studies will have to address this issue in more detail. 
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 Interestingly, Angptl4 inhibited oxLDL uptake when macrophages were 
preloaded and activated with VLDL. Accumulation of intracellular triglycerides 
may trigger inflammatory pathways and ER stress that may cause upregulation 
of oxLDL uptake [6], [17], [26]. In this context it would be of interest to 
determine the effect of preloading of macrophages with lipid on oxLDL 
receptors and study the potential impact of Angptl4.  
Besides lowering oxLDL uptake, Angptl4 seems to reduce atherosclerosis by 
reducing chemotaxis. Specifically, we found that Angptl4-overexpression led to 
decreased accumulation of monocytes/macrophages in the atherosclerotic 
plaque. Additionally, Angptl4-Tg macrophages exhibited a decreased 
chemotactic response in an in vitro migration assay. Recently we showed that 
the C-terminal portion of Angptl4 binds to integrin β1 and β5 and stimulates 
integrin-linked signaling pathways [34, 35]. Since integrin β1 and β5 are highly 
expressed by macrophages (http://biogps.org; data not shown), these data raise 
the prospect that Angptl4 may influence macrophage chemotaxis via integrin β1 
and/or β5. Alternatively, it is possible that Angptl4 impacts chemotaxis via its 
N-terminal domain. To our knowledge, there are no data linking macrophage 
LPL to chemotaxis.   
 Expression of Angptl4 in macrophages was markedly induced by TLR4 and 
TLR3 agonists, as well as by lipid loading. More modest induction was 
observed upon treatment with NOD2 agonist muramyl dipeptide. A stimulatory 
effect of LPS on Angptl4 mRNA has also been observed in vivo in heart, 
skeletal muscle and adipose tissue [36]. In the same study, several pro-
inflammatory stimuli including LPS, IL-1β and TNFα upregulated Angptl4 
expression in 3T3-L1 adipocytes. The stimulatory effect of lipids (as fatty acids 
or lipoproteins) on Angptl4 expression has been extensively studied and 
confirmed in a variety of cell types, suggesting Angptl4 may mediate effects of 
lipids. In intimal macrophages, induction of Angptl4 by lipids and other 
inflammatory stimuli may be a protective mechanism to reduce foam cell 
formation and mitigate anti-inflammatory responses, resembling its role in 
mesenteric lymph node macrophages [17]. 
 There is increasing interest in the link between obesity and associated 
adipose tissue inflammation, and atherosclerosis. Despite the chronic feeding of 
a high fat/high sucrose diet, animals showed only minor weight gain and were 
not obese at the end of the experiment. The inhibitory effect of Angptl4 
overexpression on macrophage recruitment in atherosclerotic plaques may also 
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be manifested in the adipose tissue, possibly leading to lower inflammatory 
status of adipose tissue. Detailed analysis of the inflammatory status of adipose 
including determination of the abundance of numerous immune cells will be the 
subject of future investigations. 
 In conclusion, the present study reveals a protective role of Angplt4 in 
atherosclerosis development that is independent of changes in levels of plasma 
lipoproteins. Furthermore, the study suggests an inhibitory effect of Angptl4 on 
macrophage oxLDL uptake and chemotaxis.  
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APPENDIX 
Appendix Table 1: Composition of diet T(4021 04) 
 
Purified diet T
Composition Weight (g)  Percentage
8500 STAND.VIT.PREMIX 37,50 0,25
8503 ST.SPOR.PREMIX 37,50 0,25
7559 CaHPO4.2H2O (LAAG F) 195,00 1,30
7560 CaCO3 REINST/Me.2069 150,00 1,00
7547 KH2PO4 105,00 0,70
7546 KCl. 105,00 0,70
7083 ZOUT (GEZAKT). 45,00 0,30
7611 MgSO4.7H2O 60,00 0,40
7552 MgO SCHWER REINST 30,00 0,20
7082 METHIONINE SYNTH. DL 30,00 0,20
7514 CHOLINE CL 50% 300,00 2,00
7599 ZURE CASEINE. 3.000,00 20,00
7584 DICACEL2+4/cellulose 930,00 6,20
7579 MAISZETMEEL GEL INST 1.500,00 10,00
7639 MAISOLIE/CORN OIL. 150,00 1,00
7529 CACAO-BOTER. 2.250,00 15,00
7154 SUIKER/sucrose 6.075,00 40,50
15.000,00 100,00
Analysis Unit Portion
1 Cr.Prot g/kg 176,16
2 Cr. Fat g/kg 160,45
3 Cr.Fiber g/kg 62,69
4 Minerals g/kg 23,62
5 Moisture g/kg 29,33
6Sug.+St. g/kg 495,16
7 Nfree ex g/kg 508,47
8 Dry Mat. g/kg 967,82
9 Lysine g/kg 12,42
10 Methion. g/kg 6,78
12 Cystine g/kg 0,52
13 Threonin g/kg 7,12
14 Tryptoph g/kg 2,32
15 Isoleuc. g/kg 10,08
16 Arginine g/kg 6,12
17 Phenylal g/kg 7,28
18 Histidin g/kg 4,64
19 Leucine g/kg 19,04
20 Tyrosine g/kg 9,44
21 Valine g/kg 11,76
22 Alanine g/kg 3,96
23 Asp.acid g/kg 9,26
24 Glut.ac. g/kg 35,10
25 Glycine g/kg 5,12
26 Proline g/kg 16,06
30 Calcium g/kg 7,12
31 Phos.tot g/kg 4,17
34 Potass. g/kg 5,68
35 Magnes. g/kg 1,57
36 Sodium g/kg 1,15
37 Chlorine g/kg 7,59
38 Sulfur g/kg 0,54
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49 C8-C12:0 g/kg -
50 C14:0 g/kg -
51 C16:0 g/kg 40,10
52 C16:1 g/kg -
53 C18:0 g/kg 52,70
54 C18:1 g/kg 55,05
55 C18:2 g/kg 10,50
56 C18:3 g/kg 0,10
57 C20-C22 g/kg 1,51
61 Vit. A IU/g 18,00
64 Vit. D3 IU/g 2,00
65 Vit. E mg. 62,67
67 Vit. K3 mg. 10,00
68 Vit. B1 mg. 20,00
69 Vit. B2 mg. 11,56
70 Vit. B6 mg. 15,33
71 Niacin mg. 39,20
72 Pant.ac. mg. 15,90
73 Vit.B12 mcg. 50,00
74 Folic.ac mg. 7,84
75 Choline mg. 7.457,80
76 Biotin mcg. 306,65
77 Inositol mg. 499,98
82 Starch g/kg 78,50
83 Sugars g/kg 405,00
86 Lactose g/kg 0,40
91 Cellulos g/kg 55,80
93 Glucose g/kg 3,70
96 Iron mg. 129,98
97 Mangan. mg. 63,50
98 Zinc mg. 52,40
99 Copper mg. 17,97
100 Cobalt mg. 0,14
101 Iodine mg. 0,47
102 Selenium mg. 0,19
104 Chromium mg. 0,49
105 Nickel mg. 0,07
107 Fluorine mg. 2,12
109 Arsenic mg. 0,07
111Lead mg. 0,80
113 Alumin. mg. 3,31
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Appendix Figure 1: Mean fold change of mRNA levels of macrophage markers Cd68 
and F4/80, in liver of Angptl4Tg.E3L mice compared to E3L control, fed for 24 weeks 
dietT with 0.4% additional cholsterol. Quantification was done with qRT-PCR. 
*Significantly different between E3L and Angptl4Tg.E3L, according to Student’s t-test 
(*P<0.05). 
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Abstract  
 
Most of the modulatory effects of fatty acids on inflammation can probably be 
attributed to fatty acid metabolites, including prostaglandins, leukotoxins, 
resolvins, endocannabinoids, ceramides and diacylglycerols. However, there is 
accumulating evidence that fatty acids are able to directly activate or suppress 
inflammatory pathways. The aim of the present study was to elucidate 
transcriptional targets of fatty acids in macrophages, as part of a general goal to 
elucidate mechanisms through which fatty acids exhibit a direct role in 
modulating inflammatory processes in macrophages. To that aim we performed 
microarray analysis in elicited mouse peritoneal macrophages treated with fatty 
acids, oleic (C18:1) or palmitic acid (C16:0), intralipid or chyle for 6 hours. We 
identified Hig-2 to be strongly upregulated by all treatments, which prompted 
us to further characterize its function. We found expression of Hig-2 to be the 
highest in peritoneal macrophages and white adipose tissue. Hig-2 was 
increased in lipid loaded mouse macrophages together with another lipid droplet 
coated protein Plin2. Hig-2 was highly induced by hypoxia in mouse 
macrophages, while intralipid and hypoxia showed a synergistic effect. 
Transcriptional regulation of Hig-2 was independent of PPARs. Further 
characterization of the transcriptional regulation of Hig-2 in macrophages is 
currently in progress. Chronic high fat feeding increased Hig-2 expression 
levels in adipose tissue but not in liver. Immunohistochemistry indicated 
colocalization of Hig-2 with Cd68 in infiltrating macrophages as part of crown-
like structures. We propose that Hig-2 has a specific role in macrophages and 
may function as an interesting target in the study of obese adipose tissue.  
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Introduction 
 
 Numerous studies have examined the impact of fatty acids on inflammatory 
pathways in tissues and cells. These studies point to a proinflammatory effect of 
saturated fatty acids, while n-3 PUFA have mostly anti-inflammatory properties 
[1]. Most of the modulatory effects of fatty acids on inflammation can probably 
be attributed to fatty acid metabolites, including prostaglandins, leukotoxins, 
resolvins, endocannabinoids, ceramides and diacylglycerols [1]. However, there 
is accumulating evidence that fatty acids may be able to directly activate or 
suppress inflammatory pathways.  
 Immune cells and particularly macrophages are equipped with a number of 
receptors that are able to recognize antigens, called pattern recognition receptors 
(PRR). Among those, the TLR family has been the most extensively 
characterized. Saturated fatty acids have been demonstrated to elicit TLR4-
dependent and TLR2-dependent responses in several cell types, including 
macrophages [2-5]. Subsequent studies have provided compelling evidence that 
saturated fatty acids activate NF-κB and stimulate expression of NF-κB targets 
such as COX-2, iNOS and IL-1α in macrophages by activating TLR4 signaling 
in a MyD88, IRAK-1 and TRAF6 dependent manner. In contrast, unsaturated 
fatty acids are ineffective or may even act as antagonists [2], [6]. Apart from 
TLR receptors, GPR120, a member of the G-protein coupled receptor (GPCRs) 
family was recently proposed to serve as a specific sensor for n-3 fatty acids in 
macrophages that mediates the putative insulin sensitizing and anti-diabetic 
effects of n-3 fatty acids in vivo by repressing macrophage-induced tissue 
inflammation [7]. 
 The aim of the present study is to explore transcriptional targets of free fatty 
acids in macrophages, as part of the general goal to elucidate mechanisms 
through which fatty acids exhibit a direct role in modulating inflammatory 
processes in macrophages.  
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Methods and Materials 
 
Materials: GW501516, Rosiglitazone was purchased from Alexis (Axxora, 
Raamsdonkveer, The Netherlands). Wy14643 was obtained from Eagle Picher 
Technologies laboratories (Lenexa, Kan). SYBR green was from Eurogentec 
(Seraing, Belgium), and all other chemicals were from Sigma (Zwijndrecht, The 
Netherlands). Fatty acids were from Larodan Free Chemicals (Malmo, Sweden). 
Chyle was isolated from rats fed a palm-oil based diet overnight, as previously 
described [8]. 
 
Cell culture: Peritoneal macrophages were obtained from C57Bl/6 mice by 
intraperitoneal injection with 1 mL 4% thioglycolic acid. After three days, mice 
were anesthetized with 1.5% isoflurane, bled by orbital puncture and killed with 
CO2. The macrophages were collected from the peritoneal cavity by washing it 
with 10 mL DMEM supplemented with 1% penicillin:streptomycin (P:S). 
Erythrocytes were removed by incubating the cell pellets with red blood cell 
lysis buffer (RBC) for 5 min on ice. After removal of the RBC, the cells were 
suspended in warm DMEM with 10% heat inactivated fetal calf serum (HI 
FCS) and seeded in a density of 3*10
5
 cells/cm
2 
and incubated at 37°C in a 
humidified 5% CO2 incubator. Three hours post plating, the cells were washed 
twice with warm PBS to remove non-adherent cells. Attached macrophages 
were kept always in fresh medium for two more days, before the experiments. 
 
RAW 264.7 cells were grown in DMEM supplemented with 10% HI FCS and 
1% P:S. 
 
Human THP-1 and U937 monocytes were grown in RPMI 1640 medium 
supplemented with 10% HI FCS and 1% P:S. They were differentiated into 
macrophages for 2 days with 100ng/mL phorbol-12-myristate-13-acetate 
(PMA) and after PMA was washed away, cells were kept for 2 days in fresh 
complete medium.  
 
Bone marrow derived cells macrophages were obtained from bone marrow cells 
via the following process: Bone marrow cells were obtained from the long 
bones of the hind legs of C57Bl/6 mice. The bones were removed, rubbed clean 
with 70% ethanol and washed with PBS. Bones were cut at the edges and the 
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bone marrow was flushed in 5ml of DMEM, with the use of a syringe. Acquired 
pellet was washed twice with PBS and resuspended in differentiation-medium 
consisting of 80% DMEM with 10% HI FCS and 1% P:S and 20% L929 
conditioned DMEM (10% HI FCS,1% P:S). The cells were seeded in a density 
of 1*10
5
 cells/cm
2
 and incubated for two days. After two days, 50% of the 
original volume of differentiation-medium was added and incubated again for 
three days. The medium was refreshed again and the cells were incubated 24h 
again before initiation of the treatment. 
 
Binding of free fatty acids to BSA: Before applied to the cells, free fatty acids 
were bound to BSA (5ug/mL per 1L) by incubation at 37
o
C for 30 min, 
as previously described [9]. Fatty acids were used in concentration of 250μM. 
 
Intralipid was used in concentration of 2mM 
 
PPAR agonists: The PPARα agonist Wy14643 was used in a concentration of 
1μM, the PPARβ/δ agonist GW501516 and PPARγ agonist rosiglitazone were 
used at a concentration of 0.5μM. 
 
Induction of hypoxia: Hypoxia was induced by the addition of 100μM iron 
chelator 2,2'-dipyridine (DP).  
 
Microarray Analysis: RNA from peritoneal macrophages was extracted with 
TRIzol reagent and purified using RNeasy Mini kit (Qiagen, Venlo, 
Netherlands). RNA quality was assessed on an Agilent 2100 bioanalyzer 
(Agilent Technologies, Amsterdam, the Netherlands) with 6000 Nano Chips 
using a Eukaryote Total RNA Nano assay. RNA from three different wells per 
condition was pooled and gene expression was measured with microarray 
analysis, using Affymetrix Mouse Genome 430 2.0 Arrays. Hybridization, 
washing and scanning of the arrays were done according to standard Affymetrix 
protocols. Scans of the Affymetrix arrays were processed using packages from 
the Bioconductor project. Raw signal intensities were normalized by using the 
GC-RMA algorithm [10]. Probesets were defined according to Dai et al. using 
remapped CDF version 12.0.0 based on the Entrez gene database [11]. In order 
to balance between random responses and relative weak transcriptional effects 
by the treatments, genes that met the cut-off of mean absolute fold change >1.2 
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were considered significantly regulated. Since we used pools of RNA per 
conditions, no statistics were feasible.  
 
Immunobloting: Rabbit-produced antibody against mouse Hig-2 was 
purchased from Santa Cruz. The antibody was used at 1:1000 dilution. 
Secondary antibody was a peroxidase-conjugated goat anti-rabbit IgG, 
purchased from Jackson Immunoresearch, West Grove US, and used at 1:5000 
dilution. Immunoprecipitation was performed in standard RIPA buffer. 18 ug of 
protein from cell lysates, collected in RIPA buffer was loaded.  
 
High-Fat Diet: Mice were purchased at The Jackson Laboratory (Bar Harbor, 
ME) and bred in our local facility. C57Bl/6 received a low-fat diet (LFD) or 
high-fat diet (HFD) for 18 weeks providing 10 or 45 energy percent in the form 
of triglycerides (D12450B or D12451, Research Diets, New Brunswick, NJ). 
The lard component in these diets was replaced by palm oil. At the end of the 
feeding experiment, liver and epididymal white adipose tissue were dissected, 
weighed, and immediately frozen in liquid nitrogen. The animal experiments 
were approved by the animal experimentation committee of Wageningen 
University. 
Immunohistology: Parafin preserved sections of liver and adipose tissue were 
used. Antibody for Cd68 was purchashed by Abdserotec and for Hig-2 from 
Bioconnect. The first day sections were left overnight at 37
o
C. Second day, we 
performed deparafinization of the sections, followed by inhibition of 
endogenous peroxidases for 30min. Hig-2 and Cd68 antibodies were used in 
dilution 1:500, overnight.  Negative control was not incubated with primary 
antibody. The third day incubation with senondary antibody was performed.  
Secondary antibody was used in dilution 1:200 and it was applied on the 
sections for 45min. Visualization of the complex was done with DAB staining. 
Hematocylin staining was perfomed as well. Areas that were stained obtained a 
brown colour. Furthermore, a general HE (hematoxylin eosin) staining was 
performed to visualize the structure of the tissue. 
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RNA isolation and qRT-PCR: Total RNA was isolated with TRIzol Reagent 
(Invitrogen, Breda, the Netherlands). 1μg of total RNA for the in vivo studies 
and 350ng of total RNA for the in vitro experiment was reverse transcribed 
using iScript (Bio-Rad, Veenendaal, the Netherlands). cDNA was amplified on 
BioRad MyIQ or iCycler machine using Sensimix polymerase (Invitrogen, 
Breda, the Netherlands). PCR primer sequences are shown in table 2. 
Table 2: Primer Sequences used for QPCR 
Primer 
Name 
Forward sequence Reverse sequence 
mHig-2 TGCTGGCGATCATGTTGACC TGACCCCTCGTGATCCAGG 
hHig-2 AAGCATGTGTTGAACCTCTACC TGTGTTGGCTAGTTGGCTTCT 
mPlin2 GCCTCTCAACTGGCTGGTAG ACAGCAAAAGGGGTCATCTG 
hPlin2 ATGGCATCCGTTGCAGTTGAT GATGGTCTTCACACCGTTCTC 
mCd68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
mCd36 GAGCAACTGGTGGATGGTTT TCACTTCCTGTGGATTTTGC 
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Results 
 
Hig-2 is a novel target of fatty acids in mouse macrophages 
 
To screen for novel targets genes of fatty acids in macrophages, we treated 
thioglycolate elicited mouse peritoneal macrophages with palmitic acid (C16:0) 
or oleic acid (C18:1) for 6 hours and performed Affymetrix microarrays. 
Alternatively, peritoneal macrophages were treated with lipid emulsions in the 
form of rat chyle or Intralipid. Genes were ranked according to fold-induction 
by C16:0 and displayed in a heat map. Fold-induction by C18:1, intralipid, and 
chyle are shown in parallel. Interestingly, the RIKEN gene 2310016C08 was 
found to be the most highly upregulated gene by fatty acids (Figure 1). RIKEN 
2310016C08 was first described as a novel gene, that is inducible by hypoxia 
and glucose deprivation, giving rise to the name hypoxia inducible gene 2 (Hig-
2) [12]. Later it was described as a lipid droplet associated protein and a specific 
target of HIF-1, but not HIF-2 in human cancer cell lines. Our data show that 
Hig-2 is the gene most highly upregulated in response to fatty acids in mouse 
peritoneal macrophages. The official gene symbol of RIKEN 2310016C08 and 
Hig-2 is Hilpda. 
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Figure 1: HIG-2 is the highest regulated gene by free fatty acids. Microarray 
analysis on macrophages treated 6 hours with palmitic acid (C16:0), oleic acid (C18:1), 
intralipid (IL) and Chyle. Differentially expressed genes ranked from the highest to the 
lowest according to C16:0 group. Fold change of the top 20 differentially expressed 
genes and their functions are shown. Colours correspond to fold change values 
compared to the control. Red represents upregulated gene and green represents 
downregulated genes. 
 
We next determined the expression profile of mouse Hig-2 gene in several 
mouse tissues. Remarkably, Hig-2 was most highly expressed in thioglycolate-
elicited mouse peritoneal macrophages, followed by white adipose 
tissue>colon>brown adipose tissue>skeletal muscle (Figure 2). Based on its 
elevated expression, we could speculate that Hig-2 may have a specific role in 
macrophages. 
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Figure 2: Mouse Hig-2 shows the highest expression levels in mouse peritoneal 
macrophages and white adipose tissue. qRT-PCR quantification of Hig-2 mRNA 
levels, on mouse tissues. Expression levels of Hig-2 was normalized to the average 
values of 4 different housekeeping genes (36B4, U18S, actin and cyclophilin). mRNA 
levels of Hig-2 per tissue were divided by the Average mRNA expression level of Hig-2 
in all tissues measured, which was set at 1. 
 
In order to test the consistency of induction of Hig-2 mRNA levels by fatty 
acids in macrophages, we treated several macrophage cell lines and primary 
cells with oleic acid (C18:1). Despite a dramatic increase in macrophage lipid 
accumulation (Figure 3A), Hig-2 expression was only modestly or not increased 
by C18:1, in M1 and M2 human monocyte derived macrophages, respectively 
(Figure 3B). A similar lack of increase in Hig-2 by C18:1 despite enhance lipid 
accumulation was observed in human U937 macrophages and human THP-1 
macrophages, even though expression of the well characterized lipid droplet 
coating protein Plin2 was induced by C18:1 (Figure 3C,D). In contrast, 
expression of Hig-2 and Plin2 mRNA were increased in parallel by C18:1 in 
mouse RAW 264.7 and mouse peritoneal macrophages (Figure 3D). 
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Figure 3: Hig-2 regulation by fatty acids in different macrophage cells lines A. Oil 
red O staining on human M1 and M2 differentiated human monocyte derived 
macrophages, treated with C18:1 (250uM ) for 24 hours B. qRT-PCR quantification of 
mRNA levels of Hig-2 in M1 and M2 macrophages treated with C18:1 (250uM) for 
24hrs C. Oil red O staining on human U937 macrophages treated with C18:1 for 6h 
(left). qRT-PCR quantification of mRNA levels of Hig-2 and Plin2 in U937 
macrophages treated with C18:1, for 6hrs (right) D. qRT-PCR quantification of mRNA 
of Hig-2 and Plin2 in mouse and human cell line and primary cells after 6hours 
incubation with oleic acid (C18:1). Y-axis represents mean fold change. Errors bars 
represent SEM.*Significantly different between treatement (C18:1) and control, 
according to Student’s t-test (*P<0.05).  
 
Similar inductions of Hig-2 mRNA in RAW264.7 and peritoneal 
macrophages were observed in response to intralipid (Figure 4A). Upregulation 
of Hig-2 mRNA by intralipid was associated with marked induction of Hig-2 
protein in both types of macrophages (Figure 4B). 
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Figure 4: Upregulation of Hig-2 mRNA and protein in mouse RAW264.7 and 
mouse peritoneal macrophages after incubation with intralipid A. Mean fold 
change of mRNA levels of Hig-2 gene, quantified with qRT-PCR. Mouse RAW246.7 
cells and mouse peritoneal macrophages were incubated for 6 hours with intralipid.* 
Statistically different between the treated (IL) and control group, according to Student’s 
t-test (*P<0.05). B. Immunoblot showing that Hig-2 protein levels are increased in 
mouse RAW 264.7 and mouse peritoneal macrophages cell lysates, after 6 hours and 24 
hours incubation with intralipid. 
 
Hig-2 expression is upregulated by chemical hypoxia 
 
In order to investigate whether Hig-2 is upregulated by hypoxia in 
macrophages, we exposed mouse peritoneal macrophages, mouse RAW 264.7 
and BMDMs to chemical hypoxia by incubating them with the iron chelator 
2,2'-dipyridine (DP), an inhibitor of the respiratory chain reaction, and 
compared the effect with intralipid. Both DP and intralipid were almost equally 
potent in inducing Hig-2 in all tested macrophages, while together they 
produced a synergistic increase in Hig-2 expression. In contrast, Plin2 
expression did not respond or was even reduced by DP, while intralipid alone or 
in combination with DP effectively increased Plin2 mRNA levels (Figure 5A). 
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Hig-2 induction in lipid loaded macrophages is PPAR independent  
 
Considering that fatty acids act as ligands for PPARs and that Plin2 is a 
PPAR target gene [13,14], we explored the possible regulation of Hig-2 by 
PPARs. To that end we treated mouse peritoneal macrophages, mouse RAW 
264.7, human U937 and human THP-1 macrophages with pharmacological 
agonists for PPARα (WY14643), PPARβ/δ (GW501516) and PPARγ 
(Rosiglitazone). Whereas Plin2 was consistently upregulated by agonist for 
PPARβ/δ and PPARγ, we did not observe any effect of PPAR agonists on Hig-2 
mRNA levels, except of a 1.8-fold increase by GW501516 in RAW 264.7 
macrophages. There results suggest that in contrast to Plin2, Hig2 is probably 
not a PPAR target gene, at least in macrophages. 
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Figure 5: Hig-2 is induced by hypoxia mimetics and not by PPAR agonists in 
macrophages A. Mean fold change of mRNA levels of Hig-2 and Plin2 measured in 
mouse peritoneal macrophages, mouse RAW 264.7 macrophages and BMDMs, under 
normoxia, hypoxia (induced by hypoxia mimetic DP, 100uM), intralipid (2mM) and 
combined DP and intralipid. Duration of incubation was 6 hours. B. Mean fold change 
of Hig-2 and Plin2 mRNA levels in mouse peritoneal macrophages, mouse RAW 264.7 
macrophages, human U937 and human THP-1 macrophages treated for 6 hours with 
PPARα (WY 14643), PPARβ/δ (GW 501516) and PPARγ (Rosiglitazone). Expression 
levels were quantified by qRT-PCR. Error bars represent SEM.*Significantly different 
between treatment and control group, according to Student’s t-test, (* P<0.05, 
**P<0.01). 
 
Hig-2 is induced in adipose tissue upon high fat diet  
 
Obesity is associated with macrophage infiltration in adipose tissue. We found 
Hig-2 to be expressed at high levels in white adipose tissue and in peritoneal 
macrophages. Thus, we set out to investigate the expression of Hig-2 in liver 
and adipose tissue in lean mice and mice rendered obese by chronic high fat 
feeding. Whereas 18 weeks potently induced Cd36 in the liver in concert with 
development of fatty liver (Figure 6A,C), expression of Hig-2 as well as 
macrophage marker Cd68 were not increased. In contrast, chronic high fat 
feeding significantly increased Hig-2 and Cd68 mRNA in adipose tissue (Figure 
6B). Immunohistochemistry indicated colocalization of Hig-2 with Cd68 in 
infiltrating macrophages as part of crown-like structures (Figure 6D) 
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Figure 6: Hig-2 is upregulated in adipose tissue upon high fat diet and it colocalizes 
with the macrophages. Gene expression of Hig-2 and Cd68 and Cd36 in liver (A) and 
Hig-2 and Cd68 in white adipose tissue (WAT) (B) after 18 weeks high fat diet C. 
Hematoxylin eosin (HE) staining showing liver steatosis after 18 weeks on HFD. Low 
fat diet (LFD) is used as a control D. Immunhistological staining of white adipose tissue 
(WAT) sections from low fat diet (LFD) and high fat diet (HFD) group. Hig-2 staining 
is observed together with Cd68 macrophage staining (brown colour), around crown like 
structures. 
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Discussion  
 
Fatty acids have been shown to regulate a wide range of genes in several cell 
types. However, the impact of fatty acids on gene expression in macrophages 
has not been extensively investigated. Using microarray we identified Hig-2 as 
the most sensitive target gene of fatty acids in macrophages. Hig-2 has been 
previously described to be induced by hypoxia, chemical hypoxia and lipid 
accumulation in human renal carcinomas cells, human HeLa cells and human 
HuF7 cancer cell lines [12], [15]. In line with these data, we also found Hig-2 
mRNA and protein levels to be upregulated under conditions of lipid droplet 
accumulation as it is induced by intralipid in mouse RAW 264.7 and mouse 
peritoneal macrophages. Although most of the existing work on Hig-2 is on 
human cell lines, fatty acid treatment of human THP-1, U937 and human 
monocyte derived macrophages (M1 and M2) did not result in increased Hig-2 
expression levels, despite enhanced intracellular lipid accumulation, as 
manifested by Plin2 induction and confirmed by Oil red O staining.  Basal 
expression of Hig-2 in THP-1 and U937 macrophages seems to be similar to its 
expression in mouse RAW 264.7 and primary mouse macrophages (Ct 24-27). 
Since cancer cell lines may have very different characteristics from primary 
cells, further studies on human primary cells such as human monocyte 
macrophages are necessary to study the differential regulation of Hig-2 in 
human and mouse macrophages. For that purpose, the high variation between 
human donors necessitates a big sample size in order to draw reliable 
conclusions. The data presented here on Hig-2 expression in M1 and M2 human 
monocyte derived macrophages are based on the average result of two different 
donors and cannot be considered conclusive.  
Previously Gimm et al. visualized Hig-2 in HeLa cells using 
immunofluorescent staining. Hig-2 was found to partially colocalize with Plin2 
to the periphery of lipid droplets, and after staining for organelle markers, its 
localization in other cellular organelles such as mitochondria, endoplasmic 
reticulum, Golgi, autophagosomes and peroxisomes was excluded. Lipid 
droplets in non-adipose tissues have very small size, often less than 1µm [16]. 
In addition, lipid droplets are often juxtaposed to the endoplasmic reticulun 
(ER), mitochondria and peroxisomes [17], which makes it difficult to 
distinguish them from other cellular organelles without using electron 
microscopy. Saturated fatty acids are known to induce endoplasmic reticulum 
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stress and promote the formation of foam cells [18]. The ER is a large organelle 
running throughout the cytoplasm and therefore it cannot be excluded that Hig-
2 acts upon the lipid droplets formation via the ER. Although the intracellular 
localization of Hig-2 might be indicative of its function, further studies are 
necessary to elucidate how it may be involved in the formation of foam cells. 
Gimm et al. showed that overexpression of Hig-2 in HeLa cells clones increased 
lipid droplet formation. Currently, we are exploring siRNA mediated Hig-2 
knockdown in macrophages, which we expect to reveal the potential 
involvement of Hig-2 in lipid droplets formation under baseline and conditions 
of hypoxia or Intralipid/fatty acids incubation. So far attempts to knock down 
Hig-2 in mouse RAW 264.7 macrophages have proven to be difficult. 
In contrast to adipocytes, the primary function of macrophages is not to 
deposit lipids. Biogenesis of lipid bodies in macrophages is a process that 
happens in vivo during inflammatory reactions of different causes, such as 
bacterial infection, uptake of modified lipids or systemic inflammation. Lipid 
laden macrophages (foam cells) are sources of proinflammatory cytokines. 
Gimm et al. showed that Hig-2 overexpression is accompanied by lipid 
accumulation and cytokines expression in HeLa cells. Although it is likely that 
secretion of cytokines a is consequence of the lipid accumulation, we cannot 
exclude a direct role of Hig-2 in cytokine production by the macrophage.  
In adipose tissue, which becomes enriched with macrophages during obesity, 
we observed no staining of Hig-2 at the periphery of adipocytes and thus around 
the lipid droplets. Instead, Hig-2 was present in the recruited macrophages. 
While both Hig-2 and Cd68 mRNA were increased in the adipose tissue, neither 
Hig-2 or Cd68 increased in the liver, despite steatosis as reflected by increased 
Cd36 mRNA levels.  These data indicate that increase in Hig-2 mRNA is not 
necessarily connected with lipid droplet formation and might be a result of 
macrophage activation. This may be indirectly supported by the observation that 
Hig-2 is activated by hypoxia, which has been described to stimulate 
macrophage activation and phagocytic functions [19,20].  
Plin2 has been also described to be induced during hypoxia [21]. In contrast 
to Hig-2, in mouse macrophages Plin2 was found to be a specific target of 
PPARs and was not induced by chemical hypoxia. This discrepancy might be 
due to a difference between DP-induced hypoxia and hypoxia induced by a 
decreased oxygen tension, which is the most common way to study hypoxia. 
However, based on our results we may speculate that Hig-2 is regulated 
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differently than a typical lipid droplet associated protein. In order to clarify the 
regulation of in vivo, it would be useful to measure its expression in the liver, 
adipose tissue and macrophages derived from PPARα-/- and PPARβ/δ -/- mice 
fed a high fat diet, as well as in Hif-1 KO mice.  
This study provides a preliminary description of a newly identified target of 
fatty acids, Hig-2, in macrophages. Apart from what has already been suggested 
in the present discussion, the acquisition of a Hig-2 KO mouse would be 
extremely helpful to further characterize its function. Exposure of Hig-2 KO 
mice to high fat diet may reveal the potential involvement of Hig-2 in obesity 
and hepatic steatosis. 
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Increased levels of plasma triglycerides is one of the features of the 
metabolic syndrome and is considered a risk factor for cardiovascular disease 
[1,2]. Metabolic syndrome is associated with delayed postprandial clearance of 
plasma triglycerides, leading to hyperlipidaemia. After a meal triglycerides are 
packaged into chylomicrons in the small intestine and via the lymph system 
reach the blood and the peripheral tissues. Triglyceride-rich chylomicrons 
deliver free fatty acids to the organs after undergoing lipolysis by lipoprotein 
lipase, which is anchored to the capillary endothelium [3]. Under physiological 
conditions, organs respond to the increased plasma levels of triglycerides, by 
increased uptake of lipids, increased mitochondrial fat oxidation, esterification 
and storage of fatty acids as intracellular lipid droplets [4-6]. In metabolic 
syndrome ectopic fat storage to tissues with limited fat deposition, such as liver, 
skeletal muscle and heart [7,8], concomitant with improper balance of fat 
uptake, intracellular lipid accumulation and fat oxidation in those organs, give 
rise to cellular lipotoxicity. Lipotoxicity is a general term used to describe the 
condition of cell dysfunction or cell death due to excess accumulation of fat [9]. 
Mitochondrial dysfunction, endoplasmic reticulum stress, apoptosis and 
inflammation are some of the cell dysfunctions observed in lipotoxicity [10] and 
have been reported to be common characteristics of lipid related diseases, such 
as myocardial dysfunction, atherosclerosis and liver steatosis. Apart from the 
intracellular levels of lipids, the composition of fatty acids has been recognized 
as a separate factor in lipotoxicity occurrence. Accordingly, saturated fatty acids 
have been described as more lipotoxic compared to unsaturated fatty acids. 
Despite the big effort to understand the functions of dietary fatty acids at the 
cellular level, still the mechanisms via which they may perturb cell function 
remain unclear. In the first part of this thesis, we explore direct target genes of 
different dietary polyunsaturated fatty acids (PUFAs), in the mouse heart and 
we investigate the role of Angptl4, a highly responsive gene to dietary fatty 
acids, in the prevention of cardiac lipotoxicity. In the second part of this thesis, 
we explore the role of Angptl4 in the context of atherosclerosis and 
inflammation. Finally, we present a preliminary characterization of Hig-2, 
which we found to respond potently to fatty acid uptake and hypoxia in 
macrophages and we further explore its expression under high fat diet in liver 
and adipose tissue.  
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Fatty acids differ in their lipotoxic potential 
 
Fatty acids may affect lipotoxicity in several ways. They are substrates for 
production of lipotoxic compounds, they affect cell membrane organization and 
gene transcription [11-13]. Evidence suggest that fatty acids differ in their 
lipotoxic and inflammatory potential. Under conditions of increased influx of 
fatty acids, limited TG storage, or uncontrolled lipolysis, may direct fatty acids 
towards other metabolic pathways than lipid droplets, giving rise to a variety of 
lipotoxic derivatives, such as diacylglycerol, ceramides, C6-C22 acylcarnitines 
or other intermediates of impaired beta oxidation or lipid peroxide free radicals 
[14]. Increased levels of these intermediates have been associated with insulin 
resistance in skeletal muscle, cell apoptosis and myopathy in the cardiac muscle 
[15,16]. Long chain-saturated fatty acids, such as palmitate are precursors for 
ceramide synthesis. The latest is a highly bioactive lipid, which attacks cell 
membranes and promotes apoptosis. In addition, saturated fatty acids have been 
shown to induce endoplasmic reticulum stress, with subsequent effects on 
apoptosis, insulin sensitivity and uptake of modified lipids, such as oxidized 
LDL by macrophages [17,18]. In contrast n-3 PUFAs, DHA and EPA give rise 
to eicosanoids, such as resolvins and protectins, that have anti-inflammatory 
properties [19,20]. In turn, n-6 PUFAs have been described as pro-
inflammatory, since they are precursors of arachidonic acid. Those differences 
have led to the hypothesis, that the ratio between n-3/n-6 PUFA in our diet is an 
important factor of inflammatory and immune response. In line with this 
hypothesis, it has been observed that diets which have been proven beneficial 
for health, such as the Mediterranean diet are characterized by increased 
consumption of n-3 PUFA, whereas Western diet, that has been associated with 
chronic disease developement is more enriched in n-6 PUFAs [21,22]. 
Fatty acids may differentially alter antigen presentasion and immune 
response via modification of cell membrabe organisation. Membrane lipid rafts 
require lipids with saturated acyl chains and cholesterol, which pack tightly to 
form a liquid ordered phase. This tight packing is conferred by favorable van 
der Waals forces between saturated acyl chains, in addition to hydrogen 
bonding between neighboring sphingolipids and between the variable 
sphingolipidamide and the 3-OH of cholesterol. Unsaturated acyl chains, 
including PUFAs, do not pack well with cholesterol molecules and therefore 
form a liquid disordered phase [23]. It has been speculated that through these 
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physical properties PUFA acyl chains can modify membrane lateral 
organization and protein appearance on the cell surface, which may alter antigen 
presentation, cytokine production, lymphocyte proliferation, surface molecule 
expression, phagocytosis, and apoptosis or inhibit the activity of Tcells, such as 
natural killer (NK) cells [24,25]. 
Finally fatty acids can directly affect gene transcription, via interaction with 
nuclear receptors. PPAR ligand dependent activation by PUFA has been the 
most well characterized nuclear receptors. So far, three different isotypes of 
PPARs have been identified PPARα, PPARβ/δ and PPARγ. PPARα has been 
previously described as a master regulator of lipid metabolism. Additionally, 
PPARα has been shown to have an anti-inflammatory affect, which is partly 
mediated via NF-κB inhibition [26]. Regards the role of saturated fat on 
inducing inflammation, several studies have provided compelling evidence that 
saturated fatty acids activate NF-κB and stimulate expression of NF-κB targets 
such as COX-2, iNOS and IL-1α in macrophages by activating TLR4 signaling 
in a MyD88, IRAK-1 and TRAF6 dependent manner [31,32]. In contrast, 
unsaturated fatty acids are ineffective or may even act as antagonists. It has 
been reported that saturated fatty acids activate TLR4 by promoting its 
recruitment to lipid rafts via a mechanism involving reactive oxygen species 
[33]. Furthermore, a recent study showed rpL13a snoRNAs U32a, U33, and 
U35a to mediate the effect of lipotoxic myristate, palmitate and stearate in 
respect to increased ROS production, ER stress and subsequent cell death, while 
the less lipotoxic plamitoleate and oleate didn’t have the same effect [34]. 
Gene regulation by fatty acids in the focus of this thesis. In Chapter 3 we 
explore gene regulation by fatty acids in the mouse heart. Among heart’s inbuilt 
metabolic characteristcs is increased fat oxidation rates and limited storage 
capacity. Therefore, increased formation of lipid droplets or lipotoxic 
derivatives in the myocardium results in myocardial metabolic inflexibility and 
cardiac failure. It has been suggested that cardiac increased fatty acid oxidation 
and uncoupling, occur more efficiently by oleic acid, compared to palmitic acid, 
preventing the accumulation of ROS and lipid derivatives in the cytoplasm.  A 
small number of studies have investigated the differential effects of saturated 
and unsaturated fatty acids on cardiac metabolism. According to their findings, 
rodents that had received a diet rich in saturated fatty acids had increased 
ceramide production, apoptosis and cardiac damage after 8 weeks on diet. In 
contrast, those that were fed with unsaturated fatty acids were protected [27]. 
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Furthemore, a transcriptomics analysis comparing the type of genes induced by 
either oleic acid or palmitic acid in the isolated rat cardiomyocytes showed 
increased expression of beta oxidation genes, such as Cpt1, Pdk4 and Ucp3 by 
oleic acid, whereas palmitic acid induced endoplasmic reticulum stress and 
ROS production [28]. In line with this, we were able to appreaciate a number of 
genes in our study that were robustly regulated by PPARα and they were 
involved in fatty acid oxidation, such as Acot1, Acot2 and Ucp3. In the present 
thesis, we were not able to investigate the direct effects of saturated fatty acids 
on cardiac gene transcription. The main reason for that is the fact that 
triglycerides composed of long chain saturated fatty acids are solid at room 
temperature and can not be administered as an oral gavage. Since long chain 
saturated fatty acids are the most lipotoxic for cardiomyocytes, it is of interest to 
investigate the type of genes regulated acutely by saturated fatty acid. For that 
purpose, triglycerides composed of saturated fatty acids could be delivered by 
infusing chylomicrons isolated from the lymph of rats fed a diet that contains 
exclusively tristearin or tripalmitin, although it would be quite difficult to 
determine the appropriate dose. Alternatively, VLDL-like particles could be 
prepared using tristearin or tripalmitin and subsequently infused to the mice. 
In Chapter 3 we observed that after 6hours oral gavage of different PUFAs 
fed to WT and PPARα -/- mice, many target genes of PPARα were involved in 
inflammation and immunity. Immune related functions of PPARα have been 
less explored in the heart compared to other tissues, for example liver. 
Furthermore, we observed a substantial number of PUFA target genes to be 
PPARα independent. One gene that was markedly and consistently induced by 
all fatty acids was Zbtb16/PLZF, encoding a transcription factor that controls 
the development of effector functions in Natural Killer T (NKT) cells [29]. 
NKT cells represent a unique subset of lymphocytes that are reactive to so 
called lipid antigens, which include a broad range of microbial lipids that are 
unique structures of specific microorganisms and they are presented to them 
bound to Cd1d receptor. The latest is mainly expressed on antigen presenting 
cells, such as macrophages, dendritic cells, but it is also found in hepatocytes 
and according to public databases may be also present in white and brown 
adipose tissue. NKT cells comprise up to 2% of spleen, 20% of mononuclear 
cells in the liver and 40% of CD3+ cells in bone marrow in the mouse, making 
these cells a major component of the total T cell population. A recent study, 
interestingly showed that high fat diets enriched in saturated fatty acids (SFA) 
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and monounsaturated fatty acids (MUFA) caused a depletion in hepatic NKT 
cells in the liver leading to further activation of inflammatory signaling, insulin 
resistance, and hepatic steatosis, whereas high fat diet enriched with 
polyunsaturated fatty acids (PUFAs) didn’t have this effect [30]. Cd1d 
expression in cardiomyocytes and functions of NKT cells in the heart haven’t 
been explored. We have measured expression levels of Zbtb16 in several mouse 
tissues and we find heart to be the tissue with the highest expression of Zbtb16 
followed by the white adipose tissue and skeletal muscle. Thus, we may even 
speculate that specific cardiac functions of Zbtb16 in cardiomyocytes may 
mediate the immune related effects of PUFAs, independently of their effect on 
PPAR activation. 
 
Distinct functions of PPARα and PPARβ/δ in the heart  
 
All three PPARs are expressed in the heart. PPARα and PPARβ/δ are highly 
expressed in the cardiomyocyte, while PPARγ is almost absent (Chapter 4) [35]. 
For long time, PPARβ/δ was believed to be redundant to PPARα functions in 
the skeletal muscle [36], mainly due to the observation, that in vitro activation 
studies with PPAR isotype specific agonists showed that both PPARα and 
PPARβ/δ are able to activate mitochondrial fat oxidation [37]. Although, in 
vivo data on PPARβ/δ activation with synthetic agonists have not been reported, 
mice lacking PPARβ/δ suffer from mild cardiac steatosis (normal cardiac 
triglycerides in 2-month-old mice and a twofold increase when they are 9 
months old) and decreased OXPHOS in cardiac muscle [38]. Subsequent 
studies have suggested a distinct role for each of the PPAR isotypes in the heart 
and in the skeletal muscle [39,40], based on which PPARβ/δ has greater control 
over processes related to response to oxidative stress and adaptation to substrate 
availability. Accordingly, PPARβ/δ activation has been reported to reduce 
oxidative stress-induced apoptosis in cardiomyocytes [41] and to promote 
mitochondrial biogenesis, via PGC-1 activation [42]. Furthermore, Kelly et al.; 
have investigated the cardiomyocyte specific overexpression of PPARα and 
PPARβ/δ, showing the PPARβ/δ overexpression protected against 
cardiomyopathy. PPARβ/δ specifically regulated the expression of Glut4, hence 
PPARβ/δ overexpressing hearts had a higher capacity for glucose utilization 
compared to PPARα overexpressing ones. This resulted to reduced myocardial 
injury due to ischemia/reperfusion [43]. Finally, cardiomyocyte specific 
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deletion of PPARβ/δ, in PPARα null mice impaired mitochondrial biogenesis, 
but had no further effect of fat oxidation [44]. In chapter 4 we observed that 
upon activation of PPARs with physiological ligands, Angptl4, the most highly 
upregulated gene by all fatty acids, was a specific target of PPARβ/δ, but not 
PPARα, in mice with global deletion of PPARα or PPARβ/δ. Additionally, we 
found that PPARα didn’t increase Angptl4 expression upon activation with fatty 
acids, in rat cardiomyocytes, that had been transfected with siRNA targeting 
PPARβ/δ. In the same chapter we describe that Angptl4 overexpression protects 
against cardiac lipotoxicity, while Angptl4 deletion leads to increase production 
of lipotoxic derivatives in the mouse heart. The same is probably true for the 
skeletal muscle. Staiger H. et al had showed that Angptl4 is a specific target of 
PPARβ/δ in the skeletal muscle, though expression of PPARβ/δ is much higher 
than PPARα in skeletal muscle than in the heart [45]. Overall these studies 
postulate a distinct function of PPARα and PPARβ/δ in the heart. Driven by the 
above described observations, we may speculate that PPARα secures ongoing of 
fat oxidation, which is crucial for the heart function, whereas PPARβ/δ may 
sense changes in substrate availability or even distinct lipotoxic derivatives and 
activate downstream mechanisms, which aim to protect the heart from 
lipotoxicity. Further, exploring the target genes and functions of PPARβ/δ in the 
heart would help to increase our understanding on the functions of these nuclear 
receptor. Although, initially we aimed to carry out a detailed comparison of 
gene regulation upon deletion of PPARα and PPARβ/δ after an oral gavage of 
dietary fatty acids great differences in mice genetic background made this 
comparison non feasible. 
An intriguing question deriving from this thesis is how activation of PPARs 
by dietary PUFAs led to specific activation of Angptl4 by PPARβ/δ, while 
another well described PPAR target gene Ucp3 was specifically activated by 
PPARα. It is conceivable that in vivo metabolic processing of fatty acids give 
rise to compounds that may interact specifically with certain PPAR isotypes 
leading to differential gene regulation. Liver exhibits high and very similar rates 
of fat uptake with the heart, however long chain fatty acids effect on gene 
expression in the liver are mainly mediated by PPARα, with high overlap 
between different fatty acids, which is not the case in the heart. Possibly 
differences in the routes of uptake of fatty acids between the two tissues in the 
postprandial state may be the cause of differences in gene expression. Whereas 
the heart takes up dietary fatty acids as non-esterified fatty acids after LPL-
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mediated hydrolysis, the liver internalizes dietary fatty acids as TGs within 
chylomicron remnant particles [46,47]. In the liver circulating FFAs, which 
primarily originate from adipose tissue lipolysis (“old fat”), do not seem to be 
able to activate PPARα [48,49], whereas endogenously synthesized fatty acids 
(“new fat”) seem to mediate hepatic PPARα  activation [48]. In contrast, hepatic 
PPARβ/δ can be activated by plasma FFA [49], and likely the same is true in 
skeletal muscle, as revealed by the stimulatory effect of elevated FFA on 
expression of PPARβ/δ target Angptl4 in skeletal muscle [45],[50]. Apart from 
lipolysis of chylomicrons via LPL, fatty acids may be delivered in the heart in 
the form on NEFAs bound to albumin, coming from the adipose tissue or from 
VLDL remnants, which has been shown to be internalized via the VLDL 
receptors in the heart [51]. Therefore, similar to the liver it would be interesting 
to investigate in what extent VLDL-derived fatty acids or NEFA may cause 
differential activation between PPARα and PPARβ/δ in the heart. Tissues 
differences in intracellular fatty acid processing, via which PPAR ligands 
become available may serve as a possible explanation. Recently, Zechner et al; 
described Atgl lipolysis as an essential intermediate process for intracellular 
formation and release of PPARα endogenous ligands in the heart [52]. AtglKO 
mice and cardiomyocyte specific AtglKO mice suffered from impaired fatty 
acid oxidation and cardiomyopathy, which could be corrected by PPARα 
synthetic ligand Wy 14643, but not by PPARβ/δ synthetic ligand GW 501516. 
Interestingly, it has been shown that in the liver Atgl promotes PPARα activity, 
independently of ligand-induced activation [53]. These observations suggest 
that synthetic agonists of PPARs follow different routes of PPAR activation, 
compared to fatty acids and serve as a plausible explanation for the little overlap 
that we observe in genes regulated by fatty acids and by Wy 141643 in the heart 
as opposed to the liver.  However, still remains to be investigated whether 
different routes of lipids uptake from these tissues may differentially modify the 
Atgl dependent release of PPAR ligand formation or may even by pass it. 
Accordingly, future research on PPAR functions should be directed towards 
identifying the structure of endogenous PPAR ligands, in relation to their 
intracellular or tissue origin.  
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Anti-inflammatory functions of Angptl4 
 
Angptl4 exhibits high sensitivity to lipids, responding acutely to fatty acid 
fluxes in heart (this thesis) and muscle [45], exercise, fasting [50] or high fat 
diet [54]. Angptl4 has been described to be a potent inhibitor of LPL activity 
and Angptl4 overexpressing animals are characterized by elevated plasma 
triglyceride levels, that are dramatically induced during fasting. In the present 
thesis we have shown that global overexpression of Angptl4 decreased the 
production of lipotoxic derivatives in the heart on mice that were on a high fat 
diet for 8weeks, while Angptl4 KO mice showed the opposite. In line with these 
findings cardiac specific Angptl4 transgenic animals are characterized by 
elevated plasma TG together with decreased cardiac LPL activity yet these mice 
do not exhibit any change in post-heparin plasma LPL activity or LPL activity 
in non-cardiac tissues [55]. Hence, Angptl4 produced in heart seems to 
primarily act locally to protect the heart from lipid overload and consequent 
lipotoxicity [56]. It is unclear what accounts for the primary autocrine/paracrine 
versus endocrine function of Angptl4 in tissues. Additionally, cardiac specific 
Angptl4 overexpression resulted in a cardiac dysfunction, due to decreased 
availability of fatty acids as a substrate. In the present study we didn’t assess 
cardiac function in Angptl4 Tg or Angptl4 KO mice on a high fat. However, we 
plan to do this in the future.  
Both Angptl4 and LPL are targets genes of PPARs. In the present thesis we 
have shown that Angptl4 is upregulated by PPARβ/δ in response to increased 
influx of fatty acids. In addition, we have previously shown that the same 
mechanism is employed by macrophages to prevent lipotoxocity and foam cell 
formation. In macrophages Angptl4 is specifically activated by PPARβ/δ 
agonist. Hence, we postulate that Angptl4 may serve as a lipid “gate” keeper, 
which responds to differences in intracellular levels of fatty acids and attenuates 
their increased uptake in order to prevent lipotoxicity. In line with this model, 
during hypoxia, that promotes the utilization of glucose instead of fatty acids by 
the cardiomyocytes, Angptl4 is also potently activated. We may speculate that 
via regulation of lipid fluxes Angptl4 may indirectly affect the activation status 
of antigen presenting cells, like macrophages and further influence systemic 
inflammation. In Chapter 5, we suggest another mechanism of Angptl4 on 
inflammatory response and chemotaxis. We were able to show that Angptl4 
reduced atherosclerosis in mice on Western type diet with additional cholesterol 
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for 24 weeks, without causing any changes in plasma triglycerides and 
cholesterol compared to the control group. Angptl4 overexpression led to a 
significant decrease in monocyte adherence and macrophage accumulation in 
the plaque. In line with these findings, bone marrow derived macrophages 
(BMDMs) with higher expression of Angptl4 than the WT, migrated much less 
towards the chemoattractant protein MCP-1, compared to the WT BMDMs.  
Our findings suggest an effect of macrophage produced Angptl4 on 
chemotaxis. Recent studies have showed that the C-terminal portion of Angptl4 
protein interacts physically with integrin αVβ5 and affects keratinocyte 
migration, wound healing, and extracellular matrix remodelling [57,58]. 
Therefore, the role of the C-terminal may be more relevant in understanding the 
effect of Angptl4 in chemotaxis. Interestingly, we found that few TLR agonists 
increased Angptl4 expression in human THP-1 macrophages. TLRs are innate 
immune receptors, which recognize a wide range of bacterial proteins. 
Specifically TLR 4 has been shown to be activated by saturated fatty acids, 
while unsaturated fatty acids have been reported to have no effects or even may 
act as antagonists. Angptl4-/- mice on a high fat diet with saturated fatty acids, 
but not unsaturated fatty acids turn extremely sick after 12 weeks on a high fat 
diet, exhibiting inflammation and accumulation of foam cell macrophages in 
mesenteric lymph nodes. Our findings suggest a model of action of Angptl4 on 
inflammation, which probably involves TLR activation and thus, innate 
immunity, which doesn’t necessarily exclude the effect of Angptl4 on LPL 
activity.  
Several tissues have the ability to synthesize Angptl4 protein with the 
highest expression found in the liver, followed by the adipose tissue, thyroid, 
brain and small intestine. Recently, it has been suggested that non alcoholic 
fatty liver disease shares a common cause with atherosclerosis [59], the same 
might be is conceivable for adipose tissue inflammation that is often present in 
atherosclerosis. Therefore, we may speculate that Angptl4 might have a more 
systemic effect on atherosclerosis development, via local action in these tissues. 
Adipose tissue is a great pool of adipokines/cytokines and other lipophilic 
compounds. Several adipokines, such as adiponectin, visfatin, leptin and retinol 
binding protein-4 have been associated with systemic inflammation without 
necessarily having an effect of lipoproteins metabolism [60-65]. Angptl4 
overexpression increases lipolysis in the adipose tissue. Hence we may 
speculate that Angptl4 function may affect the secretion of lipolysis released 
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proteins or other lipophilic molecules that may have an effect on systemic 
inflammation and thus atherosclerosis. Of course this is speculative and such 
compounds need to be identified. However, it is a suggestion for future 
research.  
The role of Angptl4 in atherosclerosis in humans is uncertain. So far, there 
are inconsistent results regards the effects of a loss of function mutation of 
Angptl4 (E40K) on coronary atherosclerosis. In the study of Folsom et al E40K 
carriers exhibited lower levels of circulating triglycerides, higher HDL and 
overall a lower incidence of cardiovascular disease (CAD) incidence [66]. 
However, another study examining the CAD risk found that although E40K 
carriers had lower triglycerides and higher HDL, they showed a higher CAD 
risk independent of triglycerides and HDL-concentrations [67]. 
 
Hig-2 
 
Transcriptomics data have been a treasury of valuable information, which 
allows discoveries of novel genes, much faster compared to the pre 
transcriptomics era. In chapter 6 we performed microarray analysis on 
macrophages treated with different fatty acids. Hig-2, a gene that has been 
previously described to be a target gene of hypoxia inducible factor 1 (HIF-1) 
was the highest upregulated gene by fatty acids in macrophages. HIF-1 is a 
transcription factor, which is sensitive to oxygen and levels of reactive oxygen 
species in the cells and it is upregulated during hypoxia.  Accordingly, we found 
Hig-2 to be upregulated specifically by hypoxia in macrophages, but not by 
PPAR agonists. It is also upregulated in adipose tissue and liver during high fat 
diet, where we find it to colozalize with macrophages. Gimm T. et al described 
it as a lipid droplet associated protein [68]. Accumulating information on lipid 
droplets reveal that this cellular organelle have a rather complicated 
composition, which associates them with function beyond the triglyceride 
storage [69]. As it is discussed above they may host endogenous ligands of 
PPARs and other bioactive molecules. In relation to that, it is even conceivable 
that components of lipid droplets, such as lipid droplet-associated proteins, 
many of which are targets of PPARα and some are also able to promote fat 
utilization, such as Oxpat/pat-1 [70], may dissociate during lipolysis and 
regulate PPAR signalling. Indeed several lipid-associated droplets are regulated 
by ligand activation of PPARα, such as Mldp, Plin5. We didn’t find Hig-2 to be 
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a PPAR target gene in macrophages, however its regulation by PPARs has to be 
explored in other tissues, such as liver and adipose tissue. In macrophages Hig-
2 is upregulated by drug induced hypoxia, thus we may speculate that its role 
could be connected with substrate switch utilization (from fat to glucose), which 
is a characteric of hypoxia or inflammatory response, since hypoxia increases 
oxidative stress in macrophages and adipose tissue [71,72]. Lipid droplets are 
connected to the endoplasmic reticulum and also mitochondria and may affect 
the functions of these organs via proteins or lipophilic compounds exchanged 
among them. Future experiments in Hig-2-KO mice is expected to give more 
answers on the functions of Hig-2, which may serve as a link between high fat 
diet induced adipose tissue inflammation and liver steatosis and intracellular 
lipid induced inflammation.  
 
Conclusions 
 
  In conclusion, this thesis contributes new information on gene regulation by 
dietary PUFA in the mammalian heart and provides mechanistic insight on their 
previous reported beneficial effects. We show that PUFA can activate 
transcriptional mechanisms that are able to sense very early increases in influx 
of fatty acids and upregulate Angptl4 in order to prevent excess uptake of fatty 
acids and protect the cardiomyocyte from lipotoxocity. The upregulation of 
Angptl4 was due to selective activation of PPARβ/δ, but not PPARα by 
linolenic acid. Furthermore, we provide new insight in the role of Angptl4 on 
lipid metabolism and inflammation by describing a potential anti-inflammatory 
role of Angptl4, which protects against atherosclerosis development, possibly in 
an LPL independent manner. Finally, this thesis provides novel information on 
target genes of fatty acid on macrophages, by exploring the case of Hig-2, the 
most highly upregulated gene by fatty acids in macrophages. 
 
 
 
 
 
 
 
 
 
 
Chapter 7: General Discussion 
177 
References: 
 
1. Talayero, B.G. and F.M. Sacks, The role of triglycerides in atherosclerosis. Curr 
Cardiol Rep, 2011. 13(6): p. 544-52. 
2. Franssen, R., et al., Obesity and dyslipidemia. Med Clin North Am, 2011. 95(5): p. 
893-902. 
3. Wang, H. and R.H. Eckel, Lipoprotein lipase: from gene to obesity. Am J Physiol 
Endocrinol Metab, 2009. 297(2): p. E271-88. 
4. Goodpaster, B.H., et al., Intramuscular lipid content is increased in obesity and 
decreased by weight loss. Metabolism, 2000. 49(4): p. 467-72. 
5. Sironi, A.M., et al., Ectopic fat storage, insulin resistance, and hypertension. Curr 
Pharm Des, 2011. 17(28): p. 3074-80. 
6. Lelliott, C. and A.J. Vidal-Puig, Lipotoxicity, an imbalance between lipogenesis de 
novo and fatty acid oxidation. Int J Obes Relat Metab Disord, 2004. 28 Suppl 4: p. 
S22-8. 
7. Montani, J.P., et al., Ectopic fat storage in heart, blood vessels and kidneys in the 
pathogenesis of cardiovascular diseases. Int J Obes Relat Metab Disord, 2004. 28 
Suppl 4: p. S58-65. 
8. Bugger, H. and E.D. Abel, Molecular mechanisms for myocardial mitochondrial 
dysfunction in the metabolic syndrome. Clin Sci (Lond), 2008. 114(3): p. 195-210. 
9. Schaffer, J.E., Lipotoxicity: when tissues overeat. Curr Opin Lipidol, 2003. 14(3): p. 
281-7. 
10. Hotamisligil, G.S., Endoplasmic reticulum stress and the inflammatory basis of 
metabolic disease. Cell, 2010. 140(6): p. 900-17. 
11. Stulnig, T.M., Immunomodulation by polyunsaturated fatty acids: mechanisms and 
effects. Int Arch Allergy Immunol, 2003. 132(4): p. 310-21. 
12. Shaikh, S.R. and M. Edidin, Polyunsaturated fatty acids and membrane 
organization: elucidating mechanisms to balance immunotherapy and susceptibility 
to infection. Chem Phys Lipids, 2008. 153(1): p. 24-33. 
13. Shaikh, S.R. and M. Edidin, Polyunsaturated fatty acids, membrane organization, T 
cells, and antigen presentation. Am J Clin Nutr, 2006. 84(6): p. 1277-89. 
14. Bosma, M., et al., Re-evaluating lipotoxic triggers in skeletal muscle: Relating 
intramyocellular lipid metabolism to insulin sensitivity. Prog Lipid Res, 2012. 51(1): 
p. 36-49. 
15. Wende, A.R. and E.D. Abel, Lipotoxicity in the heart. Biochim Biophys Acta, 2010. 
1801(3): p. 311-9. 
16. Iozzo, P., Myocardial, perivascular, and epicardial fat. Diabetes Care, 2011. 34 
Suppl 2: p. S371-9. 
17. Dyntar, D., et al., Glucose and palmitic acid induce degeneration of myofibrils and 
modulate apoptosis in rat adult cardiomyocytes. Diabetes, 2001. 50(9): p. 2105-13. 
Chapter 7: General Discussion 
178 
18. Chavez, J.A. and S.A. Summers, Characterizing the effects of saturated fatty acids 
on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 
adipocytes and C2C12 myotubes. Arch Biochem Biophys, 2003. 419(2): p. 101-9. 
19. Lee, C.H., Resolvins as new fascinating drug candidates for inflammatory diseases. 
Arch Pharm Res, 2012. 35(1): p. 3-7. 
20. Seki, H., Y. Tani, and M. Arita, Omega-3 PUFA derived anti-inflammatory lipid 
mediator resolvin E1. Prostaglandins Other Lipid Mediat, 2009. 89(3-4): p. 126-30. 
21. Deckelbaum, R.J. and C. Torrejon, The Omega-3 Fatty Acid Nutritional Landscape: 
Health Benefits and Sources. J Nutr, 2012. 
22. Margioris, A.N., Fatty acids and postprandial inflammation. Curr Opin Clin Nutr 
Metab Care, 2009. 12(2): p. 129-37. 
23. Edidin, M., The state of lipid rafts: from model membranes to cells. Annu Rev 
Biophys Biomol Struct, 2003. 32: p. 257-83. 
24. Costabile, M., et al., The immunomodulatory effects of novel beta-oxa, beta-thia, 
and gamma-thia polyunsaturated fatty acids on human T lymphocyte proliferation, 
cytokine production, and activation of protein kinase C and MAPKs. J Immunol, 
2005. 174(1): p. 233-43. 
25. Schroit, A.J. and R. Gallily, Macrophage fatty acid composition and phagocytosis: 
effect of unsaturation on cellular phagocytic activity. Immunology, 1979. 36(2): p. 
199-205. 
26. Genolet, R., W. Wahli, and L. Michalik, PPARs as drug targets to modulate 
inflammatory responses? Curr Drug Targets Inflamm Allergy, 2004. 3(4): p. 361-75. 
27. Okere, I.C., et al., Differential effects of saturated and unsaturated fatty acid diets on 
cardiomyocyte apoptosis, adipose distribution, and serum leptin. Am J Physiol Heart 
Circ Physiol, 2006. 291(1): p. H38-44. 
28. Lockridge, J.B., et al., Bioinformatic profiling of the transcriptional response of 
adult rat cardiomyocytes to distinct fatty acids. J Lipid Res, 2008. 49(7): p. 1395-
408. 
29. Alonzo, E.S. and D.B. Sant'Angelo, Development of PLZF-expressing innate T 
cells. Curr Opin Immunol, 2011. 23(2): p. 220-7. 
30. Hua, J., et al., Dietary fatty acids modulate antigen presentation to hepatic NKT 
cells in nonalcoholic fatty liver disease. J Lipid Res, 2010. 51(7): p. 1696-703. 
31. Lee, J.Y., et al., Differential modulation of Toll-like receptors by fatty acids: 
preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res, 2003. 44(3): 
p. 479-86. 
32. Lee, J.Y., et al., Reciprocal modulation of Toll-like receptor-4 signaling pathways 
involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and 
polyunsaturated fatty acids. J Biol Chem, 2003. 278(39): p. 37041-51. 
Chapter 7: General Discussion 
179 
33. Pushnova, E.A. and Y.S. Zhu, Quantitative restriction fragment length 
polymorphism: a procedure for quantitation of diphtheria toxin gene CRM197 allele. 
Anal Biochem, 1998. 260(1): p. 24-9. 
34. Michel, C.I., et al., Small nucleolar RNAs U32a, U33, and U35a are critical 
mediators of metabolic stress. Cell Metab, 2011. 14(1): p. 33-44. 
35. Gilde, A.J., et al., Peroxisome proliferator-activated receptor (PPAR) alpha and 
PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in 
cardiac lipid metabolism. Circ Res, 2003. 92(5): p. 518-24. 
36. Muoio, D.M., et al., Fatty acid homeostasis and induction of lipid regulatory genes 
in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha 
knock-out mice. Evidence for compensatory regulation by PPAR delta. J Biol Chem, 
2002. 277(29): p. 26089-97. 
37. Cheng, L., et al., Peroxisome proliferator-activated receptor delta activates fatty acid 
oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res 
Commun, 2004. 313(2): p. 277-86. 
38. Cheng, L., et al., Cardiomyocyte-restricted peroxisome proliferator-activated 
receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to 
cardiomyopathy. Nat Med, 2004. 10(11): p. 1245-50. 
39. Barish, G.D., V.A. Narkar, and R.M. Evans, PPAR delta: a dagger in the heart of the 
metabolic syndrome. J Clin Invest, 2006. 116(3): p. 590-7. 
40. Hondares, E., et al., PPARβ/δ, but not PPARα , activates PGC-1alpha gene 
transcription in muscle. Biochem Biophys Res Commun, 2007. 354(4): p. 1021-7. 
41. Pesant, M., et al., Peroxisome proliferator-activated receptor delta (PPARβ/δ) 
activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. 
Cardiovasc Res, 2006. 69(2): p. 440-9. 
42. Wang, P., et al., Peroxisome proliferator-activated receptor {delta} is an essential 
transcriptional regulator for mitochondrial protection and biogenesis in adult heart. 
Circ Res, 2010. 106(5): p. 911-9. 
43. Burkart, E.M., et al., Nuclear receptors PPARbeta/delta and PPARα  direct distinct 
metabolic regulatory programs in the mouse heart. J Clin Invest, 2007. 117(12): p. 
3930-9. 
44. Liu, J., et al., Cardiomyocyte-Restricted Deletion of PPARbeta/delta in PPARα -
Null Mice Causes Impaired Mitochondrial Biogenesis and Defense, but No Further 
Depression of Myocardial Fatty Acid Oxidation. PPAR Res, 2011. 2011: p. 372854. 
45. Staiger, H., et al., Muscle-derived angiopoietin-like protein 4 is induced by fatty 
acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of 
metabolic relevance in humans. Diabetes, 2009. 58(3): p. 579-89. 
46. Augustus, A.S., et al., Routes of FA delivery to cardiac muscle: modulation of 
lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol 
Metab, 2003. 284(2): p. E331-9. 
Chapter 7: General Discussion 
180 
47. Teusink, B., et al., Contribution of fatty acids released from lipolysis of plasma 
triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. 
Diabetes, 2003. 52(3): p. 614-20. 
48. Chakravarthy, M.V., et al., "New" hepatic fat activates PPARα  to maintain glucose, 
lipid, and cholesterol homeostasis. Cell Metab, 2005. 1(5): p. 309-22. 
49. Sanderson, L.M., et al., Peroxisome proliferator-activated receptor beta/delta 
(PPARbeta/delta) but not PPARα  serves as a plasma free fatty acid sensor in liver. 
Mol Cell Biol, 2009. 29(23): p. 6257-67. 
50. Kersten, S., et al., Caloric restriction and exercise increase plasma ANGPTL4 levels 
in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol, 2009. 29(6): 
p. 969-74. 
51. Bharadwaj, K.G., et al., Chylomicron- and VLDL-derived lipids enter the heart 
through different pathways: in vivo evidence for receptor- and non-receptor-
mediated fatty acid uptake. J Biol Chem, 2010. 285(49): p. 37976-86. 
52. Haemmerle, G., et al., ATGL-mediated fat catabolism regulates cardiac 
mitochondrial function via PPAR-alpha and PGC-1. Nat Med, 2011. 17(9): p. 1076-
85. 
53. Ong, K.T., et al., Adipose triglyceride lipase is a major hepatic lipase that regulates 
triacylglycerol turnover and fatty acid signaling and partitioning. Hepatology, 2011. 
53(1): p. 116-26. 
54. Mandard, S., et al., The fasting-induced adipose factor/angiopoietin-like protein 4 is 
physically associated with lipoproteins and governs plasma lipid levels and 
adiposity. J Biol Chem, 2006. 281(2): p. 934-44. 
55. Yu, X., et al., Inhibition of cardiac lipoprotein utilization by transgenic 
overexpression of Angptl4 in the heart. Proc Natl Acad Sci U S A, 2005. 102(5): p. 
1767-72. 
56. Georgiadi, A., et al., Induction of cardiac Angptl4 by dietary fatty acids is mediated 
by peroxisome proliferator-activated receptor beta/delta and protects against fatty 
acid-induced oxidative stress. Circ Res, 2010. 106(11): p. 1712-21. 
57. Goh, Y.Y., et al., Angiopoietin-like 4 interacts with matrix proteins to modulate 
wound healing. J Biol Chem, 2010. 285(43): p. 32999-3009. 
58. Goh, Y.Y., et al., Angiopoietin-like 4 interacts with integrins beta1 and beta5 to 
modulate keratinocyte migration. Am J Pathol, 2010. 177(6): p. 2791-803. 
59. Bieghs, V., et al., NASH and atherosclerosis are two aspects of a shared disease: 
Central role for macrophages. Atherosclerosis, 2012. 220(2): p. 287-93. 
60. Gerdes, S., et al., Leptin, adiponectin, visfatin and retinol-binding protein-4 - 
mediators of comorbidities in patients with psoriasis? Exp Dermatol, 2012. 21(1): p. 
43-7. 
61. Li, Z.Y., P. Wang, and C.Y. Miao, Adipokines in inflammation, insulin resistance 
and cardiovascular disease. Clin Exp Pharmacol Physiol, 2011. 38(12): p. 888-96. 
Chapter 7: General Discussion 
181 
62. Calabozo Raluy, M., et al., Fibromyalgia syndrome (fibrositis): as frequent as it is 
unknown]. Med Clin (Barc), 1990. 94(5): p. 173-5. 
63. Hayashi, M., et al., Association of adiponectin with carotid arteriosclerosis in 
predialysis chronic kidney disease. Am J Nephrol, 2011. 34(3): p. 249-55. 
64. Almer, G., et al., Adiponectin-coated nanoparticles for enhanced imaging of 
atherosclerotic plaques. Int J Nanomedicine, 2011. 6: p. 1279-90. 
65. Gauvreau, D., et al., [Novel adipokines: links between obesity and atherosclerosis]. 
Ann Endocrinol (Paris), 2011. 72(3): p. 224-31. 
66. Folsom, A.R., et al., Variation in ANGPTL4 and risk of coronary heart disease: the 
Atherosclerosis Risk in Communities Study. Metabolism, 2008. 57(11): p. 1591-6. 
67. Talmud, P.J., et al., ANGPTL4 E40K and T266M: effects on plasma triglyceride 
and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc 
Biol, 2008. 28(12): p. 2319-25. 
68. Gimm, T., et al., Hypoxia-inducible protein 2 is a novel lipid droplet protein and a 
specific target gene of hypoxia-inducible factor-1. FASEB J, 2010. 24(11): p. 4443-
58. 
69. Girousse, A. and D. Langin, Adipocyte lipases and lipid droplet-associated proteins: 
insight from transgenic mouse models. Int J Obes (Lond), 2011. 
70. Wolins, N.E., et al., OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that 
promotes fatty acid utilization. Diabetes, 2006. 55(12): p. 3418-28. 
71. Parathath, S., et al., Hypoxia is present in murine atherosclerotic plaques and has 
multiple adverse effects on macrophage lipid metabolism. Circ Res, 2011. 109(10): 
p. 1141-52. 
72. Trayhurn, P., B. Wang, and I.S. Wood, Hypoxia in adipose tissue: a basis for the 
dysregulation of tissue function in obesity? Br J Nutr, 2008. 100(2): p. 227-35. 
 
 182 
SUMMARY  
Dietary fat is a strong predictor of chronic diseases, such as cardiovascular 
diseases, obesity, diabetes, dyslipidemia and metabolic syndrome. A great 
number of epidemiological and observational studies clearly show that in 
addition to the amount of fat consumed in a diet, fat composition is an equally 
important factor in the development of chronic diseases. Evidence abounds 
indicating that adherence to a diet with high content of polyunsaturated 
(PUFAs) and monounsaturated fatty acids (MUFAs) such as the Mediterranean 
diet has substantial health benefits, while diets with high content of saturated 
fatty acids (SFAs) such as the Western type diet increase the risk for the 
development of several chronic diseases.  
Nutritional genomics or nutrigenomics investigates the interaction between 
nutrients and genes at the molecular level, by using genomic tools. Within the 
field of nutrigenomics, dietary fatty acids and their metabolites are seen as 
signaling molecules that target specific cellular response systems. Dietary fatty 
acids have been reported to bind physically to PPARs, a family of ligand 
activated transcription factors, that play a major role in metabolic homeostasis. 
Three PPAR isotypes have been identified, PPARα, PPARβ/δ and PPARγ. 
Their expression and target genes vary among different tissues and cell types. 
After a meal triglycerides are packed into chylomicrons in the small intestine 
and via the lymph system, they reach the blood and the peripheral tissues. 
Triglyceride chylomicrons deliver free fatty acids to the organs after being 
lipolylised by lipoprotein lipase (LPL), which is anchored to the capillary 
endothelium. Among different organs, heart and liver show the highest uptake 
of dietary triglycerides, postprandialy.  However, opposite to the liver, heart is a 
constant working muscle, which covers its demands on energy mainly by fatty 
acids, delivered to the heart via hydrolysis of circulating triglyceride-rich 
lipoproteins. Unbalanced fatty acid uptake and fatty acid oxidation is common 
in cardiac diseases, such as cardiac failure, myocardial ischemia and diabetes. 
Heart is characterized by decreased lipid storage capacity, therefore chronic 
elevated levels of lipids uptake and intracellular storage is considered harmful 
and may lead to lipotoxic cardiomyopathy.  
Our first aim was to explore the whole genome effects of individual dietary 
fatty acids in the intact heart via transcriptional profiling. By conducting these 
experiments in wild-type and PPARα−/− mice, we aimed to determine the 
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specific contribution of PPARα, which has been previously described as a 
master regulator of lipid homeostasis in the heart. We took advantage of a 
unique experimental model, where mice were given a single oral bolus of 
synthetic triglycerides composed of a single fatty acid. We sacrificed the mice 
6hours after the oral gavage and we compared the effects of different fatty acids 
on gene expression by microarray analysis in the total heart. Many genes were 
regulated by one particular treatment only and among those most of them 
showed large functional divergence. Although, the majority of genes responding 
to fatty acid treatment were regulated in a PPARα-dependent manner, 
emphasizing the importance of PPARα in mediating transcriptional regulation 
by fatty acids in the heart, we observed a substantial number of genes regulated 
in a PPARα-independent manner. Finally, we observed that deletion and 
activation of PPARα had a major effect on expression of numerous genes 
involved in metabolism and immunity.  
We identified response to oxidative stress as the top upregulated process 
activated by all administered fatty acids in the heart. High rates of mitochondria 
oxidation, due to increased supply of substrate after the oral gavage are coupled 
with enzymatic and non-enzymatic mechanisms aiming to counterbalance the 
production of highly reactive secondary products of the respiratory chain, the 
reactive oxygen species (ROS) in the heart. Under conditions such as chronic 
high fat diet or insulin resistance, increased lipid influx in combination with 
uncontrolled production of ROS and lipid intermediates may result in 
mitochondrial malfunctioning and lipid accumulation. Myocardial lipotoxicity 
refers to the accumulation of intramyocardial lipids and is associated with 
contractile dysfunction and even myocytes death. We found Angptl4 to be the 
top upregulated gene, in all groups that received the fatty acids oral gavage. 
Angptl4 has been described as a target gene of PPARs and an endogenous 
inhibitor of the triglyceride hydrolyzing enzyme lipoprotein lipase (LPL), which 
catalyzes uptake of circulating lipids into tissues.  We were able to show that 
the strong upregulation of Angptl4 by dietary fatty acids is mediated by 
PPARβ/δ and is part of a feedback mechanism aimed at protecting the heart 
against lipid overload and consequently fatty acid–induced oxidative stress, one 
of the hallmarks of lipotoxic cardiomyopathy. 
Angptl4 has been shown to have a potent inhibitory effect in LPL activity 
and subsequent reduction in uptake of lipids by several tissues and cell types, 
including macrophages. Furthermore, Angptl4 was shown to prevent the 
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formation of foam cells in mesenteric lymph nodes upon high fat feeding. 
Accordingly, we hypothesized that Angptl4 may affect atherosclerosis 
development by reducing foam cell formation. Thus, our second aim was to 
investigate the role of Angptl4 on atherosclerosis development. We studied 
Angptl4 expression in atherosclerotic lesions and macrophages and determined 
the effect of Angptl4 transgenic overexpression in atherosclerosis prone 
ApoE3Leiden (E3L) mice fed a Western diet containing 0.4% cholesterol. We 
observed a decrease in atherosclerosis in Angptl4 overexpressing mice on an 
ApoE3L background. This effect was independent of the plasma cholesterol and 
triglyceride levels. Importantly, Angptl4Tg.E3L exhibited a less pro-
inflammatory phenotype with decreased accumulation of 
monocytes/macrophages in the atherosclerotic plaque, suggesting an anti-
inflammatory role of Angptl4 in atherosclerosis development. 
Finally, we set out to identify transcriptional targets of fatty acids in 
macrophages, as part of a general goal to elucidate mechanisms through which 
fatty acids exhibit a direct role in modulating inflammatory processes in 
macrophages. We identified Hig-2 to be strongly upregulated by all treatments. 
We found expression of Hig-2 to be the highest in peritoneal macrophages and 
white adipose tissue. Chronic high fat feeding increased Hig-2 expression levels 
in adipose tissue but not in liver. Immunohistochemistry indicated 
colocalization of Hig-2 with Cd68 in infiltrating macrophages as part of crown-
like structures. Based on these findings we propose that Hig-2 has a specific 
role in macrophages and may function as an interesting target in the study of 
obese adipose tissue. 
In conclusion, this thesis contributes new information on gene regulation by 
dietary PUFA in the mammalian heart and provides mechanistic insight on their 
previous reported beneficial effects. Furthermore, we reveal a novel protective 
role of Angptl4 in atherosclerosis development. We propose that this effect is 
mediated by a mechanism, which is independent of inhibition of LPL-mediated 
systemic lipid clearance and it is probably related to the effect of Angptl4 on 
macrophage oxLDL uptake and chemotaxis. Finally, in the present thesis we 
start up an effort to identify fatty acid target genes in macrophages, which open 
new future research paths. 
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SAMENVATTING (Summary in Dutch) 
 De hoeveelheid vet in onze voeding draagt bij aan het risico voor diverse 
chronische ziekten, zoals hart en vaatziekten, obesitas, diabetes, dyslipidemie en 
metabool syndroom. Een groot aantal epidemiologische studies laten zien dat 
naast de hoeveelheid vet in de voeding ook de vetsamenstelling een belangrijke 
factor is in de ontwikkeling van chronische ziekten. Er zijn sterke aanwijzingen 
dat het volgen van een voeding die rijk is aan meervoudig onverzadigde 
vetzuren en enkelvoudig onverzadigde vetzuren, zoals een mediterrane voeding, 
aanzienlijke gezondheidsvoordelen oplevert, terwijl een voeding die rijk is aan 
verzadigde vetzuren, zoals een westerse voeding, het risico op diverse 
chronische ziekten verhoogt. 
 Nutritional genomics of nutrigenomcis onderzoekt de interactie tussen 
voeding en genen op moleculair niveau door gebruik te maken van genomics 
tools. Binnen het vakgebied van nutrigenomics worden vetzuren in onze 
voeding en de daaruit gevormde metabolieten gezien als signaal moleculen die 
aangrijpen op specifieke cellulaire respons systemen. Vetzuren binden aan een 
familie van ligand-geactiveerde transcriptiefactoren die een belangrijke rol 
spelen bij metabole homeostase: de zogenaamde PPARs. Er zijn drie 
verschillende PPARs bekend: PPARa, PPARb/d en PPARg. De expressie van 
de verschillende PPARs varieert aanzienlijk tussen verschillende weefsels en 
diverse celtypen. 
 Na een maaltijd worden triglyceriden verpakt in chylomicronen in de dunne 
darm en bereiken vervolgens via de lymfe het bloed en de perifere weefsels. De 
in chylomicronen aanwezige triglyceriden komen beschikbaar voor de organen 
als vrije vetzuren na lipolyse door het enzym lipoproteïne lipase dat verankerd 
zit in de wand van de capillairen. De organen die relatief de grootste 
hoeveelheid van het vet in de voeding opnemen zijn het hart en de lever. In 
tegenstelling tot de lever is het hart een orgaan dat veel fysieke arbeid verricht 
en voornamelijk in de energiebehoefte voorziet in de vorm van vetzuren die via 
hydrolyse van triglyceride rijke deeltjes beschikbaar komen. Een disbalans 
tussen opname van vetzuren en oxidatie van vetzuren is een veel voorkomend 
probleem bij hartziekten, zoals hartfalen, myocardiale ischemie en diabetes. Het 
hart heeft een zeer beperkte opslagcapaciteit aan vet. Indien als gevolg van een 
verhoogde vetopname er sprake is van een verhoogde vetopslag dan kan dit 
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schade veroorzaken en aanleiding geven tot zogenaamde lipotoxische 
cardiomyopathie. 
 Het eerste doel was om de individuele effecten van vetzuren op het intacte 
hart in kaart te brengen via transcriptionele profiling. Door deze experimenten 
uit te voeren in wildtype en PPARa-/- muizen zijn we in staat de specifieke 
bijdrage van PPARa vast te stellen. PPARa is eerder beschreven als master 
regulator van het vet metabolisme in het hart. In ons onderzoek is gebruik 
gemaakt van een uniek experimenteel model waarbij aan muizen een enkele 
orale dosis wordt toegediend van synthetische triglyceriden bestaande uit één 
specifiek vetzuur. De muizen werden 6 uur na de orale toediening opgeofferd en 
vervolgens werden de effecten van de verschillende vetzuren op gen expressie 
in het hart vergeleken door middel van microarray analyse. Een groot aantal 
genen reageerde alleen op één specifieke behandeling en binnen een set van 
vergelijkbaar reagerende genen bestond veel variatie qua functie. Het merendeel 
van de genen die op vetzuren reageerden vertoonden een afhankelijkheid van 
PPARa, wat het belang van PPARa in regulatie van gen expressie door vetzuren 
illustreert. Desondanks werden ook diverse genen onafhankelijk van PPARa 
door vetzuren gereguleerd. Tenslotte had de afwezigheid van PPARa en de 
activatie van PPARa een aanzienlijk effect op expressie van talloze genen die 
betrokken zijn bij metabolisme en immuniteit.  
 De respons op oxidatieve stress kwam naar voren als het proces dat het 
meest sterk door de diverse vetzuren geïnduceerd werd. Een intensieve 
mitochondriële oxidatie als gevolg van een verhoogde aanvoer van substraat 
door middel van de orale gavage brengt enzymatische en niet-enzymatische 
mechanismen in gang die erop gericht zijn de productie van reactive oxygen 
species (ROS) in de ademhalingsketen te neutraliseren. Onder condities zoals 
een chronisch hoog vet dieet of insuline resistentie kan de verhoogde opname 
van lipiden in combinatie met ongecontroleerde productie van ROS en lipide 
intermediairen leiden tot mitochondriële dysfunctie en zelfs het afsterven van 
myocyten. Angptl4 kwam naar boven als het gen dat het meest sterk 
geïnduceerd werd door de verschillende vetzuur behandelingen. Angptl4 is 
uitgebreid beschreven als target gen van PPARs en fungeert als endogene 
remmer van het enzyme lipoproteïne lipase, wat verantwoordelijk is voor de 
hydrolyse van circulerende triglyceride-rijke deeltjes en essentieel is voor de 
opname van vet in de weefsels. De resultaten lieten zijn dat de inductie van 
Angptl4 door vetzuren loopt via PPARb en deel uitmaakt van een feedback 
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mechanisme dat erop gericht is het hart te beschermen tegen een overdaad aan 
vet en de daarmee gepaard gaande oxidatieve stress, wat één van de kenmerken 
is van lipotoxische cardiomyopathie. 
 Van Angptl4 is bekend dat het een sterke remmer is van de LPL activiteit en 
de daarmee tevens de opname van lipiden door verschillende weefsels en cellen, 
waaronder macrofagen, onderdrukt. Onze groep heeft recentelijk aangetoond 
dat bij gebruik van een vetrijke voeding Angptl4 de vorming van schuimcellen 
in de mesenterische lymfknopen voorkomt. Bijgevolg ontstond de hypothese 
dat Angptl4 de ontwikkeling van atherosclerose zou kunnen remmen door de 
vorming van schuimcellen te onderdrukken. Het tweede doel was aldus om de 
rol van Angptl4 bij de ontwikkeling van atherosclerose te onderzoeken. Om dat 
te bereiken is de expressie van Angptl4 in atherosclerotische plaques bepaald en 
tevens het effect onderzocht van Angptl4 overexpressie in het ApoE3Leiden 
diermodel, wat gekenmerkt wordt door ontwikkeling van atherosclerose bij 
consumptie van voer dat rijk is aan vet en cholesterol. Transgene overexpressie 
van Angptl4 leidde tot een aanzienlijk afname van atherosclerose. Dit effect was 
onafhankelijk van de plasma cholesterol en triglyceriden gehalten. De Angptl4 
transgene muizen hadden een minder inflammatoir fenotype met verminderde 
ophoping van monocyten/macrofagen in the atherosclerotische plaques, wat 
duidt op een anti-inflammatoire rol van Angptl4 bij de ontwikkeling van 
atherosclerose.  
 Het laatste deel was gericht op het proberen te identificeren van 
transcriptionele targets van vetzuren in macrofagen, wat deel uitmaakt van een 
poging om de mechanismen op te helderen waarbij vetzuren ontsteking in 
macrofagen kunnen beïnvloeden. Behandeling van macrofagen met diverse 
typen vet leidde tot een sterke toename van de mRNA expressie van het Hig2 
gen. Expressie van Hig2 was het hoogst in peritoneale macrofagen en wit 
vetweefsel. Expressie van Hig2 ging omhoog in vetweefsel maar niet in lever 
van dieren die langdurig voer kregen dat rijk was aan vet. Immunohistochemie 
liet zien dat Hig2 in het vetweefsel op dezelfde plek aanwezig is als de 
macrofaag marker Cd68 en deel uitmaakt van zogenaamde crown-like 
structuren. Op grond van deze bevindingen stellen we voor dat Hig2 een 
specifieke rol heeft in macrofagen en zou kunnen dienen als belangrijke target 
bij de bestudering van vetweefsel. 
 Samengevat draagt dit proefschrift nieuwe informatie aan over regulatie van 
genen door vetzuren in het hart en tevens beter mechanistisch inzicht aanlevert 
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voor de beschreven gunstige effecten van onverzadigde vetzuren. Tevens toont 
het proefschrift een nieuwe beschermende rol van Angptl4 bij de ontwikkeling 
van atherosclerose, waarschijnlijk via een mechanisme dat onafhankelijk is van 
het effect van Angptl4 op vet klaring door LPL maar waarschijnlijk gerelateerd 
is aan effecten van Angptl4 op opname van geoxideerd LDL door LDL en op 
chemotaxis. Tenslotte laat het proefschrift de identificatie zien van nieuwe door 
vetzuren gereguleerde gene in macrofagen, wat nieuwe 
onderzoeksmogelijkheden biedt. 
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“ It was long, many things changed in my life in the last five years, I had to 
manage a great deal of new information and projects, I felt hopeful and 
hopeless about it several times, but I’ve walked down this long road and now I 
do feel a bit wiser than before.”  
Great last words on my PhD experience! 
 
Now enough about me! Acknowledgements follow!!! 
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